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Abstract
The molecular complexity of cardiogenesis is revealed by the high incidence of heart
phenotypes resulting from mutation to any of a vast number of genes across multiple
pathways. Many proteins, in pathways critical for correct embryonic patterning, are
thus also identified as playing a role in aspects of heart development. A
developmental role for Sox4 has been shown in mouse cardiogenesis, as apparent by
the phenotype of two published alleles. Both null and conditional null mutant alleles
exhibit septation defects, oedema, and lethality by E14.5. However, the causative
step in development, where a loss of functional Sox4 marks the beginning of the
defect, has not been described; nor has it been uncovered whether mutation to Sox4
results in dysregulation of other aspects of embryonic patterning.
This thesis documents the homozygous embryonic phenotype of two mouse lines,
both harbouring an ENU-induced point mutation to the HMG-box of Sox4. In
addition to the Sox4 mutation, the first mouse line examined also contains the well-
characterised satin (sa) coat mutation to the Foxql gene, a mutation closely linked to
Sox4 on chromosome 13. This mutation had been used as a phenotypic recessive
marker in the ENU mutagenesis screen from which the Sox4 allele was isolated.
Phenotypic analysis of the Sox4ENU/ENU Foxqlsa/sa phenotype reveals that the primary
cardiac defect of Sox4 arises as early as E9.5. As the satin allele has been well
characterised and does not result in cardiac dysmorphology, the cardiac phenotype
observed can thus be attributed to the Sox4 point mutation. At this developmental
stage, mutant embryos can be grouped into three phenotypic classes, which vary in
severity. A phenotype is evident at early stages of development in the most severely
affected embryos, such that only a proportion of homozygotes can be examined for
the later cardiac phenotype. At E12.5-E13.5, the cardiac phenotype of embryos
resembles that of the published Sox4 null allele. However, our analysis goes further
to uncover abnormalities in the development of the atrial septum and atrioventricular
structures. To expand on the understanding of this phenotype, a general analysis
was conducted using key molecular markers, selected to reveal consequences of the
phenotype.
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Following description of the phenotype a comprehensive analysis of the expression
of Sox4 was carried out by wholemount and section in situ hybridisation. Since the
mutant phenotype arises between gastrulation (for the most severe mutants) and E9.5
(for the mildest of mutants), Sox4 expression was examined from pre-gastrulation
stages to E12.5 in wholemount, and E9.5 to E12.5 by section in situ to cardiac
regions. The most significant expression of relevance to cardiogenesis is the
identification of Sox4 transcripts in several domains. Early in development,
expression is observed in the mesoderm lateral to the cardiac crescent, a region
known to contribute to the posterior components of the heart tube, and the endoderm
adjacent to the cardiac crescent and subsequent heart tube. Section analysis of the
cardiac region of E9.5 embryos revealed the onset of specific expression of Sox4 in
the endocardium of the outflow tract and atrioventricular canal, with expression also
identified in the emerging cushion mesenchyme. Endocardial and mesenchymal
expression in the AVC and OFT continue at stages E10.5, El 1.5 and E12.5. The
spatiotemporal expression pattern of Foxql is also shown, and exhibits a degree of
overlap with Sox4 in the endoderm and in anterior structures.
Through an extensive breeding programme, it was possible to segregate the mutant
Sox4 allele from satin. Phenotypic abnormalities evident in compound homozygotes
but not in Sox4 homoygotes are convincing evidence of a genetic interaction between
Sox4 and Foxql, although the precise nature of this remains unknown.
The work carried out in this candidature provides novel evidence of the embryonic
expression and function of Sox4. It has been possible to identify the origin of the
cardiac defect caused by mutation to Sox4 as well as reveal additional aspects of an
early phenotype resulting from loss of function of Sox4. Thus, this study provides a
significant contribution to understanding the function of this gene.
ii
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This thesis presents findings from a study of the embryological and molecular basis
of a mutation in Sox4. The precise role of Sox4 is not well-understood. However,
Sox4 expression appears to be required for appropriate heart development and, in
adult tissue, significant for the progression of cancer. This introduction will first
outline what is known about Sox4 function. Second, relevant aspects of mouse
embryonic development and heart development are described, since the heart is the
primary organ affected in the mouse line characterised in this project. Third, the
genetic strategy used to generate the mouse line, which harbours an ENU-induced
mutation in Sox4, is discussed.
1
1.1 Sox4
1.1.1 The Sox family of proteins and the group C member, Sox4.
The Sox (SRY-like HMG box) family of proteins function in a wide range of
developmental and physiological processes. Sox proteins are conserved from
invertebrates to mammals, with approximately 35 proteins spanning 11 phylogenetic
groups (Bowles et. al. 2000). The family was first defined by homology with the
HMG DNA binding domain of the testis-determining factor, SRY (Gubbay et. al.
1990). Structurally, the HMG domain comprises three alpha helices orientated into
an L-shape (Figurel.la), which binds the minor groove of DNA and regulates gene
transcription (Bewley et. al. 1998; Wegner 1999). The L-shape structure of the
HMG domain is maintained by a hydrophobic core of protein residues, which are
highly conserved within the Sox family. Binding of the HMG domain to DNA
results in a 70-85° bend and an unwinding of the DNA helix, in addition to widening
of the minor groove (Ferrari et. al. 1992) (reviewed in (Wegner 1999)). The
majority of Sox proteins appear to bind DNA as monomers, with a few identified
exceptions: Members of phylogenetic group D (Sox5, Sox6) homodimerise via a
leucine zipper motif, only identified in members of this group (Lefebvre et. al.
1998); SOX9 and Sox 10 (within group E) have both been found to dimerise in a
DNA-dependent manner (Peirano et. al. 2000). Furthermore, SOX9 dimerises to
activate gene expression in chondrogenesis, while it acts as a monomer to activate
expression of genes involved in sex determination (Bernard et. al. 2003).
Mouse Sox4 (RP23-262C6.1, AA682046 and Sox-4) and its orthologs in human
(SOX4), rat (Sox4_predicted), Xenopus (sox4), chick (SOX4) and zebrafish (sox4a)
are members of the group C division of Sox genes. In group C, Sox4 is
phylogenetically related to Soxll (mouse, human, rat, chick, Xenopus and
zebrafish), Sox 12 (mouse), SOX 12 (formerly SOX22) (human), Sox 24 (rainbow
trout), and the invertebrate Sox C proteins (C.elegans and D.melanogaster). The
Sox4 locus resides on mouse chromosome 13 band A3-A5 (Critcher et. al. 1998) and
the short arm of chromosome 6, 6p22.3 (Critcher et. al. 1998), in human.
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Figure 1.1: Domains of the Sox4 protein. (A) The L-shaped HMG box of Sox4
comprises three alpha helices; (B) The Sox4 protein harbours an HMG box DNA
binding domain at the N terminus and a trans-activation domain at the C
terminus. Additional motifs include a glycine-rich repeat (GRR) and a stretch of
serine repeats (SRR) at the C terminus. Figure adapted from: (A) Van Houte
et.al. 1995 and (B) Goldsworthy et.al. 2008.
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Structurally, the HMG domain is located close to the N terminus (van de Wetering
et. al. 1993). The Sox4 HMG domain is known to bind a strict DNA motif of 10
base pairs. Additional motifs include the nuclear localisation signal (NLS) (Rehberg
et. al. 2002), glycine-rich repeats and the C-terminus serine-rich repeats which act as
the transactivation domain (Goldsworthy et. al. 2008; van de Wetering et. al.
1993)(Figurel.lb).
The transactivation potential of Sox4 has been characterised with assays based on an
early finding that Sox4 was capable of binding a T cell-specific enhancer of the
CD3e gene (van de Wetering et. al. 1993). Reporter-gene assays revealed that Sox4
activated transcription, and the transactivation domain was subsequently identified
by fusion to the GAL4 DNA binding domain (van de Wetering et. al. 1993). More
recently, a comparison of the transactivation ability of Group C Sox proteins has
been conducted, using the same sequence from the CD3s enhancer mediating
reporter gene activation (Hoser et. al. 2008). Whilst all three Sox C proteins
recognise this sequence, it was found that Soxl 1 exhibits the strongest
transactivation potential, followed by Sox4, with Sox 12 demonstrating a weak ability
to activate transcription (Hoser et. al. 2008).
1.1.2 Expression of Sox4 in model species, and its overlap with Soxll.
The expression of Sox4 has been analysed in a range of tissues and animal models.
In adult mouse tissue, Sox4 expression has been shown in specific organs by in situ
hybridisation and northern blotting. In the hair follicle, expression of Sox4 is
observed in the hair germ epithelial cells, located at the base of the hair follicle
(Kobielak et. al. 2007). Adult tissues which express Sox4 include: thymus, femur,
heart, pancreas, liver, kidney, spleen, mammary gland, skeletal muscle, pituitary
gland, skin, CNS (regions of the brain and spinal cord), eye, digestive tract, lung and
gonads1.
Since Sox4 and Soxll recognise a conserved DNA sequence, and they also
demonstrate functional overlap, it is possible that during development, co-expression
1 http://www.informatics.jax.org/
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of Soxl 1 with Sox4 might functionally compensate for ablation of Sox4 in mutant
lines.
The expression of both Sox4 and Soxll is detected in the developing mouse
pancreas. At E12.5 and E14.5 Sox4 and Soxll positive cells are broadly expressed
in the epithelium. By El 8.5 these two transcripts overlap in endocrine cells of the
islets of Langerhans (Lioubinski et. al. 2003).
Furthermore, the expression of Sox4 has been described in mouse central nervous
system (CNS) development by wholemount in situ hybridisation at E8.5 and El0.5.
Detailed analysis has been conducted on sections of the neural tube between El0.5
and E16.5, and on anterior forebrain sections between El 1.5 and P7 (detailed in
(Cheung et. al. 2000)). In the brain and spinal cord, the expression of Sox4
predominantly overlaps with Soxl 1. Analysis by Cheung et.al. additionally revealed
expression of Sox4 in wholemount at El0.5 in the limb bud, dorsal root ganglia
(DRG), and pharyngeal arches - expression domains which were present in chick at
the equivalent stage (Maschhoff et. al. 2003).
During heart development, in both mouse and chick, the first reported expression of
iSox4 is at embryonic day (E)l 1.5 in mouse and HH18 (approximately equivalent to
El0.5) in chick. Sox4 expression is reported in the developing cushions of the
atrioventricular canal (AVC) and the outflow tract (OFT) (Hoser et. al. 2008;
Maschhoff et. al. 2003; Schilham et. al. 1996). The expression of Soxll does not
overlap with Sox4 in the heart. This has been shown by wholemount in situ
hybridisation analysis to Soxll in mouse (Hargrave et. al. 1997; Kuhlbrodt et. al.
1998) and soxllA and soxl IB in zebrafish (Rimini et. al. 1999). Additionally, the
developmental expression of a [3-galactosidase marker introduced into the Soxll
locus reveals only weak cardiac expression from El4.5 at the arterial pole (Sock et.
al. 2004) - subsequently confirmed by quantitative PCR, demonstrating extremely
low expression of Soxll in the heart at E14.5, E16.5 and E18.5 developmental stages
(Hoser et. al. 2008).
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Although these studies have identified a wide range of tissues that express Sox4, its
expression at cellular resolution in many sites is unclear, as is the subcellular
localisation of the protein, particularly during embryonic development.
1.1.3 Known functions of Sox4.
The current understanding of the mechanism (or possible mechanisms) of action of
Sox4 stems from analysis in multiple disciplines. A null allele was created in mouse
and examined, to a limited degree, until embryonic death at E14.5. Expression of
Sox4 in the immune system gave rise to an interest in the role of Sox4 during
development of cells involved in immunological responses, B and T cells.
Additionally, there is increasing evidence that Sox4 is strongly upregulated in
numerous types of cancer, and cancer cell lines. Thus considerable research is
focused on increasing the understanding of the role of Sox4, its target genes, and its
molecular function. The role of Sox4 in these systems is summarised below. The
evidence for a role in heart development will follow in the next section (section
1.1.4).
Development and maintenance ofbiological systems
Sox4 is necessary for development of certain cells within the immune system. Sox4
null embryos demonstrate inability of B cells to mature beyond the pro-B cell stage
(Schilham et. al. 1996). Sox4 is activated through IL5-mediated signalling (Geijsen
et. al. 2001). This activation requires binding of Sox4 to syntenin, which associates
with the intracellular domain of the IL-5a receptor. Signalling through the IL-5a
receptor is important for regulating B cell differentiation (Moon et. al. 2001).
Furthermore, explanted cultures of the foetal thymic organ from null embryos
indicated a deficiency in the ability to produce CD4 and CD8 positive T cells
(Schilham et. al. 1997).
In the pancreas, embryos homozygous for the null mutation in Sox4 demonstrate
normal pancreatic bud formation and differentiation to E12.5. Explant culturing for
eight days from El 1.5, to examine differentiation beyond the cardiac lethality,
showed that loss of Sox4 does not prevent differentiation of endocrine cells, but
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homozygous mutant pancreas fails to form normal islet structure (Wilson et. al.
2005). The molecular requirement for Sox4 in this process has not been described.
The role of Sox4 in CNS development has been explored (Cheung et. al. 2000). In a
comparison of gene expression (Sox2, Soxll, Mashl, Ngnl and Ngn2) was carried
out on forebrain and spinal cord sections from two E12 Sox4 null embryos, little
difference was observed between the expression of these genes. Hence, this group
concluded that there was sufficient homology between Sox4 and Soxll expression
domains such that Soxll could compensate for an absence of Sox4 at this
developmental stage in the CNS.
Also in the CNS, control of the levels of Sox4 is required for oligodendrocyte
development (Potzner et. al. 2007). Sox4 is expressed highly in oligodendrocyte
precursor cells. However, overexpression of Sox4 in oligodendrocyte precursor cells
interfered with the ability of these cells to undergo terminal differentiation. A
similar role of Sox4 is observed in glial cells suggesting that Sox4 counteracts
differentiation (Hoser et. al. 2007).
Other roles of Sox4 have been described outside of the embryonic period.
Physiologically, its expression is modulated by hormones in the mammary glands
and uterus (Hunt et. al. 1999) and in vitro studies reveal that Sox4 functions to
promote apoptosis via Caspase-1, following induction of the cellular cascade by
PGA2 and deltal2-PGJ2 (Ahn et. al. 1999; Ahn et. al. 2002).
It is evident from current work that Sox4 plays a dynamic role during development
of a number of organ systems.
Tumorigenesis
The most well-described activity of SOX4 is within the field of cancer genetics.
Indeed most SOX proteins have been implicated in tumorigenesis (Dong et. al.
2004). Research implicates SOX4 involvement in a diverse variety of carcinomas.
SOX4 expression is upregulated in: breast cancer cell lines (Graham et. al. 1999);
small cell lung carcinoma (Friedman et. al. 2004); myeloid tumours (Boyd et. al.
2006; Tonks et. al. 2007); adenoid cystic carcinoma of the salivary gland (Frierson
et. al. 2002); prostate cancer (Fiu et. al. 2006); and colon cancer (McCracken et. al.
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1997). Additionally, SOX4 has been identified as a marker between desmoplastic
medulloblastoma (in which SOX4 expression is low) and the more aggressive
classical medulloblastoma, which exhibits a high level of both SOX4 and SOX11
(Lee et. al. 2002).
Blocking SOX4 expression in a prostate cancer cell line (LNCaP) and breast cancer
cell lines (MCF-7 and BT-474), by siRNA, induces apoptosis (Liu et. al. 2006).
Expression of SOX9 appeared to be up- or down- regulated in parallel to levels of
SOX4, suggesting that regulation of SOX9 may be, in part, by the action of SOX4. In
addition, Liu et.al. revealed that expression levels of BCL10, CSF1 and
NcoA4/ARA70 fluctuated in parallel to altered levels of SOX4. Moreover, it was
identified that SOX4 could bind to the promoters of both TLE1 and PUMA/BBC3.
However the implications of this binding action for the development of prostate
cancer has not been described.
In tumourigenesis, SOX4 has been suggested as a regulator of metastasis, since
inhibitory RNAs which bind SOX4 transcripts are expressed in normal breast
epithelial cells. Expression of microRNA is lost in tumour cells undergoing
metastasis (Liao et. al. 2008; Tavazoie et. al. 2008). Additionally, knockdown of
SOX4 transcript in vitro is capable of reducing proliferation of colon carcinoma cells
(SW480), while overexpression enhances cells proliferation (Sinner et. al. 2007).
This effect is thought to occur via an interaction of SOX4 with (3-catenin, thereby
regulating canonical-Wnt target genes, including CyclinDl.
Thus, it appears that Sox4 plays extensive roles in developmental, physiological and
pathological processes. None of these roles are fully understood.
1.1.4 The role of Sox4 in cardiogenesis - Information from the study of a Sox4
targeted null allele and a conditional Sox4 allele.
A targeted null mutant allele of Sox4 has been described (Schilham et. al. 1996).
The phenotype was described as being a severe heart phenotype, with inadequate
septation and valve development. Additionally mutants demonstrated an inability of
B cells to differentiate. The Sox4 null mutant was then further investigated with
embryos staged between El2-14, in which the heart phenotype was described as
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Figure 1.2: Null alleles of Sox4 demonstrate a cardiac phenotype at E13.5-14.
Schilham et.al. described the E14 Sox4 null cardiac phenotype (sagittal sections,
wild-type A; mutant B). (A) The wild-type heart demonstrates normal septation of
the outflow tract and ventricles (thick black arrows). Additionally, atrioventricular
valves are normal. (B) In contrast, Sox4 null mutant hearts demonstrate a failure of
septation (thick black arrows) and additionally common arterial trunk from the right
ventricle. Penzo-Mendez et.al. described the Sox4 conditional null phenotype,
inactivated throughout the embryo (frontal sections, wild-type C, mutant D). (C)
The wild-type heart demonstrates normal septation and semilunar valve formation
(black arrowheads). (D) Mutant hearts demonstrate ventricular septal defects
(black arrow) and semilunar valve hypoplasia (black arrowheads) and common
arterial trunk. Abbreviations: A, atrium; Ao, Aorta; AT, aortic trunk; AVC,
atrioventricular canal; CT, common arterial trunk; LV, left ventricle; PT, pulmonary
trunk; RV, right ventricle; SV, semilunar valves. Images A and B from Schilham
et.al. 1996; Images C and D from Penzo-Mendez et.al. 2007.
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highly variable ranging from severe valve and septation defects to a mild septation
defect of the right ventricle (Figure 1.2a and b). Left-right abnormalities were not
described. The cardiac phenotype was considered to be a consequence of a lack of
expression in the endocardial-derived cushions of the AVC and OFT, at E12.5.
Interestingly, it was reported that no macroscopic phenotype was observed prior to
E13.5. Embryos were only examined from E12-14.5. Yet a gap in this work can be
seen when examining the percentages of homozygous mutants obtained in their
genetic crosses (Ya et. al. 1998b). Ya et.al. reported that 18-20% of embryos in their
study were homozygous for the Sox4 null mutation. In order to satisfy the
Mendelian ratio, this implies that the mutation must result in variable lethality from
an earlier stage of development, which was not addressed in their paper.
In 2007, over ten years after the targeted null allele was described, a report of a
conditional null allele was published (Penzo-Mendez et. al. 2007). When inactivated
in all tissues, the phenotype of embryos was reported to be the same as that
previously proposed for the null allele (Figure 1.2c and d). Given that Sox4
demonstrates multiple expression domains throughout embryogenesis, the
conditional allele will be highly useful to examine the function of Sox4 in other
systems, without embryos succumbing to cardiac insufficiency.
1.1.5 Overlap of the Soxll null phenotype with the Sox4 null phenotype.
As already described, Sox4 and Soxll are phylogenetically related, and thus there
may be functional overlap in their common expression domains (described in section
1.1.2).
Little is known about the function of Soxll in developmental pathways. Limited
expression domains have been described and overlap considerably with those
published for Sox4 (section 1.1.2), particularly in the developing nervous system.
Soxll has been proposed to be involved in epithelial-to-mesenchymal transition
(EMT), given that its expression domains predominantly include regions of EMT
during development (Hargrave et. al. 1997). Cardiac aspects of the Soxll null
phenotype also overlap with that described for the Sox4 mutant (Sock et. al. 2004).
Hearts of Soxll null embryos exhibit ventricular septal defects, double outflow tract
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from the right ventricle and inadequate OFT septation. Interestingly, Soxl 1 null
mice survive gestation and die shortly after birth, presumably from aberrant heart
function. It has been suggested by Sock et.al. that Sox4 and Soxl 1 may be partially
functionally redundant (Sock et. al. 2004), but clearly in cardiogenesis this is limited
- especially since expression of Soxl 1 in the heart is not detected until El4.5. How
this reconciles with the phenotype in Soxl 1 mutant embryos has not been described.
Additionally it has been proposed that Sox4 may regulate Soxl 1 in heart
development (Sock et. al. 2004). This is one possible explanation for the increased
severity, and thus earlier lethality, in the Sox4 null. The third mouse Group C Sox
gene, Soxl2, does not demonstrate a phenotype when inactivated and it has been
proposed that the presence of functional Sox4 and/or Soxl 1 render Sox 12 redundant
(Hoser et. al. 2008).
1.1.6 Summary
In summary, Sox4 has been demonstrated to be involved in multiple pathways in
both embryonic development and adult physiology. The dramatic change in
expression observed in tumorigenesis suggests that it may play a role in proliferation
(as supported by analysis in cell lines) or in repressing terminal differentiation (a
concept supported by the requirement of oligodendrocytes and glial cells of the CNS
to downregulate Sox4 expression in order to reach full maturity). Alternatively, in
some tumours SOX4 is required for metastasis, thus may be required for EMT.
Additionally, Soxll has been proposed to be involved in EMT. There is
considerable overlap in the published expression domains and null phenotypes
between Sox4 and Soxll suggesting that they may, to a certain degree, be
functionally redundant, with the exception of heart development prior to E14.5, as
only Sox4 is expressed in this organ at these stages. Nevertheless, the convincing
evidence of Sox4 being essential for appropriate cardiogenesis warrants further
investigation to determine the embryonic origin of this phenotype. Determining the
requirement for Sox4 in one developmental system (cardiogenesis) may indirectly
contribute to the understanding of its action, and thus be useful for deciphering its
activity in other processes.
11
1.2 Early Mouse Development
The blastocyst is a symmetrical polar structure which implants into the uterine wall
at 4.5 days post coitum (dpc). It comprises trophectoderm cells to enclose the cells
of the inner cell mass (ICM) and the blastocoel cavity lined by primitive endoderm
(PE). The trophectoderm forms extraembryonic tissue while only the ICM
contributes to embryonic tissue. The ICM can be harvested, in vitro, to enable
derivation of embryonic stem (ES) cells. In vivo, the ICM expands into the
blastocoel cavity to form a sheet of single-layer epithelial cells - the embryonic
ectoderm, also called "epiblast". The primitive endoderm overlying the embryonic
ectoderm expands with the ICM into the blastocoel cavity as a monolayer termed the
visceral endoderm. In parallel, primitive endoderm adjoining trophohlast cells forms
parietal endoderm. Together, trophectoderm and parietal endoderm are termed
Reichert's membrane (this and following paragraph describing morphogenic changes
and embryonic anatomy are more extensively described in (Kaufman 1992; Lu et. al.
2001)) (Figure 1.3)).
In mouse at 6dpc, a cluster of distal visceral endodermal cells move anteriorly within
the visceral endoderm to form anterior visceral endoderm (AVE) (Figure 1.3).
Around 6.5dpc posterior cells of the proximal embryonic ectoderm, at a point
opposite the AVE, undergo a transformation to convert from epithelia to cells of a
mesenchymal nature in the process of gastrulation. The region where this transition
takes place is called the primitive streak, and the mesenchymal cells emerging are
mesoderm. Mesoderm expands and migrates in three directions: proximally to
become extraembryonic mesoderm of the allantois; bi-laterally around the embryonic
ectoderm to form the mesodermal wings, contributing to the heart and head
mesenchyme; and mesoderm which exits anteriorly from the primitive streak
contributes to axial mesoderm. In addition to the formation of mesoderm, embryonic
endoderm (also referred to as definitive endoderm), surface ectoderm and neural
ectoderm are also created from the embryonic ectoderm. Definitive endoderm (so
called to distinguish it from the visceral endoderm and parietal endoderm which are
both extra-embryonic lineages) is formed by cells which exit the streak at the most
anterior region and displace the adjacent layer of visceral endoderm (Lawson et. al.
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1987) (reviewed in (Tam et. al. 1992)). The boundaries of this endoderm are
continuous with the extraembryonic visceral endodermal layer. Embryonic ectoderm
adjacent to the AVE is responsive to inductive signals to become neural ectoderm of
the future head, while along the axis ectoderm contributes to the node and is retained
adjacent to the primitive streak developing into posterior neural tissue as axial
elongation proceeds. Once neural tube closure is complete, surface ectoderm covers


































































Figure 1.3: Early mouse embryonic development. The inner cell mass (ICM;
purple at 4.5dpc) develops into the epiblast, surrounded by extraembryonic
endoderm (5.5dpc and 5.75dpc) (VE; visceral endoderm). Anterior movement of
the anterior visceral endoderm (AVE) occurs about 6.0dpc. Mesoderm is produced
upon the start of gastrulation at 6.5dpc at the primitive streak (purple). By 7.5dpc
the cardiogenic mesoderm has migrated away from the primitve streak, laterally
around the embryo (direction is indicated by arrow). Adapted from Lu et.al. 2002.
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1.3 Formation of the mouse heart
The heart is one of the first organs to develop and become fully functional in
vertebrate embryogenesis. It is a complex organ, whose formation requires not only
the coordinated interaction of cells to form the different structural tissues, but also
organisation to give rise to left-right asymmetry of the chambers, the valves, and also
the vessels. The valves and vessels deliver blood to the heart and expel it into the
vascular system.
At the physical level, formation of the heart is one of the well-defined processes of
embryogenesis. Much of the knowledge of this process comes from the study of
model organisms. At the molecular level, many factors are known to contribute to
cardiogenesis. In contrast to our understanding of the morphological changes, the
network of molecular interactions is far from being completely characterised.
Selected aspects of cardiogenesis are described here, together with some description
of molecular regulation, as a reference for that which is discussed elsewhere in the
thesis.
1.3.1 Early heart development: cardiac progenitor cells; heart tube formation
and looping; and early chamber specification.
Early heart development
Cardiac progenitors migrate within the mesodermal wings, transiting laterally from
the streak to the anterior side of the embryo. At the early-headfold stage, the bi¬
lateral mesoderm meets and forms the cardiac crescent. The lateral mesoderm
separates into two layers (Linask 1992) - the somatopleuric (or somatic) and the
splanchnopleuric (or splanchnic) mesoderm separated by the intra-embryonic
coelom, which is precursor to the pericardial cavity (Figure 1.4a). Splanchnic
mesodermal cells in the anterior, or 'leading edge', of the lateral mesoderm are
cardiogenic, as they contain precursors to both myocardial and endocardial cells
(Manasek 1968). The mesoderm at the crescent is in close proximity to the sheet of
definitive endoderm (foregut) (Parameswaran et. al. 1995). Endocardial precursor
cells delaminate into the space between the endoderm and splanchnic mesoderm
(Viragh et. al. 1989) preceding formation of the heart tube. Within both this
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mesoderm and adjacent endoderm there is a specific region of Nkx2.5 expression
(Lints et. al. 1993). Expression of Nkx2.5 continues throughout early cardiogenesis
since it plays critical roles in regulation of gene expression leading to the four-
chambered heart.
Structure andformation of the heart tube
The heart tube is a structure comprised of bi-lateral endocardial tubes surrounded by
a layer of myocardial cells which adjoin the intra-embryonic coelomic cavity
(DeRuiter et. al. 1992) (Figure 1.4b). The endocardial tubes fuse to form the
internal endothelial layer of the central tube. Blood is pumped anteriorly in a
unidirectional fashion, from the venous pole to the arterial pole. The surrounding
myocardial layer contributes to myocardium. The extracellular matrix develops
between the endocardium and myocardium, and is termed cardiac jelly (discussed in
(Manasek 1975) ). Structurally, from the venous pole of the heart tube, the inflow
tract (IFT) comprises the left and right sinus venosus regions connected via a
common atrial chamber to the ventricular chamber and from there to the bulbus
cordis and finally the outflow tract (OFT) which is segmented into the conus
arteriosus (proximal OFT) and truncus arteriosus (distal OFT) connected to the aortic
sac (Stalsberg et. al. 1969). The aortic sac connects with the vessels of the arch
arteries (within branchial arches connected to the OFT). The heart tube is connected
by the dorsal mesocardium to the body wall.
The myocardium of the heart is patterned from two fields of cells whose lineage
separates very early during cardiogenesis from one original precursor population
(Meilhac et. al. 2004; Meilhac et. al. 2003) (Reviewed in (Buckingham et. al. 2005;
Dunwoodie 2007)) (Figure 1.5c). Clonal analysis has shown that the first heart field
(FHF) comprises myocardial cells of the cardiac crescent and subsequent heart tube.
Mesoderm of the second (also termed secondary or anterior) heart field (SHF) is
located adjacent to the involuting foregut endoderm from the crescent stage until
heart looping (Figure 1.5a, b). Initially, SHF mesoderm develops into the dorsal
mesocardium, adjoining the heart tube to the body wall. Subsequently, dorsal
mesocardial cells of the SHF integrate into the heart tube at both the venous and
atrial poles. SHF cells contribute with FHF cells to the atria and atrioventricular
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canal. Also, cells of the SHF form the OFT and right ventricle (RV), where they
predominante over the FHF contribution. The left ventricle (LV) is entirely
populated by FHF cells (Meilhac et. al. 2004; Meilhac et. al. 2003) (Figure 1.5d, e).
Initial rightward looping of the linear heart tube occurs from E8.0 and is
accompanied by expansion ('balloon-like' growth) of the prospective heart chambers
(reviewed in (Christoffels et. al. 2004a) ) (Figure 1.4c). This looping leads to the
arrangement of what will become the four chambers of the mature heart (Figure
1.4d). Looping is required for appropriate juxtaposition of the presumptive
chambers. It is additionally required for the establishment of inner and outer
curvature. Along the inner curvature, cushion development is necessary for
septation, while the outer curvature is the site of trabeculation. It is the differences in
gene expression in the SHF and the FHF, along both the rostral-caudal and dorso-
ventral axes that gives rise to the variations between ventricles, atria and
intermediate regions, as well as the left and right side of the heart.
Molecular identity ofthe primary and secondary heart fields
Clonal analysis has contributed to understanding the movement and contribution of
two distinct populations of cells within the heart. However, because of the
integration of SHF into most FHF regions, few genes are characterised as being
"FHF markers". Determining whether a gene is important for the FHF is possible by
examining mutants for a left-ventricular phenotype: Handl (Heart and neural crest
derivatives expressed transcript 1) is expressed in left ventricular myocardium and
mutants demonstrate defects of the left ventricle (McFadden et. al. 2005); Tbx5 (T-
box5) is expressed strongly at the cardiac crescent and later in the atria and left
ventricle, while mouse mutants for Tbx5 present with left ventricular hypoplasia
(Bruneau et. al. 1999; Bruneau et. al. 2001).
An understanding of the contribution of SHF cells to the OFT has come from
analysis of the FgflO-lacZ reporter mouse line (Kelly et. al. 2001). Furthermore, the
dynamic contribution of SHF cells to the heart tube is dependent upon the
differential expression of several genes, as shown by the phenotype upon gene
inactivation. Some of these are listed here:
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• Hearts of Isll {Islet-1) mutant embryos lack the OFT, right ventricle and
much of the atria (Cai et. al. 2003). Isll has been proposed to be a key
regulator of proliferation and migration of the SHF.
• An immediate downstream target of Isll {via interaction with Gata4; (Dodou
et. al. 2004)) is Mef2c (Myocyte enhancer factor 2c). The Mef2c mutant
cardiac phenotype includes an absence of the right ventricle and
underdeveloped OFT and atria (Lin, Q et. al. 1997). The primitive singular
ventricular chamber of Mej2c mutants demonstrates a significant reduction in
cell proliferation (Vong et. al. 2006).
• Both Hand2 and Foxhl mutants demonstrate right-ventricular hypoplasia
(Srivastava et. al. 1997; von Both et. al. 2004).
• Nkx2.5 has also been found to regulate proliferation of cells that form the
SHF (Prall et. al. 2007). Nkx2.5 mutant hearts appear to form a primitive
heart tube with myocardium and endocardium (Lyons et. al. 1995). The
defect was evident at E8.25-8.5 when looping morphogenesis was unable to
occur, and embryos lacked expression of the ventricular marker Mlc2v
{Myosin light chain 2v also myosin, light polypeptide 2, regulatory, cardiac,
slow; Myll). Nkx2.5 is critical for suppression of genes which (1) promote
the maintenance of cardiac progenitor cells; and (2) negatively regulate SHF
proliferation. Thus the Nkx2.5 null phenotype appears to be a consequence of
an inability of progenitor cells to proliferate and mature into SHF cells (Prall
et. al. 2007).
In summary, the developing heart tube is formed from two distinct populations of
cardiac cells arising from originally common progenitors. Work in this field has
contributed greatly to the understanding of the cellular movements within the
developing heart. However, the genetic regulation of cells within this process is far























Figure 1.4: Mouse cardiac development from the cardiac crescent to the four-
chambered heart. (A) Lateral mesoderm meets on the anterior side of the
endoderm and forms the cardiac crescent at about E7.75. A section through this
region reveals the two mesodermal layers of somatic and splanchnic mesoderm
separated by the intra-embryonic ceolom, and adjacent to the foregut endoderm.
The cardiac crescent develops into the heart tube (B) which is comprised of
endocardial and myocardial layers, attached to the body wall by the dorsal
mesocardium. (C) As the heart tube loops the endocardial cushions develop and
the interventricular septum begins to form as do trabeculae from the outer
myocardium of the ventricles. (D) By E12.5, the four-chambers of the heart are
evident and septation, as well as valve formation has occurred. Arrow indicates the
fusion of the muscular septum to the membranous region of the atrioventricular
septum. Abbreviations: anf, anterior neural folds; avc, atrioventricular canal; avs,
atrioventricular septum; ca, common atrium; cc, cardiac crescent; dm, dorsal
mesocardium; dp, dorsal pericardium; e, endocardium; ec, endocardial cushions;
fe, foregut endoderm; fg, foregut; hm, head mesenchyme; ht, heart tube; ias, inter¬
atrial septum; ivs, interventricular septum; co, intra-embryonic coelom; la, left
atrium; Iv, left ventricle; m, myocarium; ne, neurectoderm; ra, right atrium; rv, right
ventricle; OFT, outflow tract; som, somatic mesoderm; spm, splanchnic mesoderm;
tr, trabeculae. Adapted from Stennard and Harvey, 2005.
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A B
Figure 1.5: Contribution of the first and second heart fields to the developing
heart. The heart is patterned from two fields of myocardial precursor cells which
arise from an early common precursor. First heart field is marked as red. Second
heart field is marked as green (A) Crescent-stage myocardium develops from the
first heart field lineage, while the second heart field comprises adjacent mesoderm.
By E8 (B), the heart tube has formed from the FHF lineage, while the SHF
comprises adjacent dorsal mesenchyme. (C) Lineage analysis of lacZ positve cells
(blue) in E9 hearts revealed that the first and second lineages arise from a common
precursor. At E9 (D) and E10.5 (D) both first and second lineages contribute to the
heart. First heart field comprises regions shown in red; Second heart field
contributes to the regions shown in green. Abbreviations: 1, outflow region; 2,
primitive right ventricle; 3, primitive left ventricle; 4/5, atrioventricular region; 6/7,
primitive atrium; LA, left atrium; LV, left ventricle; OFT, outflow tract; RA, right
atrium; RV, right ventricle. Adapted from (A-B) Dunwoodie, 2007; and (C-E)
Buckingham et.al., 2005.
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1.3.2 Ventricular chamber formation: Trabeculation and formation of the
ventricles
Specification of the expanding and looping heart tube requires differential gene
expression. This must occur within both chamber and non-chamber myocardial
regions, such that each region acquires a distinct physiological function. Chamber
myocardium expands along the outer curvature, while non-chamber myocardium
undergoes a different series of morphological changes (discussed below, section
1.3.3). Upon looping, some genes, which are widely expressed in the linear heart
tube, become more regionalised in their domains. For example, Gata6 and Hand2
are both expressed throughout the heart tube. Yet by E9, Gata6 expression becomes
restricted to the AVC and OFT, while expression of Hand2 becomes largely
restricted to the OFT and future right ventricle (Davis et. al. 2001; Thomas et. al.
1998). In contrast, Handl expression is restricted in the heart tube. By E9, the
domains of Handl expression subsequently develop into Handl expressing regions
of the OFT and outer curvature of the left ventricle (Biben et. al. 1997; Thomas et.
al. 1998).
Chamber formation requires the initiation of a myocardium-specific programme of
gene expression, to promote differentiation, or to permit contractility. Some of these
genes include: Gap junction protein, alpha I (Gjal; Connexin43; Cx43), Gap
junction protein, alpha 5 (Gja5/ Connexin40; Cx40), Small muscle protein, X-linked
(Smpx; Chisel; Csl), Iroquois related homeohox 5 (Irx5) and Natriuretic peptide
precursor type A (Nppa; previously Atrial Natriuretic Factor, ANF). Expression of
Cx40 and Cx43 is timed with the appearance of rhythmic contractions in the heart
tube, with expression becoming restricted to working myocardium (Delorme et. al.
1997). The connexin proteins form gap junction channels between cardiomyocytes
to facilitate cardiac electrical conduction (Jalife et. al. 1999). Chisel is a marker of
chamber myocardium while Irx5 marks chamber-specific endocardium (Christoffels
et. al. 2000; Palmer et. al. 2001). Expression of Nppa marks the transition from
primary myocardium to mature myocardium (Houweling et. al. 2005; Zeller et. al.
1987). Within chamber myocardium, Nppa expression is directed by the cooperative
action of Nkx2.5 and Tbx5 on the Nppa promoter (Hiroi et. al. 2001). In contrast,
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expression of Nppa in non-chamber myocardium, such as in the atrioventricular
canal and OFT, is restricted by Tbx2 or Tbx3, which bind the Nppa promoter with
Nkx2.5 (Habets et. al. 2002). Tbx2 also represses expression of Cx40 and Cx43.
Tbx2 is expressed in myocardium of non-chamber regions (Christoffels et. al.
2004b). The function of Tbx2 is not just to restrict regions of non-chamber
myocardium from differentiating into chamber myocardium. It is thought that an
additional function of Tbx2 is to restrict proliferation in these domains, since Tbx2
has been shown to repress Nmycl expression directly (Cai et. al. 2005). Nmycl (also
v-myc myelocytomatosis viral related oncogene, neuroblastoma derived; Mycn) null
embryos demonstrate severe cardiac hypoplasia, indicating that Nmycl is required
for early myocardial proliferation (Davis, A et. al. 1993; Davis, A C et. al. 1993).
Expression of Tbx2 is tightly regulated by its repressor, Tbx20 (Cai et. al. 2005;
Singh et. al. 2005; Stennard et. al. 2005), which is expressed throughout the heart
from the early crescent stage (Kraus et. al. 2001b). Clearly, some factors are
required for both chamber formation and intermediate regions, although their role is
dependent upon local gene expression.
Trabeculae are an essential morphological feature of ventricular chamber
myocardium (reviewed in (Wagner et. al. 2007)). Development of the trabeculated
myocardium commences on the 10th day of gestation (Figure 1.6). Specified cells of
the outer curvature myocardium form projections of cardiomyocytes into the lumens
of the ventricular chambers (Icardo et. al. 1987). Trabeculation requires the
endocardium to establish contact points with the myocardium. The myocardium then
proliferates and some myocardial cells emerge as extensions into the ECM, towards
the endocardium (Icardo et. al. 1987) (Figure 1.7). Signalling during trabeculation
has been described to some extent, exploring the molecular cross-talk between the
endocardium and myocardium, via the ECM. Some of these processes are discussed
here. Most notably, Neuregulin 1 (Nrgl) is essential for trabeculation (Kramer et. al.
1996). Neuregulin 1 (Nrgl) is an epidermal growth factor signalling molecule
expressed by cells of the endocardium in the early heart tube, while its receptors
ErbB2 and ErbB4 are presented on the surface of the myocardium (Lemmens et. al.
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Figure 1.7: Formation of the trabeculated myocardium. Cells of the
endocardium and myocardium send and receive morphogenetic cues to produce
trabeculae. Myocardium is induced to proliferate and form projections into the
extracellular matrix (cardiac jelly) towards the endocardium. Expression of
Neuregulin 1 (NRG1) from the endocardium is a key factor in this process.
Adapted from Wagner et.al., 2007.
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trabeculation and a lethal cardiac phenotype (also reviewed in (Garratt et. al. 2003)).
Additionally, BmplO (Bone morphogenic protein 10) has been shown to be a
necessary factor in the process of trabeculation. Ablation of BmplO results in severe
hypoplasia (Chen, H et. al. 2004). Examination of the phenotype of BmplO mutant
hearts revealed that BmplO has dual activities within cardiac development. Its first
function is to maintain cardiac gene expression, since expression of Nkx2.5 and
Mef2c are drastically reduced in BmplO null hearts at E9.5. The second function of
BmplO is either to prevent the premature activation, or antagonise the activity of the
cell cycle regulator p57kip2 at E13.5. Through this, BmplO represses premature
terminal differentiation and promotes proliferation of cardiomyocytes (Chen, H et.
al. 2004). Thus, aspects of some signalling pathways are known to be necessary for
trabeculation, yet the complete network of communication, which results in the
formation of two distinct myocardial layers - compact myocardium and trabecular
myocardium - requires considerable investigation.
1.3.3 Development of the endocardial cushions of the AVC and OFT and
subsequent valve and septum formation
Endocardial cushion formation
Endocardial cushions develop from E9.5 between the common atria and ventricle
(atrioventricular) and from E10 within the outflow tract (Figure 1.6). They are
precursors to the valves of the heart as well as the mesenchymal-derived septum.
Thus, in this way, cushion mesenchyme contributes to septation of the heart into the
four-chambered pump, ensuring that blood flows in one direction (Figure 1.8).
Formation of the cushions relies on early signalling, from the looping heart tube
stage onwards, between the endocardium and adjacent non-chamber myocardium,
across the ECM. This signalling results in an epithelial-to-mesenchymal transition
(EMT) and the production of mesenchyme within the ECM (Markwald et. al. 1977)
(Figure 1.9a). The process of EMT requires initial induction of the endocardial cells
to delaminate. In order for this to occur, endocardial expression of the cell adhesion
molecule VE-cadherin, must be downregulated. VE-cadherin is negatively regulated
by Tgf]3 and BMP signalling from the myocardium (Boyer et. al. 1999; Nakajima et.
al. 2000; Romano et. al. 2000; Timmerman et. al. 2004) (Figure 1.9b). After
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induction, endocardial cells migrate into the ECM (delamination), acquire cell-
matrix connections and adopt a mesenchymal character. In the ECM, mesenchymal
cells proliferate, mature and undergo terminal differentiation into cells of either the
mature valves or membranous septum.
Genes expressed in the cushions, but not in other regions of the heart, may play a
role in endocardial cushion formation. Additionally, by examining embryonic
expression domains, the expression of a gene may be shown to coincide with other
regions of EMT in the embryo. Several key molecular aspects have been
characterised as being required for this process (reviewed extensively in: (Mercado-
Pimentel et. al. 2007; Schroeder et. al. 2003; Srivastava et. al. 2000; Wagner et. al.
2007)). As examples, Notch signalling and Vegf signalling are both necessary for
EMT in the heart.
Levels of Notch signalling, via Delta4, contributes to the process of EMT, by
reducing cellular adhesion between endocardial cells programmed to delaminate
(Grego-Bessa et. al. 2007; Timmerman et. al. 2004). Ablation of Notch target genes
Heyl and HeyL produces a cardiac phenotype consistent with impaired EMT
(Fischer et. al. 2007). Endocardial cells with mutations in Notch pathway factors
{Heyl/L. Hey2, Notchl) are able to delaminate but are unable to transform into
mesenchymal cells. Loss of Heyl/L function results in a reduced expression of
matrix metalloproteinase-2 (Mmp2). Mmp2 is normally responsible, in part, for
degrading the ECM as the mesenchyme proliferates and occupies the region (Song
et. al. 2000). Thus Notch signalling functions at two stages of EMT - delamination
and ECM reconstitution.
Additionally, Vegf signalling play an important role in both initiating and ending the
process of EMT (Dor, Y et. al. 2001; Dor, Y et. al. 2003) (Figure 1.9c). In the local
region of the developing cushion, low Vegf signalling is required for delamination of
endocardium. Levels of Vegf signalling are strictly regulated by NFATcl expression
in the endocardium (Chang et. al. 2004). Initially, at E9 NFAT signalling is required
for repression of myocardial Vegf. A second wave of NFAT signalling later occurs
in the endocardium at El 1 to facilitate the construction of valves.
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The mesenchymal atrioventricular cushions (AVC) are separated spatially into the
inferior (IC) and superior (SC) cushions. Proliferation of the mesenchyme within the
endocardial cushions results in expansion of the cushions. This is tightly regulated
by NFATc which coordinates the switch from mesenchyme proliferation to valve
formation in specific regions of the atrioventricular cushions (Chang et. al. 2004).
The endocardial-derived mesenchyme of the AVC assists in the formation of the
atrial septum, as well a contributing to the ventricular septum, atrioventricular
septation, mitral and tricuspid valves, and to septation of the outflow tract by
juxtaposition of AVC mesenchyme with the outflow tract cushions. The process of
septation within the heart, beyond the initial cushion formation, is complex. It
requires dynamic tissue rearrangements to correctly align the heart chambers. The
understanding of anatomy and tissue movement resulting in formation of the septal
structures has come from detailed serial sectioning and histology across specific
stages of gestation from the 10th day of gestation (E9.5). These processes will be
detailed in the following sub-sections.
Valve formation
Unidirectional valves develop between the atria and ventricles on either side of the
heart, as well as between the ventricles and the arterial vessels. This is essential for
maintaining the flow of blood within the heart. The functionality of valves relies on
the development of the valve leaflets, as well as the fibrous structure through which
the leaflets remain attached to the heart and the supporting tendinous cords and
papillary muscles. The leaflet mesenchyme differentiates into fibrous connective
tissue at both the ventricular inlet and outlet (Lamers et. al. 1995).
In the atrioventricular channels, the mitral (also, bicuspid) valve forms on the left
side of the heart and the tricuspid valve forms on the right. The mitral valve
develops with two leaflets (the mural and aortic leaflets) while the tricuspid valve
develops three leaflets (the cranial and caudal mural leaflets, and the septal leaflet).
In the OFT, the aortic and pulmonary semi-lunar valves form between the ventricles
and the arterial vessels (aorta and pulmonary artery).
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Figure 1.8: Formation of the cushions and septal structures in the
developing heart. Diagram representing a section through the developing four-
chambered heart, just before septation. Endocardial cushion mesenchyme
(yellow/orange) contributes to the atrioventricular canal (numbers 1 and 2; image
cross section as indicated by solid black line on right) and the outflow tract
(numbers 3 and 4; image cross section as indicated by solid black line on left). The
mesenchyme also contributes to atrioventricular septation. Section through the
plane marked by a dashed line reveals the positioning of the atrioventricular
cushions with respect to the dorsal mesenchymal projection (DMP) and the
mesenchymal cap (MC) of the primary atrial septum (PAS). The mesenchmal
components fuse with the cushion mesenchyme to close the primary atrial foramen.
Abbreviations; AVC, atrioventricular canal; DMP, dorsal mesenchymal projection;
LA, left atrium; LV, left ventricle; MC, mesenchymal cap; PAS, primary atrial
septum; OFT, outflow tract; RA, right atrium; RV, right ventricle. Image adapted
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Figure 1.9: Formation of the endocardial cushions and their contribution to the
developing heart. (A) Within the atrioventricular canal and outflow tract, regions of
endocardium are programmed to undergo an epithelial-to-mesenchymal transition
and delaminate into the extracellular matrix (cardiac jelly). (B) Several signalling
pathways have been identified as playing key roles in this process. BMP and TGF-f3
signalling from the myocardium act on the endocardium to repress expression of VE-
cadherin and promote EMT. Additionally, Notch signalling in the endocardium and
nascent mesenchymal cells is required (described further in the text). (C) The
process of cushion and valve formation is reliant upon a local decrease in the levels
of VEGF, as a result of Nfatc signalling from the endocardium. Outer regions of
cushion still retain high levels of VEGF expression. Once sufficient mesenchymal
cells have been produced, central VEGF levels are elevated and the process of EMT
ceases. The mesenchyme then develops into the valves of the outflow tract,
atrioventricular canal and contributes to atrioventricular septation. Adapted from (A,
B) Kirby, 2006; and (B) Wagner et.al., 2007
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Lineage analysis has revealed that the mature developed valves are predominantly
derived from endocardially-derived mesenchyme, with no contribution from
epicardial-derived cells or cardiac neural crest (de Lange et. al. 2004; Lincoln et. al.
2004), although whether or not cardiac neural crest contribute to the valves appears
dependent upon genetic background (Hildreth et. al. 2008; Nakamura et. al. 2006).
A small proportion of myocardial cells contribute in a transitory manner to the mural
valves, but are subsequently replaced by endocardially-derived cells (de Lange et. al.
2004). One of the key signalling pathways required by the endocardium, involved in
valve development and maturation, is that of NFATc/calcineurin (Chang et. al.
2004). Blocking NFAT signalling at Ell in mouse resulted in valvular defects
including a failure of the atrioventricular valves to elongate and a failure of OFT
valve morphogenesis from the endocardial cushions (Chang et. al. 2004).
The leaflets develop in different ways (de Lange et. al. 2004; Lincoln et. al. 2004).
The aortic and septal leaflets of the mitral and tricuspid valves develop from
atrioventricular cushion mesenchyme, by proliferation up to El 1.5, and are
continuous with the mesenchyme of the atrioventricular septum. The septal leaflet
develops with a connection to the interventricular myocardium until late gestation,
while the aortic leaflet develops without connections to the myocardium. In contrast,
the mural leaflets of both the mitral and tricuspid valves develop via a protrusion of
atrioventricular myocardium on the left at E9.5 and the right El0.5. The protrusion
extends into the ventricular lumen, and from El 1.5 endocardial-derived mesenchyme
proliferates on the myocardial scaffold to develop into the fibrous mural leaflets (de
Lange et. al. 2004). Within the OFT, at the end of the ll"1 day of gestation, the
endocardial cushions fuse and develop into mesenchymal swellings of the future
valves of the aorta and the pulmonary trunk (Webb et. al. 1998a). Valve




Leading up to atrial septation, the common atrium is the source of entry into the
heart. The venous entry is initially composed anatomically of the left and right sinus
horns. As cardiogenesis continues, by El 1 the pulmonary vein develops through the
mesocardium and enters left of the midline of the atrial chamber (Anderson et. al.
2006; Webb et. al. 1998b). The once bilateral sinus horns rotate for systemic
circulation to enter the heart from the right side of the mouse heart at the left and
right superior caval veins, separated at this stage by a fold in the right arterial wall
termed the sinus septum. Also by Ell, the sinoatrial valves (left and right venous
valves) have developed to mark the boundary of the left and right sinus venosus and
the right atrium (Webb et. al. 1998a).
The muscular primary atrial septum (also, septum primum, PAS) develops at the
midline of the common atrium, from the atrial wall, and grows towards the
endocardial cushions (Anderson et. al. 1999) (Figure 1.10a). Molecular markers,
such as Pitx2, have indicated that in mouse cardiogenesis the primary atrial septum
arises from cells of the left atrium (Campione et. al. 2001; Franco et. al. 2000). The
primary atrial septum is surrounded by a cap of endocardially-derived mesenchyme.
Mesenchyme from the dorsal mesocardium (the dorsal mesenchymal projection,
DMP, also vestibular spine or spina vestibuli) migrates into the atria between the left
and right pulmonary ridges at El0.5 (Anderson et. al. 1999; Mommersteeg et. al.
2006; Webb et. al. 1998a). This is a second contribution to the atrial septum and this
mesenchyme is of SHF origin and expresses Isll (Mommersteeg et. al. 2006; Snarr
et. al. 2007). As the DMP develops towards the endocardial cushions, contributing
to the closure of the PAS, mesenchyme differentiates into atrial myocardium, as
shown by expression of Mlc2a, but retains a non-myocardial mesenchymal cap,
establishing continuity with the mesenchymal cap of the primary atrial septum -































Figure 1.10: Formation of the primary atrial septum. (A) Initially, the septum
primum (blue) develops from myocardium of the atrial chamber, with a cap of
endocardial-derived mesenchyme. It fuses with mesenchyme of the atrioventricular
cushions and dorsal mesenchymal projection to form the primary septum and close the
ostium primum. Small ruptures develop in the septum primum, forming the ostium
secundum as connections between the two atria. (B) The septum secundum (green)
forms as infoldings from the myocardium adjacent to the primary septum. Human
development, adapted from Larsen et.al. 2001.
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The connecting channel which remains between the left and right atrium at the AVC,
encircled by the developing primary atrial septum, is termed the primary atrial
foramen (also, foramen primum or ostium primum). As the primary atrial septum
grows to close up the primary atrial foramen, fenestrations appear in the anterior
region of the septum, thus forming the secondary foramen (also, foramen secundum
or ostium secundum) (Anderson et. al. 1999; Webb et. al. 1998a). Closure of the
primary atrial foramen occurs on the 12th day of gestation when the mesenchymal
cap from the atrial septum and the mesenchyme from the dorsal mesocardium fuse
with the atrioventricular cushions (Mommersteeg et. al. 2006; Webb et. al. 1998a)
(Figure 1.6). Less well described is the, closure of the secondary foramen, which
commences during the 13lh day of gestation by in-foldings (also, septum secundum)
of the adjacent atrial myocardium (Anderson et. al. 1999) (Figure 1.10b).
Ventricular septation and the atrioventricular septum.
By the Ell, there is a further contribution to ventricular chamber morphogenesis -
the construction of the muscular interventricular septum. Development of the
muscular ventricular septum commences about El0.5 from the myocardium on the
apical side of the heart in a region between the two ballooning ventricular chambers.
It is composed of myocardium and extends towards the mesenchyme of the
atrioventricular cushion and outflow tract. The interventricular foramen, a
connecting space between the left and right ventricles, remains open until septation is
complete at the end of embryonic day 13 (Webb et. al. 1998a).
The anterior-most portion of the interventricular septum (IVS) is of mesenchymal
origin (Strauss et. al. 1987; Wenink et. al. 1982). As the septum is remodelled, the
interventricular foramen is closed off in two parts: The primary (ventral)
interventricular junction remains open as a ring of mesenchyme, for further
remodelling events (described below), while the secondary (dorsal) region is closed
by mesenchymal contributions from the atrioventricular cushions (Lamers et. al.
1992; Strauss et. al. 1987; Wenink et. al. 1982).
The atrioventricular septum (AVS) initially forms as a central mesenchymal mass
(also termed septum intermedium). It is comprised predominantly of the developing
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SC and IC atrioventricular cushions (Webb et. al. 1998a). Development of the AVS
involves remodelling of the inner curvature of the heart to result in separation of the
right and left sides of the heart. At about E10.5-E11, the atrioventricular canal
expands rightward, followed by expansion leftward, to enable three events to occur:
(1) Since the AVC is connected to the ring of mesenchyme of the primary
interventricular junction, rightward pulling enables positioning of the right atrium
over the right ventricle. This movement also results in alignment of the muscular
ventricular septum with the developed atrial septum (Webb et. al. 1998a) (Figure
1.11); (2) Rightward movement of the AVC enables juxtaposition with the
developing sub-aortic cushions of the OFT to bring the sub-aortic region of the OFT
in connection with the left ventricle; and (3) the final result of this movement is a
sealing off of the interventricular connection (Flenderson et. al. 2009; Lamers et. al.
1992; Webb et. al. 1998a).
To summarise, the connection of the interventricular septum with the mesenchyme of
the atrioventricular cushion is essential for septation of the right and left ventricles.
Moreover, this mesenchyme is continuous with the cushions of the OFT such that the
ventricles also makes the appropriate arterial connections.
Septation of the outflow tract
It has been shown by lineage tracing that the myocardium of the OFT undergoes a
counterclockwise rotation between the stages of E9.5 and E12.5 - in preparation for
septation and positioning of the future aorta and pulmonary trunk (Bajolle et. al.
2006). Septation of the OFT is necessary for the developing arterial circulation and
commences in the 11th day of gestation (Webb et. al. 1998a) (Figure 1.12). It is at
this stage that the outflow ridges meet and fuse. Cushions of the distal OFT, together
with cells of cardiac neural crest origin, contribute to septation of the intrapericardial
segments of the aorta and pulmonary trunk (Kirby, M. L. et. al. 1995) (reviewed in
(Anderson et. al. 2003; Webb et. al. 2003)). By E12, the ridge mesenchyme, largely
of neural crest origin, contributes to a septal structure within the OFT dividing the
aortic and pulmonary outlets (Jiang et. al. 2000; Webb et. al. 1998a) (Figure 1.6). It
is within each of the outlets of the proximal OFT, that the mesenchyme of the
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The proximal aspect of the outflow cushions is continuous with the mesenchyme that
contributes to atrioventricular septation and results in the connection of the aorta to
the left ventricle. The mesenchymal septal structure undergoes a process of
myocardialisation through an influx of cardiac myocytes from the wall of the OFT,
and connects to the mesenchyme at the tip of the ventricular septum (Lamers et. al.
1992; McBride et. al. 1981; van den Hoff et. al. 1999). Furthermore, the SHF
contributes myocardium and smooth muscle to the remodelling of the OFT (Waldo
et. al. 2005b).
In addition, remodelling of the OFT is intimately linked to the presence and
infiltration of cells of extra-cardiac origin - the cardiac neural crest cells.
Contribution ofcardiac neural crest to the developing outflow tract
Neural crest cells delaminate from the dorsal neural tube along the axis of the
embryo. It is known that the migration of NC cells results in their contribution to an
extensive range of tissues (Le Douarin 1982). Cardiac neural crest cells (NCC) exist
as a subpopulation of neural crest cells and originate from rhombomeres 6-8
(Fukiishi et. al. 1992). In mouse, NCC delaminate during the 8th embryonic day (Lo
et. al. 1997). NCC subsequently traverse the 2nd, 3rd, 4th and 6th pharyngeal arch
arteries to contribute both to aortic arch artery remodelling and (via the 3rd, 4th and
6th pharyngeal arch arteries) to the heart (Jiang et. al. 2000; Kirby, M. L. 1990;
Kirby, M. L. et. al. 1995; Lo et. al. 1997)(Figure 1.13).
Cardiac neural crest cells contribute to several facets of outflow tract remodelling
and indeed are essential for the morphogenesis of pulmonary and aortic arteries. In
Wntl-Cre/R26R embryos, (3-galactosidase positive labelled cells (marking NCC) are
first observed in the aortic sac and adjacent to the endocardium in the distal OFT
(truncus arteriosus) at E9.5 (Jiang et. al. 2000) (Figure 1.6). By E10.5, again in
Wntl-Cre/R26R embryos, but also in embryos with Pax3-Cre/R26R or Cx43-LacZ,
NCC are found to constitute the majority of the distal OFT cushions, and a
proportion of the proximal OFT cushions (also, conotruncal region) where they
contribute with endocardial-derived mesenchyme (Epstein et. al. 2000; Jiang et. al.
2000; Lo et. al. 1997).
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Appropriate outflow tract septation occurs as consequence of the correct timing of
the development of the outflow cushions, OFT rotation and the infiltration of NCC.
Septation occurs concurrently within both the proximal and distal OFT. In the
proximal OFT the conotruncal septum develops during the 11th day of gestation.
This septum develops from both the conotruncal cushions of cardiac origin and the
extra-cardiac NCC (Jiang et. al. 2000). The NCC form a sub-endocardial layer
within the cushions as the cushions fuse (Jiang et. al. 2000). Following formation of
the septum, the contribution of NCC to the vessel walls is minimal (Jiang et. al.
2000). At E10.5 in the distal OFT, NCC begin to form the transitory spiral
(aorticopulmonary) septal (APS) structure which results in division of the aortic sac,
such that the exiting arterial vessels are divided by El2.5 (Epstein et. al. 2000; Jiang
et. al. 2000). The mesenchymal outlet septum is subjected to myocardialisation, with
cells being replaced by cardiomyocytes (van den Hoff et. al. 1999). Also by El2.5,
NCC surrounding the arch arteries, together with the APS led to vessel remodelling,
and dorsal aorta regression such that the pulmonary trunk now connects with the left
6th arch artery, while the aorta connects on the left to the 4th and on the right to the 3rd
arch arteries (Jiang et. al. 2000).
A third contribution of NCC to cardiogenesis is their presence in the developing
semi-lunar valves. In El2.5 Wntl-Cre/R26R embryos, labelled cells are evident in
the developing valve leaflets (Jiang et. al. 2000; Nakamura et. al. 2006). Their
presence is transitory, since it has been identified that in the mature crescent-shaped
cusps of the valves, contribution by cells of NCC origin is minimal (de Lange et. al.
2004; Jiang et. al. 2000).
Significant understanding of the roles of NCC in the remodelling of the mouse OFT
has come from studies of NCC deficient Splotch (Sp) mutants, in particular the Sp2H
allele. Splotch mutants harbour mutations in the Pax3 transcription factor
(Chalepakis et. al. 1993). In the developing heart, the majority of Sp2" homozygotes
present with defective interventricular septation as well as a single outflow vessel
(persistent truncus arterious; PTA) in which both the pulmonary tract and aorta
ascend from the right ventricle (double outlet right ventricle, DORV) (Conway et. al.
1997). It has been identified through lineage tracing (Pax3-cre/R26R embryos) that
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Figure 1.13: The contribution of cardiac neural crest cells to the outflow tract.
(A) Cardiac neural crest cells migrate from the dorsal neural tube, through the 3rd,
4th and 6th pharyngeal arch arteries into the anterior heart. Within the outflow
tract, neural crest cells contribute transiently to the aortico-pulmonary septum (AP),
before being replaced by myocardium. Abbreviations: AO, aorta; AP, aortico¬
pulmonary septum; P, pulmonary tract. (B) Contribution of labelled NCC (blue) to
the distal ouflow tract of the heart, arch arteries and pharyngeal mesenchyme at
E9.5. Abbreviations - ca, conus arteriosus; s, aortic sac; t thyroid diverticulum; ta
truncus arteriosus; numbers mark pharyngeal arches. (A) Adapted from Maschoff
et.ai, 2000 ;(B) Image directly from Jiang et.al. 2000.
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ford-expressing progenitors are fated to migrate into the heart as NCC (Epstein et.
al. 2000). The abundance of NCC in the OFT is reduced in Splotch mutants and the
distribution of the available NCC is abnormal (Epstein et. al. 2000).
The proximity of NCC migrating into the heart, through pharyngeal mesenchyme, as
well as within the developing OFT, to cells of the SHF is suggestive of signalling
between the two cell populations. Studies in chick have shown that a lack of NCC
results in a failure of SHF myocardium to contribute to remodelling of the arterial
pole (Waldo et. al. 2005a). In addition, the signalling molecule Sonic hedgehog
(Shh) is secreted from the pharyngeal endoderm and acts independently on each of
these lineages, but reveals that they are regulated by similar signalling pathways
(Goddeeris et. al. 2007). Furthermore, in Sp2H homozygotes, a deficiency of NCC
disrupts the distribution of SHF within the outflow and pharyngeal regions
(Bradshaw et. al. 2009). Thus the function of NCC in the OFT is entwined with that
of SHF cells, and both must be considered when examining defects of the outflow
region of the developing heart.
1.3.4 The requirement for endoderm in heart development
The formation of the cardiac crescent is partly due to the responsiveness of
cardiogenic cells to the inductive signals of the adjacent endoderm (Jacobson et. al.
1988) (Reviewed in (Lough et. al. 2000)). Studies in chick have revealed that the
expression of Myocardin in the mesoderm is dependent upon the presence of the
adjacent endoderm (Warkman et. al. 2008). Myocardin is a co-factor for Serum
Response Factor (SRF) - an early marker of cardiogenesis which, together with
Nkx2.5 directs expression of the contractile protein a-cardiac actin (Chen, C Y et. al.
1996; Wang et. al. 2002). In mouse, expression of Gata4 in the endoderm is
essential for cardiogenesis. Gata4 null embryos are unable to form the heart tube,
even though in these embryos myocardial specification can occur, as observed by the
presence of contractile cardiomyocytes (Kuo et. al. 1997). It was subsequently
shown that by enabling expression of Gata4 in the endoderm the cardiac phenotype
could be abrogated (Narita et. al. 1997). In vitro, endoderm is not essential for the
generation of cardiogenic mesoderm, as shown by cardiac gene expression analysis
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(Gannon et. al. 1995). Likewise it is not required for terminal differentiation of
cardiomyocytes prior to formation of the heart. Thus, the requirement for endoderm
in cardiomyocyte differentiation appears to be for a short time-window between
initiation of cardiac gene expression and the onset of contraction.
Molecular signalling from the endoderm also plays a significant role in the
development of the second heart field during the stages of outflow tract cushion
formation and septation. As two examples of factors that act as remote signalling
molecules, Shh and Fg/8 are expressed from the pharyngeal endoderm (PE)
(Crossley et. al. 1995; Echelard et. al. 1993). Both of these signalling factors have
been shown to play important and complex roles in cardiogenesis. Segregation of
these functions has come from conditional inactivation using selected ere
recombinase-drivers, which are expressed in domains overlapping the PE. The
action of Shh and Fgf8 on the second heart field, particularly in the formation of the
OFT is discussed here.
Shh
Germline loss of Shh expression results in extensive embryonic defects including
abnormal development of the RV, ventricular septum and OFT, as well as atrial and
atrioventricular septation defects in the heart (Chiang et. al. 1996; Washington
Smoak et. al. 2005). It is known that loss of Shh expression from the PE causes the
Shh null cardiac defects since aspects of this phenotype can be recapitulated upon
conditional inactivation of Shh in the endoderm using an Nkx2.5-cre driver, whose
expression overlaps with that of Shh only in the endoderm (Goddeeris et. al. 2007).
This finding prompted further study of the cells that respond to Shh signalling, and
the mechanism of Shh action in the heart.
The Ptchl-LacZ reporter was used to examine the effect of loss of Shh in the
endoderm on the cardiac cells which respond to Shh signalling, since Ptchl is also a
Shh target gene. The SHF-derived DMP was found to be affected by ablation of
endodermal Shh (Goddeeris et. al. 2008). The DMP contributes to atrial and AV
septation (Washington Smoak et. al. 2005). Knowing that the Shh responsive cells
were predominantly of SHF origin, SHF responsiveness to Shh was ablated by
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conditional inactivation of Smoothened (Smo), the membrane-bound transducer of
Shh signalling, under the Mef2C-AHF-Cre (Goddeeris et. al. 2008; Verzi et. al.
2005):
It was found that in the absence of Shh signalling, the dorsal mesocardium did not
generate its projection into the atria. Analysis of the migratory potential of dorsal
mesocardium in culture identified that the proportion of migratory cells could be
significantly reduced by treatment with the drug cyclopamine, which inhibits Shh
signalling (Goddeeris et. al. 2008). This provides a mechanism by which Shh
signalling in the SHF can result in septal defects resulting from inhibited migration
of the DM into the heart.
Given that the OFT is composed mostly of SHF-derived cells, it can be hypothesised
that Shh expression is required for second heart field specification and/or maturation.
Conditional inactivation of Smo revealed that responsiveness to Shh signalling is
necessary in the SF1F and NCC (through conditional inactivation of Smo with the
Wntl-cre) of the OFT for septation (Goddeeris et. al. 2007). The most recent
refinement of this understanding of how Shh signalling may be acting in the SHF has
come from studies in chick (Dyer et. al. 2009). Again through use of the Shh
inhibitor cyclopamine, blocking Shh signalling resulted in reduced proliferation of
SHF within the OFT in regions normally responsive to Shh (as indicated by
expression of the Shh target gene Ptc2) (Dyer et. al. 2009).
Fgre
Correct expression of FgfS is also crucial for cardiogenesis and the second heart
field. FgfS is expressed in multiple domains through which it may act on the
developing heart (Crossley et. al. 1995). Expression relevant for cardiogenesis
commences in the mesoderm at the cardiac crescent and subsequently the pharyngeal
endoderm and ectoderm. As constitutive targeted inactivation of FgfS results in
arrest of development at gastrulation (Sun et. al. 1999), thus the understanding of
particular roles of FgfS in cardiogenesis comes from studies of conditional
inactivation and hypomorphs. A series of hypomorphic mutant embryos were
examined for the cardiac phenotype and it was shown that the cardiac defects were
42
variable but included failed OFT septation [persistent truncus arteriosus (PTA)],
atrial septal defects (ASD), ventricular septal defects (VSD) and, in a small
proportion, valve defects (Abu-Issa et. al. 2002). The finding that the OFT was
predominantly affected in Fg/8 mutant embryos suggested that one of the roles of
Fgf8 is to act on the SHF. Comprehensive studies have since been conducted to
explore the requirement of Fg/8 expression on the heart, including conditional
inactivation of the PE expression domain of Fg/8 (Park, E J et. al. 2006).
Isll-cre was used to conditionally remove Fg/8 expression from the pharyngeal
endoderm, however Isll-cre is also expressed in the SE1F (Park, E J et. al. 2006).
Since Fg/8 is initially expressed in early SHF mesoderm, the phenotype of Fg/8
inactivated under the Mef2C-AHF-cre was examined. Only embryos in which Fg/8
was inactivated by Isll-cre demonstrated defective OFT septation. Thus Fg/8
expression in the PE is required by cells within the OFT for septation (Park, E J et.
al. 2006). Whether this requirement for endodermally-derived Fg/8 is specifically
depended on by SHF cells or NCC (or both) has not yet been described.
1.3.5 The septum transversum mesenchyme and the development of
epicardium
The septum transversum mesenchyme (STM) contributes to the development of
several organs during embryogenesis, including the heart and liver. Expression
analysis of Cited2 revealed a domain of expression in the anterior-most embryonic
mesoderm which, in progressive stages, moves posteriorly to the base of the
developing heart, adjacent to the invaginating foregut endoderm (Dunwoodie et. al.
1998). In its final location, this domain of Cited2 expression correlates to the tissue
known as the STM. Hence it is thought that this is the origin of the STM. The pro-
epicardium (also pro-epicardial organ, PEO) originates as mesothelial projections
from the STM. By embryonic day 9 cells have begun to migrate over the adjacent
surface of the developing atrium and ventricle, reaching the anterior cardiac
structures by El 1 (Komiyama et. al. 1987).
Of relevance to heart development, several genes are known to be involved in the
transformation of the STM into the PEO and the subsequent cellular migration.
Functional Gata4 is essential for the formation of the PEO, since conditional ablation
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of Gata4 specifically in the embryonic region (by tetraploid aggregation) results in a
complete absence of the PEO and epicardium (Watt et. al. 2004). The PEO cells
migrate over the heart via essential molecular interactions involving VCAM-1 (Kwee
et. al. 1995) and a4-integrin (Sengbusch et. al. 2002) thus forming the epicardium
((Viragh et. al. 1989); and reviewed in (Manner et. al. 2001)). The earliest cardiac
phenotype examined in mouse, as a consequence of a complete absence of the
epicardium, has been studied in embryos deficient for Gata4 (Watt et. al. 2004). At
E9.5, the myocardium of the presumptive ventricular region is thinner with fewer
developing trabeculae in Gata4' ~ hearts compared with control hearts. Additionally,
Gata4~/~ hearts are unable to undergo adequate looping (Watt et. al. 2004). A later
myocardial phenotype has been demonstrated in chick whereby inhibition of the
PEO outgrowth leads to a decrease in cardiomyocyte proliferation, and thereby
leading to a thinner compact myocardium (Pennisi et. al. 2003). This was
accompanied by an increase in myocardial cell death (Pennisi et. al. 2003). This
phenotype in chick develops into defects of the OFT and septum of the chambers
(Gittenberger-de Groot et. al. 2000).
The epicardium overlies the myocardium as an epithelial sheet. From this stage, they
contribute to cardiogenesis in a number of ways. The PEO and subsequent
epicardium express both Wtl (Moore et. al. 1999) and Tbxl8 (Kraus et. al. 2001a).
Much of the understanding of the roles of epicardium in cardiogenesis has involved
utilising this expression. Wtl knockout mice exhibit cardiac defects including thin
ventricular myocardium (Moore et. al. 1999). In these mice the epicardium is
present but malformed. The El0.5 stage epicardium has been shown to be a source
of retinoic acid and fibroblast growth factor (FGF) signalling (Fgf9, Fgfl6 and
Fgf20) which regulate myocardial proliferation (Lavine et. al. 2005; Stuckmann et.
al. 2003).
Lineage tracing epicardial cells using the Tbxl8-cre/R26R and TbxlS-nLacZ reporter
transgenes has revealed the contribution of epicardial cells to cells of the
cardiomyocyte lineage (Cai et. al. 2008). As early as E9.75, cells which expressed
Tbxl8 have migrated into the heart. By E10.5 cells of the epicardial lineage have
entered the heart and differentiated into cardiomyocytes evident in the developing
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ventricular septum and scattered within the walls of the ventricles and atria (Cai et.
al. 2008). The contribution of IE/7-expressing epicardial cells to the cardiomyocyte
lineage is also evident at E15.5 within the heart (Zhou, B et. al. 2008).
A second wave of entry of epicardial cells into the heart occurs from El2.5 to
contribute to the smooth muscle cells of the coronary vessels through to adult stages
(Cai et. al. 2008). Furthermore, an additional population of endothelial cells which
also originate in the PEO as the early epicardium play a key role in endothelial
development of the coronary vasculature (Lie-Venema et. al. 2005).
The molecular and cellular mechanisms for the formation of the epicardium and its
contribution to the heart are still poorly understood. Thus any genetic deficiencies,
which yield phenotypes similar to those known for epicardial defects, may contribute
to understanding this process.
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1.4 An ENU mutagenesis phenotype-driven screen
identifies recessive mutations on mouse chromosome
13.
1.4.1 Introduction to ENU mouse mutagenesis
Mouse mutagenesis is a powerful tool for modelling human diseases. One approach
is to isolate models that exhibit a particular phenotype using a so-called phenotype-
driven mutagenesis screen. The power of this unbiased approach and its ability to
dissect complex biological systems has been amply demonstrated in a variety of
organisms including zebrafish and the mouse (Baraban et. al. 2007) (Cordes 2005;
Hrabe de Angelis et. al. 2000; Rathkolb et. al. 2000). The success of this approach is
critically dependent on the availability of a highly efficient mutagen. This is
important because the rate of mutagenesis determines how many novel mutations
will be examined for a given number of animals. For example, if a mutagen
introduces 30 mutations per animal then examining 50 animals surveys 150 new
mutations. In the mouse the chemical N-ethyl-N-nitrosourea (ENU) is well-
established as an efficient mutagen suitable for phenotype-driven screens (Barbaric
et. al. 2007; Justice et. al. 1999; Russell et. al. 1979). Through transfer of an ethyl
group to a DNA base, ENU causes mispairing or base substitution during DNA
replication. ENU predominantly affects A/T base pairing in GC-rich regions. The
concentration of mutagen has been optimised (Russell et. al. 1982; Weber et. al.
2000) and although the exact mutation frequency achieved will vary between
experiments the average frequency of mutations in mouse experiments is 1x10" per
locus (Hitotsumachi et. al. 1985). In practice, if we assume that the mouse genome
contains 30,000 genes this translates to a rate of 30 new mutations per animal
surveyed in a phenotype-driven screen.
An additional advantage of ENU is that because it induces point mutations it can lead
to the creation of loss-of-function or gain-of-function mutations. Allelic series can
be created for a gene of interest. A point mutation could affect coding sequence, a
splice site, or a critical base within the promoter or enhancer of a gene. In this way,
ENU can alter protein levels and /or function. Using this approach it is possible to
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garner novel information about gene regulation and function that may otherwise not
be determined by a targeted null mutation.
1.4.2 A region-specific phenotype-driven mutagenesis screen to create mouse
models of human 6p deletion syndromes.
A phenotype-driven screen was conducted to create mouse models with a recessive
mutation in genes in a region of chromosome 13 (Bogani et. al. 2005). The region of
interest on chromosome 13 correlates to human chromosome 6p and thus mutants
identified could potentially be examined as animal models for, and represent, 6p
deletion syndromes. Deletions of chromosome 6p are rare, yet the phenotype is
multifaceted and is characterised broadly by heart and kidney defects and
craniofacial abnormalities (Davies et. al. 1996; DeScipio 2007; Suzuki et. al. 2006),
indicating that the region contains genes required for correct embryonic
development. By creating mouse models with aspects of the abnormalities of 6p
deletion syndrome, it is possible to determine the developmental origin of the
phenotype. This not only generates models which can be used to investigate the
function of individual genes but also allows an investigation of possible gene
interactions, which may underlie aspects of contiguous gene deletion syndromes.
Two mouse lines were essential for this mutagenesis screen (Figure 1.14). Firstly,
the Del(13)Svea36H mouse line, which harbours a chromosomal deletion of 12.7 Mb
across the region of interest on mouse chromosome 13 (Arkell et. al. 2001; Mallon
et. al. 2004). This region is syntenic to the deleted region of human 6p. Secondly,
the Foxqlsa/sa mouse line contains satin allele - a recessive visible marker for coat
appearance (Flong et. al. 2001; Major 1955)(described below, section 1.4.4 and
associated Figure 1.16). Foxql falls within the limits of the Del(l3)Svea36H
chromosomal deletion. Thus it is possible, using a standard two-generation deletion
breeding protocol, to uncover recessive mutations that lie within the deleted region





















Figure 1.14: Genetic crosses conducted in the recessive ENU mutagenesis
screen. Satin mice were mutagenised with ENU, and crossed to BALBc wild-type
mice. G1 progeny, harbouring novel mutations (red asterisk) were crossed to mice
harbouring the Del36SveaH chromosomal deletion. Del36SveaH mice are
hemizygous for a region of chromosome 13, as a result of the chromosomal
deletion. Thus crossing Del36SveaH mice to the G1 progeny, results in mice
hemizygous for satin and the surrounding loci (iv). G2 progeny were either (i) wild-
type, (ii) wild-type carriers of the deletion, (iii) wild-type carriers of the satin allele
and a novel ENU mutation (red asterisk) or (iv) harbouring a novel recessive
mutation linked to satin. Abbreviations: Del, deletion chromosome; sa, satin allele.
Adapted from Willoughby, 2006.
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To perform the genetic screen, Foxqlsa/sa males were treated with ENU and then
crossed to BALB/cOlaHSD females (Figure 1.14). Thirty male offspring (Gl) from
each ENU treated male were paired with females carrying the Del(l3)Svea36H
chromosome. The DeI(13)Svea36H mouse line was utilised such that, in some
offspring, the region of interest would be hemizygous, while the remainder of the
genome is heterozygous. Thus, only a mutation which falls within the limits of the
hemizygous region would result in a recessive phenotype. Nearly two thousand Gl
crosses were completed (n=1730). To identify embryonic lethal mutations, offspring
from the Gl cross (G2) were scored for the appearance of the satin phenotype.
Strains in which less than or equal to one progeny amongst 25 exhibited the satin
coat were presumed to harbour a newly-induced recessive lethal mutation located
within the Del(l3)Svea36H region and were subjected to further breeding and
inheritance testing (Bogani et. al. 2005). Overall 13 lines were found to carry a
heritable mutation and phenotype linked to the satin locus.
1.4.3 Identification of an ENU mutation in Sox4.
Recombination mapping in one of the lines, termed "M91", indicated that the
causative mutation resided within 0.8cM either side of the satin allele. Sox4 was
considered a strong candidate gene, since the recessive lethal phenotype of line M91
phenocopied that published for the targeted allele of Sox4 (Schilham et. al. 1996).
Sequence analysis of Sox4 confirmed that a point mutation had been introduced into
the Sox4 sequence. The mutation was identified as a T to C transition at nucleotide
8962, which results in an amino acid change from a serine to proline at position 70
(Ser70Pro) (Figure 1.15a). Ser70 is a residue in the middle of the first alpha-helix of
the E1MG box of the Sox4 protein. Homozygous mutant embryos of this allele
recapitulate the Sox4 null phenotype at El4.5 (section 1.1.4), and shows septal
defects (VSD) and double outlet right ventricle (DORV) (Bogani et. al. 2005)
(Figure 1.15b).
2
RefSeq accession number NM 009238
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A DNA binding domain Trans-activation domain
HMG □ GRR SRR





Mouse [ KRPMNAFMVWSQIERRKIMEQSPDMHNAEISKRLGKRWKLLKDSDKI PFIQEAERLRLKHMADYPDYKYRPRKKVK
Rat [KRPMNAFMVWSQIERRKIMEQSPDMHNAEISKRLGKRWKLLKD SDKIPFIQEAERLRLKHMADYPDYKYRPRKKVK
Pugu [ KRPMNAFMVWSQIERRKIMEQS PDMHNAE ISKRLGKRWKLLRDSDKI PFIKEAERLRLKHMADYPDYKYRPRKKVK
Ze b rafis h [ KRPMNAFMVWSQI ERRKIMEQS PDMHNAE ISKI LGKRWKLLKD SDKI PFIREAERLRLKHMADYPDYKYRPRKKVK
[ KRPMNAFMVWSQI ERRKIMEQS PDMHNAE ISKRLGKRWKLLKD SDKI PFIREAERLRLKHMADCPDYKYRPRKKVK
| [KRPMNAFMVWPQI ERRKIMEQS PDMHNAEISKRLGKRWKLLKDSDKI PFIQEAERLRLKHMADYPDYKYRPRKKVK
IGT/4
B
Figure 1.15: ENU-induced mutations to Sox4. (A) The ENU-induced serine-70-
proline mutation falls within the HMG domain of Sox4 (Red letter; Line MUD91). An
additional mutation was identified to cause a tyrosine to cysteine substitution (Red
letter; Line IGT/4). There is conservation of these residues between mouse and
other species (human, rat, fugu, zebrafish). (B) The serine-70-proline mutation
results in cardiac defects at E14.5. 3D reconstruction from magnetic resonance
imaging of the heart of a wild-type embryo (left), demonstrates normal septation
and outflow from the ventricles. Homozygous mutant embryo (right) demonstrates
a ventricular septal defect (VSD) and double outlet right ventricle (asterisk).
Abbreviations: Ao, aorta; Ao-A, aortic arch; GRR, glycine rich repeat; HMG, HMG
box domain of Sox4; LV, left ventricle; LVOT, left ventricular outflow tract; PT,
pulmonary trunk; RV, right ventricle; RVOT, right ventricular outflow tract; SRR,
serine rich repeat; VSD, ventricular septal defect. Adapted from Goldsworthy et.al.,











Figure 1.16: Diagram indicating the domains of Foxql and the consequence
of the satin deletion. (A) Satin mice (right), exhibit a glossy coat compared with
wild-type iittermates (left). (B) Foxql demonstrates a winged-helix (WH) DNA
binding domain and other regions of conserved sequence. In satin mutants (sa/sa)
a frameshift occurs from residue 228, as a consequence of a 67bp intergenic
deletion. Adapted from Hong et.al., 2001.
As in any mutagenesis experiment it is possible that a second, unidentified mutation
is responsible for the observed phenotype. Three lines of evidence argue against
this. Firstly, since the identification of the M91 strain the line has been maintained
by continuous outcross to non-mutagenised animals followed by selection of the
Sox4 mutation, this will have the effect of removing the mutagenised genome other
than in the area immediately surrounding Sox4. A second mutation would need to be
linked extremely tightly to Sox4 to persist within the Sox4 mutant animals studied
within this thesis. Secondly, if we assume an average mutagenesis frequency
(lxlO"3) (Flitotsumachi et. al. 1985) and a Poisson distribution (Keays et. al. 2006),
the likelihood of the Del(l3)Svea36H segment containing two mutations is extremely
low (3.8x10"9)(Bogani et. al. 2005). Thirdly, the availability of additional alleles of
Sox4 allows us to conclude the allele isolated in the screen at Del(l3)Svea36H
phenocopies the spectrum of defects seen in the targeted allele of Sox4 (Penzo-
Mendez et. al. 2007; Schilham et. al. 1996; Ya et. al. 1998b), as well as in a second
ENU-induced allele of Sox4, termed "1GT/4" (Goldsworthy et. al. 2008)(Figure
1.15a). Moreover, complementation tests between the two ENU-induced alleles
demonstrate that these both result from mutations in Sox4 (Bogani et. al. 2005;
Goldsworthy et. al. 2008). These three lines of evidence demonstrate that a second,
unidentified mutation causing the phenotypes observed in the M91 strain is
extremely unlikely.
1.4.4 Foxql
Foxql (Forkead box, subclass q, member 1; formerly Hepatocyte nuclear factor-3
homologue 1 or Hfhl) is a member of the family of Forkhead box (Fox)
transcriptional regulators, defined by the presence of the "winged helix" or "forkhead
box" domain, which is responsible for recognising specific DNA target sites
(Clevidence et. al. 1994; Clevidence et. al. 1993). Little is known about the function
of this protein, beyond its DNA binding ability.
Three mutant alleles of Foxql have been created. Previous annotation of the
phenotype caused by mutant alleles of Foxql revealed a disorder in the development
of hair follicles - giving rise to the satin phenotype (Figure 1.16a). The first
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identified allele (the allele used for the mutagenesis screen, section 1.4.2) (Foxqlsa)
harbours a radiation-induced intragenic 67 base-pair deletion of nucleotides 686 to
752 and two additional base substitutions at positions 766 and 7673 (Hong et. al.
2001; Major 1955). The deletion is predicted to alter the protein sequence by
causing a novel translocated frame of 148 amino acids after the winged-helix domain
(Figure 1.16b). A second allele of Foxql (Foxqlsa'eI) was generated by ENU
mutagenesis, which induced a T to G transversion at nucleotide 383 (not shown).
This point mutation results in the replacement of an isoleucine residue by a serine
residue in the winged-helix domain (Hong et. al. 2001). The Foxql null allele was
created and the phenotype examined (Goering et. al. 2008). In addition to the satin
phenotype, it was found that Foxql is involved in gastric physiology and in gastric
acid secretion in the adult. Foxql null adults are otherwise normal.
Little is known about the role of Foxql in embryonic development, since phenotypes
are not described. Only on a specific hybrid genetic background (129/Sv x
C57B1/6J) does the Foxql null reveal an embryonic lethality, which is not fully
penetrant (Goering et. al. 2008). In homozygous crosses of this specific genotype,
approximately 50% of embryos demonstrate abnormal forebrain development at
El0.5 and death at El2.5. Of these crosses, the remaining homozygotes are viable.
The cause of embryonic lethality remains unknown as extraembryonic tissues, as
well as the heart and liver, develop normally. Thus the role of Foxql in development
remains poorly understood.
1.4.5 Purpose for examining the recessive phenotype of Sox4ENU/ENU Foxqls"/s"
embryos.
In human, SOX4 and FOXQ1 are sometimes deleted in cases of 6p deletion
syndrome, making either locus hemizygous. Terminal deletions of 6p have been
found to include the FOXQ1 locus, while interstitial deletions of 6p have been shown
to delete the SOX4 locus (Davies et. al. 1996). Mutations in SOX4 have not been
described for human disease. However, because of its chromosomal location, and
overlap in expression domains with SOX11 in other systems, SOX4 has been
recently proposed as a candidate for human nonsyndromic cleft lip and palate
3 GenBank accession number AF154426. Numbers are from the translation initiation site.
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(Juriloff et. al. 2008). The Sox4ENU Foxqlsa mouse line provides a new means to
study the compound phenotype resulting from disruption to the function of both
genes. Additionally, given the absence of evidence for a role of Foxql in heart
development (with any of the mutant alleles), it is possible to consider a cardiac
phenotype as solely the consequence of the ENU mutation in Sox4.
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1.5 Aims of this Thesis.
Little is known about the developmental requirement for Sox4. It has been shown in
earlier sections of this chapter, that interest in Sox4 is increasing in other biological
systems such as cancer. The ENU mutant allele discussed in the previous section
provides a novel system in which to explore the developmental requirement for Sox4
further and may thereby contribute to the important body of work deciphering the
biological function of Sox4. The fundamental concern of this thesis is to contribute
to the understanding of Sox4 in mouse embryonic development, with a particular
focus on its role in cardiogenesis. This is specifically detailed in the following aims:
1. To analyse aspects of the cardiac phenotype present in
Sox4env FoxqlStt mutant embryos. Here, the aim was to determine
exactly when the mutant phenotype arises during development and at what
point is the mutation lethal; how this phenotype is presented specifically in
cardiac tissue at specific stages of development; and, upon analysis of cardiac
tissue, can the phenotype be related to the expression domains explored in
Aim 2 below. Studies of the cardiac phenotype of the mutant line are
reported in Chapter 3. Also to contribute to this aim, although extending
beyond research examining the cardiac phenotype, Appendix 1 records the
derivation of mouse embryonic stem cells from Sox4ENU/ENU Foxqlsa/sa
homozygous mutant blastocysts, and an examination of mutant ES cell
contribution in chimasric mice.
2. To characterise the expression of Sox4 and Foxql during
mouse embryogenesis by in situ hybridisation. The phenotype of
the line harbouring these mutant alleles is the basis for an examination of the
expression patterns of both Sox4 and Foxql. To achieve this fully with Sox4
and establish the underlying developmental expression, domains must be
explored by in situ hybridisation of both whole and sectioned embryos. This
work is presented in Chapter 4 as a comprehensive account of the
spatiotemporal expression domains of Sox4 and Foxql during mouse
embryogenesis, which extends published accounts of Sox4 and Foxql
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expression by including more developmental stages and greater detail than
that published to date.
3. To examine molecular marker expression in Sox4ENE
Foxqls" compound mutants. Building on aim 1, the phenotype
presented Chapter 3 was further explored using key molecular markers of
heart development. This data is reported Chapter 5.
4. Commence analysis of the phenotype of Sox4ENU/ENU
embryos wild type for Foxql combining methods of analysis
used in Aims (1) and (3). Following an extensive breeding programme,
it was possible to segregate the satin allele from the Sox4ENU mutation.
Chapter 6 describes the homozygous phenotype and mRNA in situ
expression of selected molecular markers in embryos mutant solely for the
Sox4 ENU allele.
The final chapter of this thesis (Chapter 7) provides a summary of the key results
made in this project and a discussion of future directions made possible by the
discoveries presented in the body of the thesis.
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Chapter 2: Materials and Methods
2.1 Materials
2.1.1 Components of buffers and solutions.
General solutions and buffers
Standard solutions were made as described in Sambrook et.al. (Sambrook et. al.
1989). Chemicals were of analytical grade and predominantly were supplied by
Sigma or Invitrogen. Restriction enzymes were purchased from either New England
Biolabs or Roche. Solutions of alcohols and Xylene were purchased from Fisher
Scientific.
For general laboratory use, solutions were prepared using milli-Q water and sterilised
were appropriate. Solutions for use in RNA applications were prepared using
DEPC-treated milli-Q water and autoclaved, with the exceptions of PBS, EDTA and
SSC, which were DEPC-treated directly and autoclaved.
Embryo dissection - solutions and buffers
Embryos were dissected either in 10% FCS - FCS diluted to 10% in PBS, filter
sterilised through a 0.2p filter (Millipore, Billerica, MA, USA); or in M2
(Invitrogen).
In situ hybridisation - solutions and buffers
Hybridisation solution: Hybridisation solution was pre-prepared and frozen at -20 °C.
The solution comprised 50% ultrapure formamide, 5x SSC pH 4.5, 0.1% Triton X-
100, 0.5% CHAPS, 5mM EDTA and made to volume with DEPC-treated water.
Prior to probe addition, 50p.g/ml yeast tRNA and lOOpg/ml heparin were added to
the solution.
PBT: PBS with 0.1% Tween.
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PBTx: PBS with 0.1% Triton X-100.
PFA: 4% paraformaldehyde in PBS.
0.1M TEA: 6.67ml of 7.49M Triethanolamine, make to 450ml with DEPC-treated
dH20, pH to 7.8-8 and adjust volume to 500mL. Store at 4 °C.
TBTX: 50mM TrisCl (pH 7.5), 150mM NaCl, 0.1% Triton X-100.
TBST: TBS with 0.1%Tween
NTMT: lOOmM NaCl, lOOmM Tris.Cl (pH 9.5) 50mM MgCl2 0.1% Tween-20.
RNA extractions
Extraction kits was used for all RNA extractions:
• miniRNA extraction (Qiagen).
• microRNA extraction (Qiagen).
Plasmid DNA extraction
Extraction kits were used for all plasmid DNA extractions:
• miniprep extraction (Qiagen).
• maxiprep extraction (Qiagen).
PCR clean-up
Two kits were utilised for the purification of PCR products depending upon what the
product would next be used for. Alternatively, for most products to be sequenced,
PEG precipitation was carried out (section 2.3.8).
• DNA Clean and Concentrator (Zymo Research, Orange, CA, USA): if the
product was to be subsequently subcloned, or sequenced.
• Gel DNA recovery kit (Zymo Research): if the product was to be subcloned,
or was not the sole amplicon of the PCR.
Tissue culture - solutions and medium
Solutions were prepared depending upon the cell line to be cultivated:
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General ES cell Culture Medium
Serum medium
Solutions were prepared and sterilised, or supplied ready-made by the Institute for
Stem Cell Research (ISCR) tissue culture staff. General ES cell culture medium
comprised Glasgow Minimal Essential Medium (GMEM, Sigma) supplemented with
10% foetal calf serum (Biosera, Ringmer, East Sussex, UK), 0.1% (0.1 mM) MEM
Non-Essential Amino Acids Solution (Invitrogen), 2mM L-glutamine (Invitrogen),
ImM sodium pyruvate (Invitrogen), 0.1 mM 2-mercaptoethanol and lOOU/ml LIF.
Serum-free medium
Serum-free ES cell culture solution was made and supplied by Stem Cell Sciences
UK Ltd. (Cambridge, England, UK).
Freezing Medium
Cells were frozen in 5-10% DMSO in culture medium with 10% serum.
2.1.2 Equipment
Unless otherwise specified, thermocycling was performed in either:
PCR: Gene Amp PCR system 9700 (Applied Biosystems Inc. Foster City, CA,
USA).
qPCR and Light-cycler genotyping PCR: Light cycler 480 (Roche).
2.1.3 Oligonucleotides.
Oligonucleotides were constructed by MWG-Biotech (Eurofins MWG Operon,
Ebersberg, Germany). Primers used for results shown in this thesis are listed in
Table 2.1.
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Table2.1:Listofligonucleotidesequencesdtheirarg tg ,f rr ul sp e t di isi . TargetlocusForwardsequenceReversesequence Satin(genotyping)GAGATCAACGAGT CCTGCGAAGGAGCTGGAGAACTTG Sox4(genotyping)GAGCACTTC GGGGAGATCTCGGCGTTT Sox4lightcyclerampliconGGGACAGCTCGGACTCGGGAGATCTCGGCGTTT Sox4lightcyclera/dacceptor:CTGCGACCACACACTAAAGCdonor:GCTCCATGATCTTGCGCCGCTCG Wnt11CTGCATGAAGAGAAGGTACTGC G TGAAGCT Fzd7TGCAATGTTCTTCAGTTTCTCAGGTAATCTGTCCTCCCGACAATG TgfB2TGGAGTTCAGACACTCAACACAAAGCTTCGGGATTTATG T TBPGGGGAGCTTATA TCCAGGAAATAATTT GC CA
occurred during the night. Pregnant females were sacrificed by cervical dislocation
and embryos dissected. Embryo dissections were conducted in either M2 medium,
DEPC-PBS supplemented with 10% foetal calf serum, and filter sterilised, or DEPC-
PBS. Embryos were staged by the emerging pattern of extraembryonic ectoderm or
the allantois (for 7.5dpc) (Downs et. al. 1993) while later stages were staged by
somite number or the presence of developmental landmarks (limb development, eye
pigmentation etc).
2.2.4 Microdissection
To facilitate comparative gene expression between regions of the heart,
microdissection was carried out. Glass pipettes were pulled above a Bunsen flame
and used to slice tissue, in dissection medium, under a microscope.
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2.3 Molecular Biology Protocols
2.3.1 Primer design
Primers for standard PCR and for the generation of in situ hybridisation probes were
designed using the online programme Primer3 (v0.3.0; Whitehead Institute for
Biomedical Research). Primers for quantitative PCR were designed online using
software of the Universal Probe Library Assay Design Center (Roche Applied
Science, Roche).
2.3.2 Cloning of DNA, Bacterial Cell Transformation and Culture
Probes designed were amplified by PCR from either cDNA from tissue known to
express the gene of interest, or from the appropriate I.M.A.G.E. clone. The
appropriate band was extracted (if it were not the sole band from the PCR) and
ligated into either pTOPO (Invitrogen) or pGEM-Teasy (Promega Corporation,
Madison, WI, USA) vectors, according to company instructions.
Plasmids, obtained from other laboratories, were resuspended from filter paper in
5Ctyd TE or dELO. Samples were quantitated and an appropriate amount was
transformed into bacterial cells.
In all instances, competent TOP 10 cells (Invitrogen) were transformed with ligation
products, or other plasmid constructs, by the heat shock method according to the
manufacturers instructions. Cells were spread on warmed LB-agar plates, containing
the appropriate antibiotic (Ampicillin or Kanamycin) dependent on the plasmid
transformed. Plates were incubated at 37°C to facilitate bacterial growth for a
minimum of 16-18hrs.
To obtain DNA, on average 10 colonies were picked and used to inoculate 3ml LB
broth containing the appropriate antibiotic. Once at the appropriate density, bacterial
broths containing plasmids which required further screening (say, for in situ probe
generation where knowledge of insert orientation was required) were used to streak a
section of an LB-agar/antibiotic plate and the remainder subjected to mini-
preparation according to the manufacturers instructions. Plasmid DNA was screened
for insert orientation by a test restriction digest. Appropriate clones could then be
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grown in larger cultures for maxi-preparation (according to the manufacturers
instructions).
Cultures growing bacteria containing plasmids which did not require screening (say,
plasmids which were obtained from other laboratories or pre-existed in the
laboratory of this candidature) were used to inoculate a larger culture of growth
medium for maxi-preparation the following day.
For each plasmid bacterial cells were archived by freezing in 10% glycerol. Glycerol
stocks were stored at -80°C. If it was required to re-grow the bacteria from glycerol
stocks, a sterile pipette tip was used to stab the frozen cell-solution (without thawing
the glycerol stock), and inoculated in warmed growth media for culture.
2.3.3 Preparation of Nucleic Acids
Plasmid preparation
Bacterial culture growth volume was dependant upon the amount of plasmid
required. Minipreps or maxipreps were performed by use of kits according to the
manufactures instructions (Qiagen).
Genomic DNA preparation for genotyping - from adult mice
Ear tissue samples were digested for 2 hours at 55°C in 400p\ TE SDS and
Proteinase K. DNA was extracted by chloroform/salt treatment and precipitated,
then washed, in ethanol. DNA was resuspended in an appropriate volume of TE.
Genomic DNA preparation for genotyping - from embryos
A small amount of embryo-derived tissue (usually the ectoplacental cone or a portion
of the yolk sac, or amnion) was digested directly in PCR buffer lacking magnesium ,
but supplemented with Proteinase K. Samples were incubated at 55°C for 2 hours
before proteinase K inactivation at 70°C for 10 minutes. Normally, 0.5p\ of digested
tissue was used in a 20pl PCR, although occasionally it was necessary to dilute the
sample further.
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2.3.4 Quantitation of Nucleic Acid
All spectrophotometric quantitation of nucleic acid was performed using a NanoDrop
ND-1000 (NanoDrop technologies/ ThermoScientific Wilmington, DE, USA).
2.3.5 Polymerase Chain Reaction (PCR)
In general, DNA was amplified by PCR in a 20pl volume containing 1.5mM MgCf
(Qiagen); lx PCR buffer (Qiagen), 0.2mM dNTP (Qiagen), ImM of each primer
lunit of Taq DNA polymerase (Qiagen, unless otherwise stated).
Satin Genotyping
The satin allele harbours a 67bp intergenic deletion (Figure 2.1a). Using PCR
primers that flank the deletion embryos/ mice containing the mutant allele can be
genotyped (Bogani et. al. 2005; Willoughby 2006). This produces bands of 388bp
for the wild type and 321bp product for the satin allele. It was necessary to perform
a touch-down PCR for this amplicon. Conditions for this are as follows. 95°C 1 min,
followed by 19 cycles of: 95°C for 10 sec, 65°C 30 sec (-0.5°C per cycle), 72°C for
20 sec. This was followed by 14 cycles of: 95°C for 10 sec, 55°C for 20 sec; 72°C
for 20 sec. A final extension of 10 min was performed at 72°C. To enhance
amplification, the PCR required addition of 1M betaine (Sigma).
Sox4 PCR for Sequence Analysis
The ENU induced point mutation can be amplified for sequence analysis using the
following PCR conditions (Bogani et.al. 2005; Willoughby 2006). 95°C 10 min,
followed by 13 cycles of: 95°C for 30 sec, 59°C 60 sec (-0.5°C per cycle), 72°C for
60 sec. This was followed by 32 cycles of: 95°C for 30 sec, 52°C for 60 sec; 72°C
for 60 sec. A final extension of 5 min was performed at 72°C. In addition, standard
PCR conditions were optimised with 10% DMSO. It was necessary to use Amplitaq
gold (Applied Biosystems) as the polymerase (Figure 2.1b, c).
2.3.6 Genotyping the 5ax4ENU allele using the Roche Light Cycler 480.
ENU usually induces point mutations into the genome. The .Sox4ENU allele harbours
a point mutation making it impossible to genotype by PCR alone. The majority of
genotyping throughout this project relied upon detecting the Foxq]salm intergenic
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deletion - a 67bp difference which could be resolved by PCR across the locus. At
each generation a select number of mice from backcross litters and embryos from
intercross litters were additionally genotyped for the Sox4 ENU allele by sequence
analysis. Part-way through the breeding programme, it was decided that genotyping
should be carried out for both loci. To facilitate this, it was necessary to design a
strategy for use of the Roche light cycler and the 'genotyping master' programme
and reagents (Figure 2.2). Amplification across the mutation produces a product of
220bp. PCR reactions were prepared according to the manufacturers instructions
(Roche Genotyping Master kit), although conditions were optimised with the
addition of 1M betaine (Sigma).
2.3.7 Gel electrophoresis
In order to resolve the 67bp deletion of the Satin mutation, PCR products were run
on an Invitrogen pre-cast E-Base system with a 2% gel. For other applications
separation of DNA fragments generated by PCR or restriction digest, or RNA
following extraction, was carried out by standard agarose gel electrophoresis. Gel
concentration was typically 1-2% w/v agarose with 0.5pg/ml ethidium bromide in
lxTAE running buffer. Samples were diluted in lx loading dye and run at 100V for
an appropriate time. Bands were visualised on a UV transilluminator.
2.3.8 Purifying PCR products - PEG precipitation
An inexpensive and effective method of removing enzymes and nucleotides from a
PCR for sequence analysis is precipitation by polyethylene glycol (PEG). This was
used predominantly for products which required sequencing. PEG precipitation
makes use of a 20% PEG, 2.5M NaCl solution (20g PEG 8000, 14.6g NaCl and
dPBO to 90 ml, shake; leave 20+ min at 37°C to allow the PEG to go into solution,
then make up mixture to 100ml). In a 1.5ml eppendorf tube, combine each PCR
solution and an equal volume of PEG/salt, then incubate for 15 minutes at 37°C.
Centrifuge the solution at maximum speed for 15 minutes to pellet the precipitate
then discard the solution. Wash the pellet with 125pl 80% EtOH, centrifuge at
maximum speed for 2 minutes, after which discard the supernatant and re-wash,
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before leaving the pellet to dry. Resuspend the DNA PCR pellet in dH20 at a
volume half of the original PCR solution.
2.3.9 Sequencing
Purified PCR products were submitted for automated sequence analysis by the
University of Edinburgh's School of Biological Sciences Sequencing Service. For
this, 8ng of DNA in 5ql was combined with lpl of 3.2pmol uni-direction primer.
Sequencing reactions were carried out according to the manufacturers specifications,
using the ABI PRISM Big-dye terminator premix sequencing kit (Perkin-Elmer
Waltham, MA, USA). Samples were subject to sequencing thermocycling then run
on an ABI sequencer (Applied Biosystems).
2.3.10 Restriction enzyme digest
Restriction enzyme and buffers (NEB Inc. or Roche), were used to carry out
restriction enzyme digests on plasmid DNA prior to the creation of in situ probes
(Table 2.2) according to the manufacturer's instructions. Digests were incubated at
37°C or another temperature if specified. Incubations were carried out for 2 hours or
overnight, and then electrophoresis was performed to verify complete digest.
2.3.11 RNA Extraction and Analysis
RNA Extraction and Quantitation
For the purpose of expression analysis RNA was extracted from tissue of interest.
Two kits were utilised for this purpose. For general RNA extraction (ES cells or
tissue with relatively large cell number), a miniRNA (Qiagen) kit was used. In cases
of extraction from tissue of small sample size (for example, outflow tracts of the
heart), a microRNA (Qiagen) kit was used. In both cases, the manufacturers
instructions were followed.
Reverse Transcriptase - PCR
To enable determination of RNA expression, RNA was reverse transcribed. For this,
the Superscript III Reverse Transcriptase kit (Invitrogen) was used. Reactions were
set up and procedure carried out according to the manufacturers instructions.
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Quantitative PCR
To examine the gene expression in micro-dissected outflow tracts. The Roche Light-
cycler PCR machine was used in conjunction with the Light cycler 480 Probes
master kit solutions and probes (Roche). For the purpose of determining gene
expression of Wntll, Fzd7 and Tgfb2, as well as the Tbp internal control, probe
numbers 96, 20, 73 and 97 (respectively) were used. Primers (Table 2.1) were used
at a concentration of 1 uM; probes were used at a concentration of 0.1 uM. Standard
curves were created using wild type cDNA as template. Samples were prepared and
run with reagents in conditions according to the manufacturers instruction.
67
Wild type Heterozygous mutant Homozygous mutant
Figure 2.1: Genotyping assays for DNA from mice and embryos
harbouring the Foxql satin deletion and the Sox 4 ENU mutation.
(A) Image of a 2% agarose gel following electrophoresis of the Foxql wild
type and satin amplicons, demonstrating the 67bp intergenic deletion; (B)
Image of an agarose gel following electrophoresis of the Sox4 amplicon
which, for genotyping required sequencing (C) Sequence traces of Sox4
amplified from mice wild type, heterozygous and homozygous for the ENU









60 65 70 75
Temperature (°C)
Figure 2.2: Method for use of the Roche Light Cycler 480 for mutation
analysis of the Sox4 allele.
(A) Amplification around the ENU point mutation produces a product of 220bp.
PGR was optimized with 1M betaine and 0.5mM primers; (B) Following the PCR
programme, products were subjected to a melt curve programme by denaturation at
95°C, then annealing at 60°C, 50°C and 40°C of the probes. The 22bp sensor probe
[S] was 5' labelled with Cy5 and a 3' phosphatase, the 23bp anchor probe [A] was
labelled at the 3' end with fluorescein. Annealed probes and amplicons were melted
to 95°C with continuous acquisitions of fluorescence at 670nm; (C) Melting
temperature of amplicons for the alleles of Sox4. The wild type allele melts at 66-
67°C and the ENU mutant peak at 70-71°C. Wild type peak is yellow, heterozygous
peaks are pink and homozygous peak is blue.
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2.4 Whole mount in situ hybridisation (WMISH)
2.4.1 In situ hybridisation probes.
Plasmids containing probe sequences for in situ hybridisation were sourced from
various laboratories if not already existing in a laboratory at the ISCR (Table 2.2).
The expression profile of Sox4 and Foxql transcripts (Chapter 4) were detected using
in situ hybridisation. Since Sox4 expression was relatively widespread, alterations to
the stringency of the post-hybridisation washes were made to examine which tissues
demonstrate the highest gene expression.
Two probes were used to analyse Sox4 expression. Initially, a probe comprising
bases 516 to 2031 (coding sequence bases 662 to 1984, 146bp 5' UTR, 47bp 3'UTR)
demonstrated a complex expression pattern, readily appearing in most tissues
analysed. To determine whether this probe, which included the HMG box,
specifically detected Sox4 expression, a second probe was constructed to recognise
535bp of the 5' untranslated region (UTR) - bases 144 to 678. Primers spanning the
region were designed using the online programme Primer3 (v0.4.0; Whitehead
Institute for Biomedical Research). This second probe yielded the same expression
pattern as the original Sox4 probe and ruled out the possibility that the HMG
homology resulted in detection of other Sox genes. To examine whether expression,
detected by the probe, was due to non-specific binding, embryos were overstained
with sense (control) and antisense Sox4 probes in parallel. Neither the full-length
(Figure 2.3) nor the short 5'UTR sense probe (Figure 4.4a) produced a signal.
In order to document Foxql expression for mouse embryogenesis, it was necessary
to design and generate an in situ probe. Again the programme Primer3 was used to
design primers flanking a 208bp sequence comprising bases 495-683 of the 5'UTR
of Foxql (NM_008239.4). The Foxql sense probe did not produce a signal when
treated in parallel to embryos hybridised to the anti-sense probe (Figure 4.12c).
The primers used to amplify the sequences for the Foxql and Sox4 (5'UTR) probes
are shown in Table 2.2.
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2.4.2 Probe generation directly from PCR
For generation of new antisense probes by PCR amplification, a T7 polymerase site
(ATATATTAATACGACTCACTATAGG) was incorporated directly to the 5' end
of the reverse complemented reverse primer. To generate the control sense probe,
the T7 recognition sequence is placed on the forward primer. PCR products were gel
checked, band extracted and then subcloned and sequenced for future use.
2.4.3 Preparation of plasmid for probe synthesis
Plasmid was linearised as described (section 2.3.10) and gel checked to ensure
complete digestion. If digestion was incomplete, the digested band was gel extracted
as described (section 2.3.8). Addition of 40 pi RNase-free 3M sodium acetate,
DEPC water to the volume of 500 pi and an equal volume of phenol-chloroform-
isoamylalcohol (ratio 25:24:1), enabled DNA purification. DNA was precipitated in
ethanol, resuspended in 50pl and quantitated.
2.4.4 Digoxigenin (DIG) labeled RNA probe synthesis
In situ probes were generated using, predominantly, reagents from Roche. 1 pg
plasmid was made to 12.5 pi, or 12.5 pi of purified PCR product, was combined with
2 pi lOx transcription buffer, 2 pi lOx DIG, 1.5 pi RNase inhibitor and 1 pi of the
appropriate RNA polymerase. Reactions were incubated for lhr at 37°C, an
additional 1 pi of polymerase was added and then incubated for another hour. Probe
RNA was DNAse treated with DNase (Promega) in the presence of lOx buffer,
according to the manufacturers instructions. Usually, probe RNA was then purified
as follows: Samples were diluted to 50pl with DEPC-treated milliQ water. 5pi of
RNase-free 3M NaOAc was added, followed by 2.5x volume of RNase-free 100%
ethanol. To precipitate, samples were incubated at -20°C for 30 minutes and then
pelleted in a refrigerated microfuge for 10 minutes. Pellets were washed twice with
RNase-free 70% ethanol to remove unincorporated nucleotides.
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Figure 2.3: In situ hybridisation with sense transcripts of the full-length
Sox4 probe does not produce a signal.
(A) A wild-type 9.5dpc embryo subjected to in situ hybridisation with the
sense probe of full-length Sox4. With the exception of the probe
hybridisation, the embryo in (A) was treated in the same solutions throughout
the procedure as that of the antisense full length probe in (B); (B)
Overstained (24 hours) antisense probe.
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2.4.5 Wholemount in situ hybridisation on mouse embryos
The wholemount in situ hybridisation protocol used successfully for the in situ
results presented in this thesis was described extensively in (Christiansen et. al.
1995) and later published separately in (Hargrave et. al. 2006). It is based on the
Wilkinson protocol (Wilkinson 1992). Embryo powder was not used.
Variation to the protocolfor some Sox4 in situ hybridisation
In each of the documented in situ images, it is important to note that variation in the
time of developing altered signal intensity. Additionally a modification in this
protocol was made to increase the stringency of probe-transcript binding. To
examine levels of Sox4 expression the concentration of CHAPS in the hybridisation
step and post-hybridisation washes was increased by a factor of 10.
2.4.6 Section in situ hybridisation on mouse embryos
Sections of embryonic tissue were prepared on slides as described (section 2.6.1).
All steps were conducted in glass staining dishes unless otherwise stated, with slides
moved on a metal rack. All equipment was baked overnight prior to use.
Preparation ofslides for hybridisation
Slides were de-waxed in two lOmin. changes of Xylene, and rehydrated through an
Ethanol series to PBS. Tissue was treated for 20-35 min. (depending on age of
embryo) in a solution of 10 ug/ml proteinase K in PBS at 37 °C. Slides were rinsed
in PBS and immediately re-fixed in 4% PFA for lOmin. Slides were rinsed
thoroughly in PBS and then acetylated for 10 min. in a solution of 0.1M
Triethanolamine/0.25% acetic anhydride. Slides were washed through several
changes of PBS, then dehydrated through an ethanol series and dried for up to lhr.
Probe hybridisation
Probes were denatured in hybridisation solution as for wholemount in situ
hybridisation, then made to a volume of 200pl with pre-warmed hybridisation
solution. An incubation chamber was prepared. This was a pipette tip box,
humidified with a paper towel in the bottom chamber soaked in a formamide/SSC
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solution to the same proportions as in the hybridisation buffer (but using less pure
formamide and non-DEPC-treated SSC). Three slides were placed in each box,
elevated above the paper towel. Probe solution was applied to each slide and a piece
of parafdm cut to the dimensions of the slide, was placed over each slide. Slides
were incubated from 55-65 °C overnight.
Post-hybridisation
Slides were washed in a decreasing concentration of SSC (5x, 2x, 0.2x) then washed
several times in TBST. Slides were placed in a humidified (with TBST) incubation
box for subsequent blocking and antibody steps. Tissue was blocked in lx blocking
reagent (Roche) for at least lhr at room temperature. Anti-DIG antibody was applied
at a concentration of 1/2000, diluted in TBST with lx blocking reagent. Antibody
incubation was performed for at least 2hrs at room temperature, but in most cases
overnight at 4 °C. Slides were subsequently washed in several changes of TBST,
with the last two changes also containing 2mM Levamisole. Slides were washed in
NTMT with 2mM Levamisole, before being placed back in the incubation chamber.
Detection ofsignal and slide processing
Slides were incubated with BM purple (Roche) at room temperature during the day,
then 4 °C overnight, until adequate signal had developed. Slides were washed in
PBSTx (ImM EDTA), then dH20 prior to dehydration in 70% and 100% Ethanol
solutions. Slides were treated in Xylene and mounted with DePeX mounting media
(BDH/ VWR international, LLC. West Chester, PA, USA).
2.5 Detection of apoptosis
Wholemount TUNEL was performed using the ApopTag In Situ Apoptosis detection
kit (Chemicon/ Millipore, Billerica, MA, USA). Embryos were dissected as
described (section 2.2) fixed in PFA and dehydrated in a MeOH/PBT series to 100%
MeOH. If embryos were visible, the following steps were performed in 2ml snap-
lock tubes with as much solution as possible. Embryos were permeabilised by
rehydration to PBT and incubated in proteinaseK (at lOug/ml) for an appropriate
time. Embryos were washed in 2mg/ml glycine/PBT for 2 minutes and then
subjected to further washes in PBT. Embryos were post-fixed in 4%PFA for 20
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minutes at room temperature and then further washed in PBT five times. Embryos
were further fixed in prechilled ethanohacetic acid (mixed in a ratio of 2:1) on ice,
for 10 minutes and then washed three times in PBT. For terminal transferase
reaction, the procedure is as follows: Embryos were incubated for one hour at room
temperature in equilibration buffer, then the solution was replaced with working
strength TdT enzyme, with sufficient liquid to cover the embryos. Working strength
TdT was prepared by a 2:1 ratio of reaction buffer and TdT enzyme with tritonX-100
to a final concentration of 0.3%. Embryos were incubated at 37°C overnight. The
following morning the reaction was stopped by washing several times over 3 hours at
37°C in working strength stop/wash buffer (1:17 with distilled water) followed by a
final wash thrice in PBT. Embryos were blocked in 2mg/ml BSA, 5% sheep serum
in PBT for a minimum of one hour. Antibody solution was prepared as for
wholemount 1SH, (section 2.4) with 1/2000 anti-digoxygenin AP-conjugated Fab
fragments (Roche) in PBT with 1% sheep serum and 2mg/ml BSA. Antibody
solution replaced blocking solution and embryos were incubated for a minimum of
two hours at room temperature or overnight at 4°C. Embryos were washed several
times the following day with an overnight wash in PBT supplemented with 2mg/ml
BSA. Detection of labelled tissue was by equilibrating the embryos in fresh NTMT
and then incubating in NBT/BCIP (Roche) according to the manufacturers
instructions. Stain was visible from 5 minutes and stopped shortly after depending
on intensity, by washing in PBT. Embryos were fixed in 4%PFA for 30 minutes,
washed in PBT and photographed immediately.
2.6 Histology
The majority of histology procedures for this project were carried out by Mr Ron
Wilkie (ISCR Histology Department).
2.6.1 Wax embedding and microtome sectioning
Embryos or tissue regions were dehydrated through an ethanol series (70%, 80%,
90%, 95%, 100%) then cleared in 100% xylene. Using a plastic pipette, embryos
were transferred to pre-prepared molten wax in glass embryo cups at 65°C.
Depending on the size of the embryo, the wax was twice changed after an
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appropriate time. Embryos were orientated under a microscope as the wax solidified.
Wax blocks were mounted on microtome cassettes and sectioned at 7pm intervals.
Sections were floated in a water bath at 37°C and collected onto gelatinised slides.
Sections were dried overnight at 37°C prior to further staining. For cutting sections
for use in section in situ hybridisation, embryos were dehydrated in ethanol solutions
made with DEPC-treated dEEO. Water bath water was DEPC-treated; slides were
washed in DEPC-treated dfEO prior to collecting sections. Collected sections were
dried overnight in an oven at 42 °C and stored at room temperature prior to RNA in
situ hybridisation (section 2.4.6).
2.6.2 Haematoxylin and Eosin staining
To characterise tissue morphology, embryos which had been wax-sectioned were
subjected to staining with haematoxylin and eosin. Sections were de-waxed through
two 5 minute xylene washes and rehydrated in 2 minutes each of a decreasing
ethanol series (90%, 70%, 50%, 30%) and washed in running tap water for 2
minutes. For optimal colour staining, sections were stained in a haematoxylin
solution for 2 minutes washed in tap water and stained in 0.5% eosin for 15 sec.
Slides were transferred quickly to 70% EtOEI and then to 100% EtOH. Slides were
incubated in two consecutive xylene washes, each for 5 minutes, and then mounted
using DPX and coverslipped.
2.6.3 Gelatin embedding and cryostat sectioning
Embryos demonstrating in situ stain were sectioned by a cryostat. Treated embryos
were returned to a PBS solution, then placed into 7.5% sucrose/PBS for incubation
at 4°C from 30 minutes to overnight depending upon embryo size. The solution was
then changed to a 15% solution of sucrose/gelatin. Embryos were incubated in this
solution at 37°C until the solution had fully penetrated the embryo and the embryo
had sunk in the tube. Embryos were orientated and set in this solution, then frozen in
liquid nitrogen. Sections were cut to 8pm thickness using a Leica CM 1900 cryostat
(Leica Microsystems, Wetzlar, Germany), mounted onto charged slides and
coverslipped using an aqueous mounting solution.
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2.7 Cell Culture
2.7.1 Derivation of mouse ES cells
ES cell derivation, under serum-free conditions was performed as published in
(Nichols et. al. 2006), using serum-free medium (Stem Cell Sciences Inc.).
2.7.2 General Culture of mouse ES cells
Derived ES cells were plated on gelatinised plates or flasks and passaged when they
reached confluency. For passaging, cells were rinsed in PBS (culture grade,
Invitrogen), treated with 0.1% Trypsin and incubated at 37°C for a few minutes.
Once detached from the flask, culture medium was added to the cells and the
solution of cells was transferred into a tube for centrifugation. Cells were gently
pelleted (3 min 300 rcf) and then re-suspended for plating into a pre-equilibrated
gelatinised flask. Cells were maintained in culture at 37°C under 7% CO2.
2.8 Generation of Chimeric Mice
Derived ES cells were injected into C57BL/6J blastocysts and transferred into
recipient psuedopregnant mice by the ISCR transgenic facility. Transgenic pups
were born and assessed for ES cell contribution by coat colour.
Adult mouse tissue contribution by ES cells was determined as follows: Tissue was
harvested from organs (see below) and DNA extracted (Section 2.3.3). Tissue was
genotyped by PCR for the satin allele (Section 2.3.5). By reducing the PCR cycle
number by 10 cycles, the PCR was able to be interpretated as semi-quantitative.
Tissue examined: gut, eye, tongue, brain, ovary, telencephalic lobes, thymus, lung,
thyroid, diaphragm, tail, skin, skull, spleen, pancreas, kidney, liver, skeletal muscle,
femur bone, bone marrow, atria, interventricular septum, ventricle.
2.9 Microscopy
A Zeiss Stemi SV11 microscope (Carl Zeiss, Welwyn Garden City, UK) with bright
field optics, fitted with Zeiss achromat objectives and a Coolsnap-c/ camera
(Photometries Ltd, Tucson, AZ, USA), was used for some whole mount embryo
imaging, photography of in situ cryo-sections and some photography of
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Haematoxylin and eosin stained section (figures 3.9 and 3.10). Images were
captured using Open lab software (Improvision/ PerkinElmer, Coventry, UK).
An Olympus 1X51 (Olympus, Essex, UK), fitted with UplanFLN objectives and a
Qlmaging camera (Qlmaging, Burnaby, BC, Canada) was used to image ES cells in
culture. Images were captured using QCapture software (Qlmaging).
A Nikon AZ100 macroscope (Nikon UK Ltd, Kingston-on-Thames, UK) fitted with
0.5x, lx, 2x, 4x and 5x objectives and a Qimaging Micropublisher 5 cooled colour
camera (Qlmaging) was used to image some wholemount in situ staining of embryos
and some section in situ staining by placing slides on an agarose-filled petridish,
inverted on a white page for minimising background shadow. Image capture was
performed using IPLab Spectrum (Scanalytics Corp, Fairfax, VA).
A Zeiss Axioplan II fluorescence microscope with Plan-neofluar or Plan Apochromat
objectives (Carl Zeiss, Welwyn Garden City, UK) and a Qimaging Micropublisher
3.3mp cooled colour CCD camera (Qlmaging) was used to image most haematoxylin
and eosin stained sections and section in situ slides. Images were captured using in-
house scripts (MRC, HGU) written for IPLab Spectrum software.
2.10 Image Analysis
All images were processed in Adobe Photoshop CS3 (Adobe Systems Inc., San Jose,
CA, USA). Scale-bars are demonstrated where necessary. Determining the size of
scale bars was achieved by photographing a microscale rule and calibrating the
OpenLab or IPLab software to interpret length in place of pixels.
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Chapter 3: Analysis of the Sox4enu
Foxq1sa Phenotype.
3.1 Introduction
The Sox4 transcription factor has been shown to be critical for embryonic
development, since the null mutation in Sox4 causes lethality by El3. Embryonic
death in homozygous nulls has been attributed to heart defects and oedema (section
1.1.4) (Penzo-Mendez et. al. 2007; Schilham et. al. 1996). A novel mutant allele of
Sox4 (termed M91 and hereafter referred to as this in the context of the work by
Bogani et.al., prior to the allele being used for this work) was identified from a
phenotype driven recessive ENU mutagenesis screen (Bogani et. al. 2005). This
allele carries a point mutation predicted to alter the protein sequence of the highly
conserved HMG box domain of Sox4 (section 1.4.3). Given that ENU-induced
mutations can produce alleles of different severity and function, this allele may
enable further characterisation of Sox4, beyond that determined from the published
null alleles.
Initial observations of the M91 embryonic phenotype were carried out during
screening of the ENU line (Bogani et. al. 2005). The heterozygous mouse line
carried mutations in Sox4 and Foxql, and was maintained on a mixed C3H/HeH and
101/HeH background. Crossing this line to mice heterozygous for the
Del(l3)Svea36H deletion produced embryos hemizygous for the Sox4 and Foxql
mutant alleles. Crosses to yield homozygous embryos of this allele generated the
same embryonic phenotype as the crosses to Del(13)Svea36H. An additional ENU
mutation in Sox4 was identified in a parallel mutagenesis screen (with non-satin
males chemically mutagenised). Genetic crosses were carried out between
heterozygotes of each Sox4 allele (Dr. Ruth Arkell pers.comm.). Compound
heterozygous mutant embryos from these crosses, revealed the same embryonic
phenotype as that described for homozygotes for either ENU-induced Sox4 mutant
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allele (Bogani et. al. 2005; Goldsworthy et. al. 2008). This, and other lines of
evidence discussed in Chapter 1 (section 1.4.3) indicate that mutation in Sox4 is
responsible for the cardiac phenotype observed.
At E14.5, M91 Sox4 mutant embryos demonstrated significant overlap with the
published null phenotype (Bogani et. al. 2005 compared with Schilham et. al. 1996
and Ya et. al. 1998b). The published phenotypic outcome of targeted germline
inactivation of Sox4 includes both OFT defects and VSD at E14 (Schilham et. al.
1996; Ya et. al. 1998b). The phenotype is described at El3.5 in the analysis of the
conditional Sox4 null allele (Penzo-Mendez et. al. 2007). This was observed at
El4.5 in an M91 mutant by magnetic resonance imaging (MR1). The M91 mutant
published by Bogani et.al. also shows an atrial septal defect in the primary atrial
septum, a common atrioventricular junction and a dysplastic mitral valve at E14.5
(Bogani et.al. 2005), which have not been described from the histological analysis of
nine E14 or eight E13 Sox4 null embryos examined by Ya et.al. (Ya et. al. 1998b).
Whether this additional atrial and atrioventricular phenotype is a fully penetrant
phenotype in the M91 line is unclear. If the atrial and atrioventricular phenotypes
are a consequence of the Sox4EAU allele, then this suggests an additional function of
the ENU allele of Sox4 not uncovered by complete gene inactivation. However it
remains possible that differences in genetic background may modulate the phenotype
of the Sox4 null and Sox4ENU alleles. To determine whether this is the case would
require a parallel study of these alleles on the same genetic background.
Formation of the heart commences at the late head-fold stage six days prior to the
published Sox4 phenotype. Earlier still, patterning of cardiac progenitors occurs
during gastrulation. The cardiac phenotype of the conditional Sox4 null allele was
examined at E13.5 (Penzo-Mendez et. al. 2007). The Sox4 null allele was examined
at E12-E14 (4xED12, 8x ED 13, 9xED14) (Ya et. al. 1998b). Schilham et.al. had
previously reported that a macroscopic phenotype was not observed at El3, yet Sox4
null embryos rapidly develop a macroscopic phenotype and are dead (or dying) by
E14 (Schilham et. al. 1996). At E12-E14, it was observed that Sox4 null mutant
embryo constitute only 18-20% of embryos dissected, instead of the expected
Mendelian ratio of 25% [Materials and Methods in (Ya et. al. 1998b)]. Bogani et.al.
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show that the M91 mutation results in a final embryonic lethal time-point which is
the same as that of the null (mutants dead or dying during El4) (Bogani et.al. 2005).
At El5.5, in the same series of genetic crosses, all hemizygote mutant embryos
(n=25) were dead (compared, with dead or dying during El4), and comprised 16% of
embryos dissected at this stage (Dr Ruth Arkell pers.comm). This finding, together
with the percentage of mutant embryos in the data provided by Ya et.al. suggests that
Sox4 mutations result in lethality earlier than El4. These observations prompted the
present study of earlier embryonic stages to examine the timing of lethality and
whether an uncharacterised Sox4 homozygous phenotype exists, forming the basis of
this chapter of my thesis, with the aim: To conduct detailed wholemount and
histological section analysis of the cardiac defects present in Sox4ENU/ENU Foxqlsa/s"
mutant embryos.
Homozygotes have been examined from E7.5 to the starting point of the known
lethality (El3.5). Since the ENU mutagenesis screen was carried out on mice that
harboured the satin allele of Foxql, this study also provides an opportunity to
examine whether an extra-cardiac Sox4 phenotype is modulated by the satin
mutation in Foxql (and equally, whether the satin phenotype is altered by the
mutation in Sox4, as the satin phenotype is well characterised). Given that the null
allele of Foxql does not demonstrate cardiac dysmorphologies (Goering et. al.
2008), it is unlikely that the satin allele plays a role in cardiogenesis (section 1.4.4).
This, and the genetic crosses described (section 1.4.3), implies that the abnormal
cardiac phenotype in these embryos is a consequence of the mutation in Sox4.
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3.2 Results
To explore the phenotype of the Sox4ENU allele, the M91 mouse line (as published in
Bogani et.al.) was imported into the ISCR animal unit and backcrossed to C57B1/6J.
Subsequent generations of mice were intercrossed to characterise the homozygous
phenotype on this background.
3.2.1 Homozygosity of the Sox4 NU allele causes cardiac abnormalities in E12.5
and E13.5 embryos on a C57B1/6J background.
One of the first points of investigation was to examine the phenotype of the
Sox4enu/enu Foxqlsa/sa embryos. This intent was twofold: (1) to examine the E12.5
and El3.5 phenotype of the Sox4 ENU mutation since published information was
limited to El4.5 (Bogani et. al. 2005) and (2) to compare this with the cardiac
phenotype of the Sox4 null (Schilham et. al. 1996; Ya et. al. 1998b).
Upon dissection, mutant embryos could be visually distinguished from unaffected
siblings. At E12.5 and E13.5 embryos showed oedema and haemorrhaging (E12.5
not shown; E13.5 Figure 3.1b, c), in contrast to the morphologically normal stage-
matched control embryo (E12.5 not shown; E13.5 Figure 3.1a). This was verified by
section analysis to reveal the severity of the oedema, both immediately below the
body wall and around internal structures (E12.5 not shown; Figure 3.1e, f, compared
to control, d). Haemorrhaging and oedema are indicative of a lowering of vascular
integrity and increased pressure on vascular endothelial cells as a consequence of
cardiac deficiency and inadequate movement of fluid. Oedema was identified as part
of the phenotype of Sox4 null homozygosity, thus this is the first visible overlap in
phenotype of the Sox4E*b allele with that of the null allele.
Embryos staged E12.5-13.5 and homozygous for both Sox4 and Foxql mutant alleles
were examined by sectioning and staining with haematoxylin and eosin. Sections
through cardiac tissue revealed that all mutant embryos examined at these two stages
exhibit a number of abnormalities within the heart (Table 3.1). Outflow tract
anomalies include early evidence for incomplete septation between the pulmonary
trunk and aorta below but not above the developing endocardial ridges at E12.5. At
E13.5, this phenotype is more notable with persistent truncus arteriosus (PTA) being
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present at or below the developing semi-lunar valves. In the control E13.5 heart, the
outflow septation is complete, while El3.5 mutants also demonstrate double outlet
right ventricle (DORV). Sectioning through the interventricular septum in mutant
embryos showed incomplete ventricular septum formation. Although the septum
was not fully closed in the control hearts, in mutant hearts the interventricular
foramen was more prominent. Mutants also showed abnormal atrioventricular valve
(AW) morphogenesis. In most embryos, evidence for valve development could be
observed on both the left and right sides of the atrioventricular septal mesenchyme,
in the regions which will develop into the mitral and tricuspid valves. In one of four
El2.5 embryos and one of two El3.5 it could not be determined from the sections
whether the heart had both right and left sided valve development (Table 3.1).
Subsequent figures reveal aspects of the phenotypes in more detail.
Defective septation in mutant embryos was evident at or below the endocardial
ridges at E12.5 and El 3.5. At E12.5 development of the septum was not obvious in
mutants (Figure 3.2f, j, compared with control b). The endocardial ridges developing
in both the pulmonary trunk and aorta appeared smaller in mutants than wild type
(Figure 3.2g, k, compared with control b and c). At E13.5 development of the semi¬
lunar valves from the endocardial ridges appeared delayed (and therefore are termed
'ridges', not 'valves') (Figure 3.3f, g, k, 1 compared with control a, b, c). Although it
was not possible to conclude from these sections whether valve development would
occur in a correct manner such that the development of the valve leaflets occurs
normally with respect to both position and leaflet number.
At El2.5, the developing OFT cushions at the boundary with the right ventricle also
appeared reduced in size, and furthermore did not appear to make contact across the
lumen (bracket Figure 3.2h and 1, compared with control d). Outflow tract defects
were more prominent in embryos staged El3.5. At or below the appearance of the
endocardial ridges, it was evident that septation had not proceeded. The lumen of the
aorta was open to the pulmonary tract in both mutant embryos (Figure 3.3f, g, j, k,
compared with control b, c). PTA was accompanied by DORV as the common trunk
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ascended from the right ventricle (Figure 3.3h and 1, compared with control d).
These defects of the outflow tract further reflect aspects of the cardiac phenotype of
the Sox4 null allele (Ya et. al. 1998b).
At the anterior-most region of the outflow tract, at both El2.5 and El3.5 it was
observed that the pulmonary trunk and aorta were septated above the endocardial
ridges (El2.5 control and mutant embryos and El3.5 mutant embryos) and
developing semi-lunar valves (El3.5 control embryos) of the pulmonary trunk in all
hearts examined (E12.5, Figure 3.2a, e, i; and E13.5, Figure 3.3a, e, i).
Deviating from the phenotype described by Ya et.al. in their publication of the Sox4
null allele, the Sox4EElJ allele also demonstrates abnormal development of the
atrioventricular septum mesenchyme and associated tricuspid and mitral valves. One
of the more prominent defects was inadequate formation of the atrioventricular
septum and developing atrioventricular valves (AW) at El2.5 and El3.5.
Development of these structures is disrupted with the mesenchyme of the developing
valves appearing malformed at both E12.5 (Figure 3.4e-g and i-k, compared with
control a-c) and El3.5 (Figure 3.5 d-f and g-i compared with control a-c). Whilst
formation of both left and right atrioventricular valves is evident to a certain degree,
in some sections it appears that there is a common atrioventricular valve between the
right atrium or common atrium and both ventricles. This was particularly
pronounced in the more severely affected El3.5 embryo in which atrial septation was
considerably delayed (Figure 3.5e). It is possible that this phenotype is partially a
consequence of the developmental delay observed in this mutant line. If the sections
from one of the two El3.5 mutants (Figure 3.5g h and i) are compared with the
control sections for E12.5 (Figure 3.4a, b and c) the development of the muscular
ventricular septum appears to be a similar. The development of the tricuspid and
mitral valves also appears more closely matched between the El3.5 mutant and the
El2.5 control hearts.
Septation and valve formation in the OFT are disrupted in embryos with defective
cardiac neural crest migration (Kirby, M. L. 1990; Nishibatake et. al. 1987). The
published Sox4 null phenotype was initially attributed to a neural crest deficiency
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(Schilham et. a/. 1996). However the Sox4ENU/ENU Foxqlsasu phenotype possibly
extends beyond that attributable to NCC, since it was also observed that mutants
demonstrated defects of atrioventricular septation and atrioventricular valve
formation. Analysis of contribution of the NCC lineage to the AW is ambiguous
(section 1.3.3) and furthermore, the requirement for NCC in the development of
these structures is unknown. Thus it is possible that Sox4 plays two roles in cardiac
development - one in the region of NCC infiltration, to contribute to OFT septation
and the second in the atrioventricular cushions, to contribute to their appropriate
morphogenesis.
In Sox4 mutants, atrial septation is inadequate for E12.5 and E13.5, although it is not
clear from these sections whether septation is delayed and thus incomplete, or
arrested. At both El2.5 (Figure 3.6) and El3.5 (Figure 3.7) variable septation of the
atria is observed. At E12.5 in the control embryo, the ostium primum has closed by
the merging of the mesenchymal cap with that of the atrioventricular septal cushion
and the vestibular spine. At this stage the primary atrial septum has developed with
the interatrial connection of the secondary interatrial foramen (also oval fossa/
ostium secundum) (Figure 3.6a, adjacent section in b). Mutant littermates
demonstrate incomplete closure of the ostium primum with sections showing regions
where the mesenchymal cap has not yet fused with the mesenchyme of the
atrioventricular septum (Figure 3.6c and e). However, neighbouring sections show
that the mesenchymal contribution to the atrial septum has developed such that the
opening of the ostium primum is limited (Figure 3.6d and f). In one El 3.5 mutant a
less developed atrial septum was present with the ostium primum unclosed (figure
3.7c, adjacent section in d). In the second El3.5 mutant and littermate control, the
primary septum had developed with the oval fossa/ ostium secundum connecting
between atrial chambers (Figure 3.7 control a and mutant e). This is not abnormal
for this stage as detailed histological analysis of wild type embryos by Webb et.al.
has shown that the atrial connection is not closed by the infolding of the myocardium
(as the secondary atrial septum) until late on the 13th day of gestation (Webb et. al.
1998). Furthermore, it is possible that a developmental delay may account for some
of the variability between control and mutant embryos and this must be considered in
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interpreting the results. The atrial septum of the mutant El3.5 embryo depicted
(Figure 3.7e and f) resembles more closely the atrial septum of the El2.5 control
embryo (Figure 3.6a and b), than the El3.5 control embryo (Figure 3.7a and b). The
formation of the primary septum in two E12.5 mutants (Figure 3.6c and e), with the
extension of the mesenchymal cap towards the atrioventricular mesenchyme across
the ostium primum, resembles the phenotype of wild type atrial septation from El 1.5
stage gestation (Webb et. al. 1998a).
Given that the control littermates demonstrate incomplete atrial septation, it is
possible that the Sox4ENU/ENU FoxqF"/sa mutants are simply delayed in this septation.
This observation appears inconsistent with that published by Bogani et.al., but our
homozygotes were not examined at E14.5. It is possible that the atrial septal defect
might be retained in Sox4ENU/ENU Foxqlsa/sa mutants until E14.5. It may also be
possible that the embryos examined by Bogani et.al. were sufficiently delayed in
cardiogenesis to be closer to E13.5. To determine this conclusively, it would be
necessary to revisit the data produced by Bogani et.al. and examine in parallel
mutant and control littermates at E14.5 and, to account for the possibility of
developmental delay, at El5.5. At El5.5 the Sox4 mutant embryos would be dead,
although a degree of histological analysis may still be possible. If embryos were
developmentally delayed by one embryonic day at E14.5 then dissecting at El5.5
would eliminate any possibility that atrial septation was simply incomplete.
Nevertheless, this is still inconsistent with the work of Ya et.al. who examined
embryos at E12-E14 and did not describe an atrial septal phenotype, although their
focus lay with the outflow tract. It is possible that, in our mutants, although the
mesenchymal cap on the primary atrial septum was present, this mesenchyme may
not have been patterned correctly. This requires a knowledge of the expression of
Sox4 in and surrounding this cardiac structure. The mesenchyme is continuous with
the mesenchyme of the atrioventricular septum. This is a region in which we also
observed a defect (El2.5 Figure 3.4; E13.5 Figure 3.5). Thus it is likely that any
possible defects in the atrial septum are linked to a defect within the mesenchyme.
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Figure 3.6: Histological analysis of the atrial septum in Sox4ENU/ENU
Foxq1sa/sa embryos at E12.5. Haematoxylin and eosin-stained sections of
E12.5 embryos were examined for atrial septum morphology. (A and B)
Transverse sections through a control embryo reveal the normal morphology
of the atrial septum at this stage. (A) The secondary interatrial foramen
(arrow, in A) is visible between the segments of the primary atrial septum
(PAS), although the opening is limited as shown by a continuous PAS in (B).
In mutant hearts (C and E) the mesenchymal cap (MC) has not fused with
the endocardial cushion mesenchyme which forms the developing
atrioventricular septum (AV) and the ostium primum (OP) is still present
(arrow, in C, E). In subsequent sections the mesenchyme has connected,
revealing the limits of the OP. Abbreviations as shown in previous figures
and additionally: AV atrioventricular septum; MC mesenchymal cap; PAS
primary atrial septum. Scale bar: 100^m.
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Figure 3.7: Histological analysis of the atrial septum in Sox4ENU/ENU
Foxq1sa/sa embryos at E13.5. Haematoxylin and eosin-stained sections of
E13.5 embryos were examined for atrial septum morphology. (A and B)
Transverse sections through a control embryo reveal the normal morphology
of the atrial septum at this stage. (A) The secondary interatrial foramen is
visible between the segments of the primary atrial septum (arrowhead, A),
although the opening is limited as shown by adjacent sections (B). In mutant
hearts it is possible to see the OP in one heart (arrowhead C), while the other
mutant demonstrates a visible secondary interatrial foramen (arrowhead, E).
In both mutants, the openings of the septum are limited (oval, D and F).




3.2.2 Sox4FNl,/FNUFoxqlsa/sa E9.5 embryos produce a variable phenotype, which
appears independent of genetic background.
To examine the ontogeny of the cardiac phenotype, we examined embryos at earlier
stages of development. The analysis presented here is representative of findings
from backcrossing the M91 line to C57B1/6J. During the course of this candidature,
studies were performed on embryos after backcrossing to two different inbred strains
- C57B1/6J and also 129/Ola after two generations of crossing to C57B1/6J from the
M91 line. Embryos resulting from intercrosses of the alleles on a predominantly
129/Ola background did not demonstrate any consistent significant differences from
the phenotype observed on the predominantly C57B1/6J background. For this
reason, only analysis on the C57B1/6J background is presented here.
Sox4tNU/ENU Foxqlsa/sa embryos were examined from E7.5 to El3.5. After
genotyping (Chapter 2; Figure 2.1 and 2.2), it became apparent that most
homozygous embryos (n=45/50; 90%) could be visibly distinguished by E9.5. At
this stage, these embryos demonstrated a variable phenotype in wholemount (Figure
3.8d to 1, compared with control in a, b and c). The heart was swollen to varying
degrees, and other organ systems also appeared to be affected. The phenotype of
embryos at this stage could be grouped into three classes (Table 3.2):
Class-I
The least severe of the three classes, class-I mutants demonstrate a swollen heart,
with inappropriate shape of the atria and ventricles (Figure 3.8d, e and f). Despite
this distension, it is still possible to distinguish regions of the heart by the presence of
the AV groove, VS groove and the narrowing and bending between the presumptive
RV and OFT, as well as bending between the distal and proximal OFT. Despite
being malformed, the class-I hearts still appear to undergo rightward looping with
the future left ventricle and AV region left of the midline, while the presumptive
right ventricle appeared correctly displaced to the right of the midline to varying
degrees (section 1.3.1; Figure 1.4c). Some class-I mutants also demonstrate defects
in the formation of the forebrain/ anterior-most neural tube. In these cases, it appears
that the neural tissue is slightly truncated, or underdeveloped. Of the E9.5 embryos
103
examined, the class-I phenotype comprises 42% of homozygotes and 10.5% of any
given intercross litter (Table 3.2).
This phenotype also appeared in 3% of heterozygotes (Table 3.2), although the
number of embryos examined is too small to conclude whether this represents a
haploinsufficient phenotype, or whether the phenotype in this 3% of all examined
(n=90) heterozygotes is unrelated to the Sox4EN' and satin alleles.
Class-II
In class-11 mutants, the severe cardiac swelling of these embryos, did not permit the
presumptive chambers and interconnecting regions to be distinguished in
wholemount with certainty. In most embryos, the heart tube simply extended
ventrally from the body and, possibly due to the distension, did not undergo adequate
looping, although the looping which occurred appeared to be directionally rightward
(Figure 3.8g, h and i). The remainder of the body was severely developmentally
delayed and the forebrain/anterior defect was more pronounced. This phenotype
class was observed in 28% of homozygote mutants (approximately 7% of an
intercross litter) (Table 3.2).
Class-Ill
The most severe defects were apparent in class-Ill mutant embryos, comprising 20%
of E9.5 Sox4ENU/ENU Foxqlsa/sa embryos (Figure 3.8j, k and l)(Table 3.2).
Development of embryos with this phenotype was severely disrupted, to the degree
that cardiomyogenic cells could only be identified as a mass of beating tissue.
Whilst embryos did demonstrate anterior-posterior patterning and a degree of
somitogenesis, class-Ill mutants revealed disruption to the remainder of body
patterning. This suggests disturbance to key early patterning signals, and/or
inappropriate differentiation. Clearly, in these embryos, abnormality must have its
inception early in development to result in such a severe phenotype by E9.5. As
results for the next chapter show that Sox4 is expressed in the embryonic ectoderm
(section 4.2.1) prior to and during gastrulation, it is possible that this severe class-Ill
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Figure 3.8: The phenotype of Sox4ENU/ENU Foxq1sa/sa E9.5 embryos can
be grouped into three classes. (A) Lateral view of a control E9.5 embryo.
Magnified view of the left (B) and right (C) side of a control heart at E9.5.
(D,E,F) Lateral view of class-l mutant embryos demonstrating swollen and
inadequately looped hearts. Anterior development is also abnormal in these
embryos. (G,H,I) Lateral view of class-ll mutant embryos demonstrating a
severely enlarged heart tube and severe anterior defects. (J,K,L) Lateral
view of class-Ill embryos displaying severe developmental abnormalities.
Abbreviations: AVC, atrioventricular canal; BC, bulbus cordis; LV, left
ventricle; OFT, outflow tract. Scale bar: A,D,E,F,G,J 500pm; K, 380pm.
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phenotype arises at this stage. Class-Ill mutants comprise as little as about 5% of
any litter (Table 3.2). Therefore it would require a very extensive breeding
programme to generate sufficient embryos to study this early phenotype in detail
with reproducibility. In this thesis, analysis presented is thus restricted to class-I and
some less severe class-I I mutants.
3.2.3 Examining the time of lethality for Sox4ENL'/ENU Foxqlsa/s" embryos.
To establish when the Sox4ENU/ENU Foxqlsa/sa phenotype is lethal, the frequency of
homozygosity was examined by pooling all genotyping results for litters. Initially
embryos were all genotyped for the satin allele, with some samples randomly
selected for sequencing at the Sox4 locus. Embryos from fourth and fifth generation
intercrosses were all genotyped at both loci, as it was in these generations that
segregation of the two alleles was first observed. Since Sox4ENU/ENU Foxqlsa/sa
embryos phenocopy published findings for Sox4 null homozygotes, litters were only
examined up to El3.5 - the known time point preceding the ultimate lethality of the
null allele. No homozygous animals were born from heterozygous intercrosses (data
not shown), indicating that the recessive lethal phenotype is fully penetrant on the
backgrounds studied.
The frequency of homozygous mutant embryos does not deviate from the expected
25% prior to El 1.5 (Table 3.3). The ratio of genotypes were tested for whether non-
Mendelian segregation is statistically significant, by chi-squared analysis with two
degrees of freedom. At E7.5 and E8.5 most mutant embryos appeared
morphologically normal (data not shown). The first evidence of a cardiac phenotype
arises about E9.5. Even at this stage, 10% of examined homozygotes did not
demonstrate any dysmorphology (Table 3.2). It is presumed that this class would
develop into the least severe of cardiac phenotypes by E13.5. At about El 1.5,
homozygotes comprise approximately 20% of the litter. This 5% decrease (from an
expected 25%) is likely to represent loss and reabsorption of the class-Ill embryos.
Very few embryos were examined at these later stages of gestation. However, it is
still evident at E13.5 that embryos with the severest phenotype have died and are
reabsorbed (with no embryo-derived tissue available to genotype). The proportion of
109
homozygotes in the litter drops to 14% (from the expected 25%) (Table 3.3),
suggesting that the majority of class-II mutants are also reabsorbed by this stage.
Homozygous embryos dissected at El2.5-13.5 all demonstrated a degree of
craniofacial abnormality, from a mild reduction in eye pigmentation to severe
anterior deformities.
These genetic ratios are consistent with that described for the Sox4 null lethality,
whereby 18-20% (n=21) of E12.5-E14.5 embryos were homozygous (Ya et. al.
1998b). If the El 1.5-13.5 stages for the study presented in this chapter are pooled,
homozygotes comprise 18.6% (n=T7) (Table 3.3).
Given that the phenotype is variable, by keeping the frequency of lethality separate
for stages, it thus appears that there are two peaks of lethality/reabsorption in
homozygotes (Table 3.3). Although implantation sites may be present, there is a lack
of definitive embryonic tissue for genotyping. The first peak is between El 0.5-
E11.5, when a loss of the 5% of abnormally developed class-Ill mutants is observed.
A second wave of embryonic death occurs during the two days prior to El3.5, such
that by El3.5, only the cardiac phenotype is apparent as a likely consequence of the
Sox4 mutation.
3.2.4 Embryos homozygous for the Sox4ENl/ENL' Foxqlsa/s" mutations
demonstrate an early cardiac phenotype at E9.5-E10.5.
To determine the developmental basis for the cardiac phenotype observed later in
gestation, hearts of embryos were examined at E9.5-E10.5, about the stage that class-
I mutants demonstrate a morphological abnormality.
Mutants exhibit trabeculation defects
Serial sections of E9.5 homozygote mutant hearts were analysed for ventricular
abnormalities. In control embryos, myocardial cells which remain at the wall of the
heart show a flattened morphology, which is suggestive of differentiated
characteristics - forming contractile muscle. Myocardial cells which form trabeculae
are morphologically distinct, being spherical with fewer cell-cell contacts and
extending towards the endocardium which lines the ventricular lumen (Figure 3.9a).
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In contrast, mutant embryos revealed varying extents of poorly developing
ventricular trabeculae (Figure 3.9b, c and d). Between mutant embryos of the class-I
phenotype, differences were observed. Embryos of the milder class-I phenotype
appeared able to form trabeculae, however the base of the trabeculae appears to lack
cellularity. It appeared that the myocardium was inadequately populated, with
insufficient cells able to undergo the transformation into trabeculae (Figure 3.9b). A
more severe class-I mutant seemed unable to construct any trabeculae. Instead, cells
retained the elongated morphology of the myocardial wall (Figure 3.9c). In this
embryo, the cells of the wall of the myocardium also appeared sparse. The
ventricular wall of embryos of the Class-II phenotype did not appear to undergo
formation of trabeculae (Figure 3.9d). In mutants of this class, the myocardium was
sparse and the space between endocardium and myocardium was more prominent.
The proepicardium is present in mutant embryos.
In the case of embryos null for Gata4 (generated by tetrapoloid aggregation),
defective formation of trabeculae at E9.5 is attributed to the absence of the
proepicardium (also pro-epicardial organ; PEO; discussed chapter 1, section 1.3.5)
(Watt et. al. 2004). However, as yet, there is no further molecular evidence for this
link (such as factors secreted from the epicardium, acting on the early myocardium).
To examine whether the PEO was present in Sox4 mutant embryos, serial sections of
class-I and class-II embryos were examined for the presence of the PEO (Figure
3.10). There was no notable difference in the appearance of the PEO in mutant
embryos of the class-1 (Figure 3.10b, c) and class-II phenotypes (Figure 3.1 Od,
compared with control, a). Therefore, absence of the PEO cannot explain the
phenotype observed in the developing trabeculae in E9.5 Sox4 hearts. This does not
exclude the possibility that cells of the epicardium are abnormal at later stages, since
they go on to play a significant role at later stages in myocardial proliferation and
maturation of compact myocardium (as discussed in section 1.3.5)
Section analysis of the A VC and OFT at E9.5.
In order to examine when the endocardial cushion defects first arise, E9.5 embryos
were examined in transverse sections at the early stages of cushion formation. At
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about E9.5, in the looped heart tube, cardiac EMT commences in the AVC with cells
from the endocardium delaminating into the underlying extracellular matrix (ECM).
Slightly later this process also occurs within the cushions of the outflow tract. Later,
at El0.5, mesenchymal cells are more prominent in the AVC and also in the OFT. In
both regions it is possible to visualise cells that have already delaminated from the
endocardium and migrated into the ECM. It is also possible at these stages to
visualise sub-endocardial cells in the distal OFT, which are likely to correspond to
NCC infiltrating the anterior heart.
Atrioventricular canal
Class-I embryos dissected at E9.5 demonstrate cardiac swelling and inadequate
looping of the heart (Figure 3.8). Sections through the heart of a control E9.5
embryo show the normal development of the AVC cushions for this stage (Figures
3.11a-c; 3.12a-c; 3.13a-c). In contrast, all mutant embryos reveal abnormal AVC
development. Class-I embryos (n=4 presented in this figure) demonstrated a degree
of cushion development, although morphology was abnormal compared with control
(Figure 3.11 d-f; Figure 3.11 g-i; Figure 3.1 lj-1; Figure 3.11m-o, compared with
control Figure 3.11a-c). In some sections, the developing mesenchyme (black
arrows Figures 3.11) does not appear to populate the cushion, but rather clusters
below the endocardium. This suggests a defect in the process of EMT, although this
phenotype could also be a result of aberrant differentiation, proliferation or
maintenance of mesenchyme in the cushion, rather than production per se.
Furthermore, in some sections of the cushions, mesenchyme did not appear to be
present (oval marked in Figure 3.1 lj and o). Although it is possible that this is a
consequence of the developmental delay exhibited by the class-I embryos, and thus a
delay may also be an explanation for the limited mesenchyme production in class-II
embryos: AVC defects were more prominent in sections through class-II mutant
embryos which showed limited (black arrows Figure 3.12d, e) or no mesenchyme
production within the atrioventricular cushions (Figure 3.12f, g-i).
A developmentally delayed E10.5 embryo also demonstrates abnormal population of
the cushions with mesenchyme (black arrows Figure 3.13). Here, the mutant embryo
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(Figure 3.13d-f) is compared with sections through a control E9.5 embryo (Figure
3.13a-c) and also a control E10.5 littermate control (Figure 3.13g-h). This
comparison shows that the low density of mesenchymal cells in the mutant cushions
is more similar to that in the E9.5 control than the E10.5 littermate control. Note that
the E9.5 embryo was sectioned transversely, while the two El0.5 staged embryos are
sectioned to cut in plane with the main length of the OFT and thus are mid-way
between transverse and frontal, but still allow a visual estimation of mesenchymal
cell density.
Outflow tract
In wholemount, the OFT of Sox4 mutant hearts appeared swollen at E9.5 (Figure 3.8,
and data not shown). Sections through the OFT reveal the variability in this swelling
between class-I mutants (Figure 3.14d-f; Figure 3.14g-i; Figure 3.14j-1; Figure
3.14m-o) compared with control (Figure 3.14a-c). Also evident in these sections is
the early production of mesenchyme within the proximal OFT cushions. This
commences by E10, later than the initiation of mesenchyme production in the AVC
(discussed section 1.3.3). The wild type sections reveal the normal mesenchyme
production for this developmental stage (black arrows, Figure 3.14a, b). In
comparison, the process is either delayed or reduced for this stage in the mutant
hearts, since fewer mesenchymal cells are observed upon examining serial sections
through this region (black arrows, Figure 3.14e, h, j, k, m, n). Interestingly, sub¬
endocardial cells are present at the distal OFT, adjacent to the aortic sac. Although
not quantified, it is evident in all mutant and control hearts that sub-endocardial cells
are present within this region (red arrows, Figure 3.14). This region was examined at
higher magnification in both control (red arrows, Figure 3.14c, lumen of OFT
marked with red asterisk) and mutant (red arrows, Figure 3.14f, i, 1, o, lumen of OFT
marked with red asterisk). The migratory appearance of the sub-endocardial cells,
together with the spatiotemporal positioning, suggests that they may be the
infiltrating NCC, although marker analysis is necessary to determine this
conclusively.
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Also within the OFT, class-Il mutant hearts did not appear to demonstrate
mesenchyme production in the proximal cushions in any of the sections examined
(Figure 3.15d,e and Figure 3.15g-i, compared with control Figure 3.15 a and b),
while the developmentally delayed mutant El0.5 heart demonstrated limited
production of mesenchyme in the OFT cushions (Figure 3.16d, compared with E10.5
control in h). To characterise the presence or absence of the mesenchyme accurately,
further than what can be determined from haematoxylin and eosin stained sections, it
would be necessary to analyse this region with mesenchymal markers. As with the
AVC, it is possible that the lack of mesenchyme in this region of the OFT is a
consequence of a developmental delay. The E9.5 control shown in these two Figures
was developmentally matched to the class-I mutant embryos. Given the substantial
defects observed in class-II and the El0.5 mutant hearts, there is not a more
appropriate control for this analysis. It would, in retrospect, for the purpose of
uncovering the origin of the cardiac phenotype, be more useful for section analysis to
be conducted on class-II embryos from E8.5-E9. To determine the extent of the
phenotype at El0.5, it is necessary to examine more mutant embryos that are less
developmentally delayed.
It is also evident from the class-II E9.5 and the El0.5 sections that there are sub¬
endocardial cells within the distal OFT. This is more prominent in the less severe
class-II mutant heart (red arrows, Figure 3.15 d-e, magnified in f) than in the more
severe class-II mutant heart (red arrow, Figure 3.15g), while the El0.5 embryo
demonstrated a degree of population which resembled the E9.5 control (red arrows,
Figure 3.16e and f, compared with Figure 3.16b and c) more closely than the E10.5
littermate (red arrows Figure 3.16g, h and i). As described for class-I mutant hearts,
the distal OFT is the site of entry of NCC into the anterior heart. It is likely that
these cells are the beginning of NCC infiltration, yet this can not be said with
certainty as marker analysis has not been conducted on this population of cells.
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Figure 3.11: Sox4ENU/ENU Foxq1sa/sa class-l embryos exhibit variable
atrioventricular canal cushion defects at E9.5, as shown by histological
analysis. Haematoxylin and eosin-stained sections through the developing
cushions of the atrioventricular canal (between the common atrium marked a
and common ventricle marked v) of a developmentally matched E9.5 control
embryo (A, B, C) compared with four class-l mutant embryos (D,E,F; G,H,I;
J,K,L; M,N,0). Hearts were examined through similar regions comparing the
approximate posterior, middle and anterior regions of the canal (three columns
of figure), as determined by examination of all sections through the heart. (A-C)
The control embryo demonstrates the normal endocardial cushion swelling and
mesenchyme production, with some mesenchyme cells evident (black arrows).
However throughout this region in the four mutant embryos (D-F, G-l, J-L, M-O)
abnormal cushion swelling and variable mesenchyme production (black arrows)
is evident. In some sections through class-l mutant hearts, the developing
cushions appeared devoid of mesenchymal cells (regions marked by oval in J
and O). Abbreviations: a atrium; v ventricle; Scale bar: 100pm (shown in C).
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Figure 3.12: Sox4ENU/ENU Foxq1sa/sa class-ll embryos exhibit variable
atrioventricular canal cushion defects at E9.5, as shown by histological
analysis. Haematoxylin and eosin-stained sections through the developing
cushions of the atrioventricular canal (between the common atrium marked a
and common ventricle marked v) of an E9.5 control embryo (A, B, C) compared
with two class-ll mutant embryos (D,E,F; G,H,I). Hearts were examined
through similar regions comparing the posterior, middle and anterior regions of
the canal, as determined by examination of all sections through the heart. (A-C)
The control embryo demonstrates the normal endocardial cushion swelling and
mesenchyme production, with some mesenchyme cells evident (black arrows).
However mutant embryos (D-l) demonstrate abnormal cushion swelling and
variable mesenchyme production (D, E). In all hearts, regions of mesenchyme
production are indicated by black arrows. The less severe mutant
demonstrates some mesenchyme production through most sections (D,E).
However, the more severe mutant (G-l) does not demonstrate production of
mesenchyme in this region (marked by oval in F-l). Abbreviations as in




Figure 3.13: A Sox4ENLJ/ENU Foxq1sa/sa E10.5 embryo exhibits
atrioventricular canal cushion defects, as shown by histological analysis.
Haematoxylin and eosin-stained sections through the developing cushions of
the atrioventricular canal (between the common atrium marked a and common
ventricle marked v) of an E9.5 control embryo (A, B, C; sectioned in the
transverse plane) a developmentally delayed E10.5 mutant embryo (D,E,F;
sectioned midway between transverse and frontal, in plane with the angle of the
outflow tract) and a stage-matched E10.5 littermate control (G,H,I; sectioned
midway between transverse and frontal, in plane with the angle of the outflow
tract). Hearts were examined through similar regions comparing the posterior,
middle and anterior regions of the canal, as determined by examination of all
sections through the heart. (A-C) The E9.5 control embryo demonstrates the
normal endocardial cushion swelling and mesenchyme production, with some
mesenchyme cells evident (black arrows). However the mutant embryo (D-l)
demonstrates abnormal cushion swelling and variable mesenchyme production.
There appears to be a significant defect or delay in mesenchyme production of
the one mutant compared with the E10.5 littermate control embryo (G-H). In all
hearts, mesenchyme production is indicated by black arrows. In the mutant
heart, the region of cushion adjacent to the ventricle appears devoid of
mesenchyme (marked by oval in F). Abbreviations as in previous figures, but





Figure 3.14: Sox4ENU/ENU Foxq1sa/sa class-l embryos exhibit variable outflow
tract development at E9.5, as shown by histological analysis. Haematoxylin
and eosin-stained transverse sections through the developing outflow tract
(OFT) of an E9.5 control embryo (A,B,C) compared with and developmentally
matched to four class-l mutant embryos (D,E,F; G,H,I; J,K,L; M,N,0). Flearts
were examined through similar OFT regions comparing two different levels (first
and second columns of figure), as determined by examination of all sections
through the heart. (A,B) The control embryo demonstrates the normal OFT
cushion swelling and infiltration of sub-endocardial cells in the distal OFT,
possibly corresponding to cardiac neural crest (red arrows A,B). Additionally,
mesenchyme production is evident in the cushions of the proximal region of the
OFT adjacent to the bulbus cordis (bc; black arrows A). (D-O) In the four mutant
embryos swelling of the outflow tract and abnormal cushion development is
evident, with little evidence for mesenchyme production in the proximal
cushions in these sections. Class-l OFT demonstrate the presence of sub¬
endocardial cells within the distal OFT (red arrows D-O). FHigher magnification
(4x) of the distal OFT in control (C) and class-l mutant (F,l,L,0), reveals the
presence of sub-endocardial cells adjacent to the lumen of the OFT (red
asterisk). Abbreviations: as aortic sac; bc bulbus cordis; fg foregut. Scale bar:




Figure 3.15: Sox4ENU/ENU Foxq1sa/sa class-ll embryos exhibit variable
outflow tract development at E9.5, as shown by histological analysis.
Haematoxylin and eosin-stained transverse sections through the developing
outflow tract (OFT) of an E9.5 control embryo (A,B,C) compared with two class-
ll mutant embryos (D,E,F; G,H,I). Hearts were examined through similar OFT
regions comparing two different levels (first and second columns of figure), as
determined by examination of all sections through the heart. (A,B) The control
embryo demonstrates the normal OFT cushion swelling and infiltration of sub¬
endocardial cells in the distal OFT, possibly corresponding to cardiac neural
crest (red arrows A,B). Additionally, mesenchyme development is evident in
the cushions of the proximal region of the OFT (bc; black arrows A). (D-l) In two
mutant embryos swelling of the outflow tract and abnormal cushion
development is evident, with no evidence for mesenchyme production in the
proximal cushions in these sections. One class-ll OFT demonstrates the
presence of sub-endocardial cells within the distal OFT (red arrows D,E).
Higher magnification (4x) of the distal OFT in a control (C) and a class-ll mutant
(F), reveals the presence of sub-endocardial cells adjacent to the lumen of the
OFT (red asterisk). (G,H,I) A second class-ll mutant embryo does not
demonstrate sub-endocardial cells in the distal OFT in these sections.





Figure 3.16: A Sox4ENU/ENU Foxq1sa/sa E10.5 embryo exhibits abnormal
outflow tract development, as shown by histological analysis.
Haematoxylin and eosin-stained transverse sections through the developing
outflow tract (OFT) of an E9.5 control embryo (A,B,C; sectioned in the
transverse plane) compared with equivalent sections of one E10.5 mutant
embryo (D,E,F; sectioned midway between transverse and frontal, in plane with
the angle of the outflow tract) and a stage-matched E10.5 littermate control
(G,H,I; sectioned midway between transverse and frontal, in plane with the
angle of the outflow tract). Hearts were examined through similar regions
comparing two different levels of the OFT (first and second columns of figure),
as determined by examination of all sections through the heart. (A,B) The
control E9.5 embryo demonstrates the normal OFT cushion swelling, production
of mesenchyme is evident in the proximal OFT cushions adjacent to the bulbus
cordis (bc; black arrows A, B), and infiltration of sub-endocardial cells in the
distal OFT, possibly corresponding to cardiac neural crest (red arrows A,B).
(D-E) In one mutant E10.5 embryo swelling of the outflow tract and abnormal
cushion development are evident, with limited mesenchyme production in the
proximal cushions in these sections (black arrows, D). Additionally, sub¬
endocardial cells are present in the mutant distal OFT (red arrows, E).
Development of the mutant heart appears to be delayed with compared with the
E10.5 littermate control embryo (G-H), which demonstrates the normal
presence, for this stage, of subendocardial cells (red arrows, G, H) and
mesenchyme production in the proximal cushions (black arrow, H). Higher
magnification (4x) of the distal OFT in control (E9.5, C; E10.5, I) and the E10.5
mutant (F), reveals the presence of sub-endocardial cells adjacent to the lumen





3.2.5 El2.5 Sox4E*u/E*1 FoxqF"/s" embryos demonstrate craniofacial defects.
Anterior defects are characteristic of 6p deletion syndromes (section 1.4.2). An
examination of embryos hemizygous for satin, arising from a Foxqlsasa
Del(13)Svea36H cross, revealed abnormalities of forebrain development
(Willoughby 2006), PhD Thesis. This phenotype overlaps with the E9.5 anterior
phenotype observed in class-I and class-U Sox4ENU/ENU Foxqlsa/sa embryos,
suggestive of a genetic interaction between the Sox4 mutant allele and satin.
The wholemount E9.5 forebrain phenotype has been described according to classes-I
and -II (Presented as classes in Figure 3.8). In addition, we examined the anterior
phenotype in embryos dissected at E12.5-E13.5 (which were examined for the
cardiac phenotype, Figures 3.1 in wholemount and, prior to sectioning, the embryos
examined in Figures 3.2 - 3.7; numbers in Table 3.3). In this study, control embryos
showed normal anterior development, with appropriate retinal pigmentation, nasal
grooves and lower jaw (Figure 3.17a, d). It was found that, in addition to cardiac
abnormalities, Sox4ENU/ENU Foxqlsa/sa E12.5-13.5 embryos demonstrated defective
morphology of anterior structures. It is presumed that mutants with a less obvious
phenotype would represent further development of E9.5 class-I embryos, while more
severe phenotypes would represent class-I I. At E12.5, less severe mutants (n=3/5)
demonstrated a smaller lower jaw in proportion to the upper jaw and nasal process,
although early vibrissae formation is evident (Figure 3.17b, e). Also in this class of
mutants, eye pigmentation was markedly decreased or delayed relative to other
hallmarks of developmental stage (eg. limb buds, somites). Some homozygotes
(n=2/5) demonstrated a more severe phenotype exhibiting severe neural and anterior
defects. In these embryos, the forebrain did not appear to have formed, the
presumptive lower jaw was malformed and facial structures of the optic vesicle and
nasal process were absent (Figure 3.17c, f). One embryo demonstrated severe
exencephaly of the hindbrain (Figure 3.17c). As these more severe phenotypes were
not described for any Sox4 or Foxql alleles, it is likely that these additional anterior
phenotypes are a consequence of a genetic interaction between the two mutant alleles
and thus a combined Sox4; Foxql deficiency.
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3.2.6 Placental appearance of El2.5 Sox4EIVl/ENV Foxqlsa/s" embryos.
Placental insufficiency is a major cause of embryonic death after E9.5. The placenta
may either show gross morphological abnormalities, or appear normal but in both
cases, it is possible that its function for maternal-foetal interaction may be in some
way compromised. Defects of the yolk sac can also result in embryonic lethality due
to insufficient circulation. Whilst an extraembryonic defect may be intrinsic to the
yolk sac, it also may be a consequence of cardiac defects and problems with blood
flow.
During the process of dissection, some embryos could be identified as homozygotes
prior to removal of the extraembryonic membranes and placenta. From El0.5, some
homozygotes showed decreased blood flow through the yolk sac when compared
with control yolk sacs. At E12.5, the visual difference of some mutant placentas was
investigated by serial sectioning and tissue staining. The placental layers can be
identified by histological analysis. The layers of labyrinth, spongiotrophoblast cells,
trophoblast giant cells and maternal decidua were identified in all placentas
examined. Sectioning through the placentas revealed morphological differences
compared with the same region in the control. However by sectioning further into
the mutant placentas, each of the four cell layers could be identified (Figure 3.18b, c
and d, compared to control a). Whilst it is possible that there could be an
extraembryonic phenotype caused by mutation in Sox4 and Foxql, this remains to be
explored. Since a specific cardiac phenotype can be observed at E9.5, and this
cardiac phenotype demonstrates overlap with that of mutation in other cardiac genes,
it is more likely that the cardiac abnormalities originate from an embryonic
requirement for Sox4 expression, and that the placental malformation is secondary to,
or independent of, this.
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3.3 Discussion
The results presented in this chapter demonstrate the phenotypic consequence of the
Sox4enu and Foxqlsa mutations. Since mutant alleles of Foxql do not demonstrate a
cardiac phenotype, the cardiac aspects of this study may be attributed to the mutation
in Sox4 and therefore this discussion of the cardiac phenotype relates exclusively to
Sox4. A separate aspect of the Sox4ENU/ENU Foxqlsa/sa phenotype, aberrant forebrain
development, reveals a possible genetic interaction between Sox4 and satin. This
finding will be discussed at the end of this section.
Determining A Role for Sox4 in Cardiogenesis
Since the publication of the Sox4 null phenotype in late heart development (Schilham
et. al. 1996; Ya et. al. 1998b), its role has received little attention, despite major
advances in the understanding of heart development over the last 10 years, and the
suggestion that an earlier defect is present in these mutants (Ya et. al. 1998b). This
doctoral research has utilised a mutant allele of Sox4 (Sox4ENU) - which demonstrates
cardiac dysmorphology and lethality that is similar to the phenotype of the null allele
at E14.5 (Bogani et. al. 2005; Schilham et. al. 1996; Ya et. al. 1998b). Additionally,
the Sox4 mutation is recessive and genetic crosses suggest that it results in a loss of
function. Therefore, it is likely that the Sox4ENU mutation leads to loss of function of
Sox4.
Our mutant allele presents with a phenotype earlier than that described for the null
allele and shows a cardiac phenotype from the 10th embryonic day. Previous studies
(Dr Ruth Arkell pers.comm.; Ya et. al. 1998b) showed that some homozygotes
(approximately 5-7%) must be lost before El 4.5, when the remainder of mutants die.
Our examination of the Sox4ENU/ENU phenotype at stages leading up to E14.5 suggests
that this loss occurred between El 0.5 and El 1.5, since up to El 0.5, 26% of embryos
from intercrosses are homozygous (115/439), and thereafter, only 19% (17/91) are
recovered. Interestingly, the percentage of homozygous embryos lost prior to El 1.5
corresponds well to the proportion of Class-Ill homozygotes dissected at E9.5 (5%;
20/189), while class-I and-II homozygotes together constitute around 17% of the
litter (70/189). This strongly suggests that the published phenotype in E14.5 mutant
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embryos must have origins in the defects, (most probably those in Class-I and -II
mutant categories) observed from E9.5. In this chapter, therefore, the E9.5
phenotype has been studied in detail. Since published studies of this allele do not
provide an account of the progression of heart defects (Bogani et. al. 2005), the
phenotype at E12.5-E13.5 was also examined comprehensively. This discussion will
first discuss the later-stage phenotype, in the context of what could further be
examined. Then the mutant phenotype presented will be compared with those of
other published mutants where known cardiac cell populations are affected, to arrive
at a set of possible cell types and processes affected by disruption of Sox4.
Approaches for further study of these possibilities will be discussed.
3.3.1 Discussion of the E12.5-E13.5 phenotype of the Sox4E*L mutant.
This analysis is the first in which the Sox4ENU allele has been examined during the
stages of cardiac septation; thus providing the first detailed phenotypic
characterisation of this mouse line, as a novel model for further characterising the
molecular regulation of cardiogenesis. For the allele examined in this study, we have
shown that the aspects of the outflow tract phenotype at E12.5 and E13.5 resemble
the outflow tract phenotype described for the null allele (Ya et. al. 1998b), but in
addition, we have identified atrioventricular cushion abnormalities which implicates
Sox4 in a further role of atrioventricular valve formation, atrial septation and
atrioventricular septation.
Histological analysis of embryos homozygous for the Sox4ENU allele has revealed
aspects of the Sox4 mutant phenotype at E12.5 and E13.5, preceding the published
E14.5 ultimate lethal phenotype. Outflow tract septation was inadequate at E12.5
and incomplete at E13.5, with mutants demonstrating PTA and DORV. This
development appeared delayed, with septation of some mutant embryos at El3.5
resembling that of El 2.5 control hearts. It was noted that the anterior regions of the
pulmonary trunk and aorta had septated, suggesting that the aorticopulmonary
septum and the distal ridges of the outflow tract had developed to a degree.
At E12.5 and E13.5, it was observed that mutants developed endocardial ridges and
appeared to initiate formation of the semi-lunar valves of the OFT. However ridges
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appeared smaller in the mutant hearts at both developmental stages - even accounting
for a possible developmental delay. Further analysis is needed to examine the
construction of the semi-lunar valves in the mutants, and whether they develop in the
appropriate number and orientation. For this, it would be most useful to examine the
anterior heart from the stages shown through to El4.5, both by sectioning and
histology, as well as by either MRI or OPT to whole embryos. Since the null allele
was examined by histology up to El4, Ya et.al. were able to describe the initial
formation of the semi-lunar valves in their mutant. Such analysis could be conducted
with the Sox4ep"l allele, particularly since the semi-lunar valvular deficiency,
resulting in an oscillatory movement of blood at the anterior pole, has been reported
as the likely cause of lethality in all Sox4 alleles at El4.5 (Bogani et. al. 2005;
Penzo-Mendez et. al. 2007; Schilham et. al. 1996; Ya et. al. 1998a).
Furthermore, the progressive development of this phenotype should be examined.
This analysis was conducted to an extent in this project, by histology on E9.5
embryos. Analysis would involve examining the quantitative contribution of cells to
the developing valves from the cushion stages of development. In parallel to this,
examination of the removal of cells, by apoptosis, would be further useful. Analysis
with cell-type specific markers could be conducted to reveal whether the regions of
myocardium, endocardium and mesenchyme are appropriately patterned for their
developmental stage. Given the cardiac domains affected by the mutation and the
phenotype observed, analysis of the contribution of the NCC and the SHF cells
would be a logical next step.
This phenotype may have its origins earlier in development. At E9.5 whole embryos
demonstrate severe swelling of the heart tube and inadequate cardiac looping, while
section analysis has shown that there appears to be a defect in the process of
trabeculation of the early ventricular chamber and a defect or delay in the production
or maintenance of cushion mesenchyme within the developing atrioventricular
cushions. Although this has so far only been examined at E9.5, it may subsequently
lead to a variable phenotype being present in derivatives of this tissue - namely the
AVS, and the mitral and tricuspid valves (sometimes appearing as a common
atrioventricular valve), as well as the mesenchymal contribution to the
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atrioventricular, atrial and ventricular septa. Since the process of EMT is a key
factor involved in the production and initial patterning and maintenance of the
cardiac mesenchyme, it is possible that Sox4 plays a role at some level in cardiac
EMT.
Thus, three potential developmental roles of Sox4 must be considered, namely (1)
that it is required in regions of NCC infiltration into the heart; and/or (2) that it is
required in some regions where SHF derivatives contribute to cardiogenesis; and/or
(3) that it is required during the process of EMT, whether this be in the endocardial
layer, the delaminating endocardium, or the mesenchyme from E9.5 and the start of
cushion formation.
The mutant phenotype implies a requirementfor Sox4function in regions of
NCC infiltration.
Defects at the arterial pole of the heart of Sox4 mutants closely overlap with those in
mouse models with defective cardiac neural crest cell (NCC) function -particularly
with respect to the septation defects. It is evident from sections of Sox4ENU/ENU class-
I and some class-II embryos at E9.5 that the subendocardial space of the OFT is in
the process of being populated with what may be NCC (Chapter 1, section 1.3.3,
Figure 1.13) - although marker analysis is essential to verify this. The density of
subendocardial cells appears variable between embryos through visual analysis of
serial sections, although this was not subjected to quantitative analysis in serial
sections of a high number of developmentally matched embryos, it is possible that
either this variation is a consequence of the developmental differences between
control embryos and mutant classes, or it reflects a variably penetrant phenotype.
Even a delay in the infiltration of NCC may result in an inappropriate molecular
programme in cells of the OFT, and thus contribute to abnormal development -
although the specific requirements for correct timing of infiltration have not been
examined in models with OFT defects.
Certainly the number of infiltrating NCC is a contributing factor to the development
of the anterior heart. This has been shown in detail by analysis of the Pax3 Splotch
mutant alleles. In the Sp2" allele, NCC fail to colonise the OFT adequately, resulting
in PTA or DORY without a common arterial trunk (Bradshaw et. a/. 2009; Conway
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et. al. 1997; Epstein et. al. 2000). The lethality of the Sp2" homozygotes about E13.5
from cardiac failure, thus makes it possible that the inadequate OFT septation in
Sox4 mutant embryos contributes to the embryonic lethality. In addition to the septal
defects, Sp2H/Sp2" hearts further reveal shortening of the OFT (Bradshaw et. al.
2009), and this feature could be examined by histology in Sox4 mutant hearts at
E10.5. In chick, ablation of NCC has been shown to contribute to this conotruncal
malformation by a reduction in cellular contribution (Yelbuz et. al. 2002). In
particular, it is the SHF which exhibits defective contribution to the anterior heart in
both NCC ablated chick embryos, and Sp2H/Sp2H embryos (Bradshaw et. al. 2009;
Yelbuz et. al. 2002). To examine NCC contribution in Sox4ENU/ENU mutants would
require crossing of the Sox4ENU line onto the Wntl-lacZ line (Echelard et. al. 1994)
or Wntl-cre crossed to the ROSA26-LacZ reporter (R26R) line (Jiang et. al. 2000;
Soriano 1999). Conducting these crosses onto the Sox4ENU background would enable
examination of the infiltration of NCC into the anterior heart. When examined over
a developmental time period, such analysis could be quantitative to determine
whether a reduction in the infiltration of NCC correlates with the severity of the
cardiac phenotype.
Analysis with a Wntl-reporter may also enable examination of the possible
contribution to other cardiac regions such as the AVC and primitive valves in the
Sox4E^JEhb mutant. The contribution of NCC in these domains appears to be
dependent on genetic background (Hildreth et. al. 2008; Nakamura et. al. 2006).
Interestingly, the study reported by Nakamura et.al. used mice which had been
substantially backcrossed to a C57BL/6J background. A C57B1/6J strain
background was the predominant background used in this analysis of the Sox4ENU
allele. Thus it is possible that the genetic modifiers on this strain background may
contribute to infiltration of NCC into the AVC and valves and thereby exacerbate the
Sox4 phenotype of this ENU allele, from that observed in the study of the null allele.
Whilst NCC have been shown to contribute to the mesenchymal population of the
developing OFT (Epstein et. al. 2000; Jiang et. al. 2000), as maturation of the valves
proceeds, the NCC are replaced by cells of endocardial origin (discussed section
1.3.3; (de Lange et. al. 2004)). Analysis of this cellular replacement in Sox4 mutant
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embryos could be examined by using a Tie2 reporter allele (Tie2-cre/ R26R
(Kisanuki et. al. 2001; Soriano 1999)) on a Sox^-mutant background for cells of
endocardial origin. Furthermore the Wntl-LacZ reporter on the Sox4 mutant
background could be utilised in crosses to examine the distribution of NCC (as
described, above). Although it would require an extensive breeding programme,
ablation of Sox4 from the endocardial lineage (by crossing Tie2-cre with the
conditional Sox4^/fl (Penzo-Mendez et. al. 2007)) would enable clarification as to
whether the requirement of the OFT for Sox4 resides within endocardial-derived
cells, where Sox4 is known to be expressed (shown in subsequent chapters, Chapter
4). Examining the phenotype and distribution of NCC in the OFT of embryos in
which Sox4 expression had been removed from the endocardium, (possibly by
involving a further genetic cross to the Wntl-LacZ line (Echelard et. al. 1994), or by
use of NCC antibodies), would assist in determining whether NCC require the
adjacent endocardial layer to express Sox4.
Outwith the developing cardiac structure, remodelling of the aortic arch arteries and
regression of the right dorsal aorta is also regulated by NCC. Whilst this was not
examined thoroughly in the present study, it is possible that a NCC defect may be
revealed if Sox4 mutant embryos exhibit abnormal persistence of the right dorsal
aorta, or abnormal regression of the 3rd, 4th and 6th arch arteries, and is certainly an
aspect of the mutant phenotype which should be examined.
To summarise, it is possible that the Sox4 OFT septation defects are a consequence
of dysregulation of NCC function. The comparison with the NCC deficient Splotch
mutant has shown that a disruption to NCC function and septation in the anterior
heart may be sufficient to result in the E14.5 lethality observed with Sox4 mutant
alleles. Nevertheless, it remains possible that the valvular deficiency may be derived
from abnormalities in the endocardial-derived mesenchyme populating the OFT
ridges. Separating the endocardial and NCC functions would require considerable
further analysis using transgenic mice.
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The Sox4enu/enu FoxqT"/s" cardiac phenotype partially overlaps with that of
mouse models where the SHF is disrupted.
Defects to the anterior heart have not only been reported in the context of a
disruption to NCC infiltration, but also the SHF population. Since these two cell
populations occupy both adjacent and overlapping regions within the OFT,
separation of gene function within either population is reliant upon specific
inactivation. Using such methods, a study of the requirement for hedgehog
signalling by the SHF has shown that Shh signalling from the pharyngeal endoderm
is essential for OFT septation. In E12.5 embryos, the ability of anterior SHF cells to
be responsive to Shh signalling had been selectively ablated via. conditional
inactivation of Smoothened by use of the Mef2C-AHF-Cre. Hearts of mutant
embryos demonstrated the presence of OFT cushions, yet there was a lack of
septation between the pulmonary artery and the aorta (Goddeeris et. a/. 2007). This
phenotype overlaps with what has been observed in the OFT of the Sox4ENU mutant,
although comparison of stage and regionally-matched sections would be necessary to
determine the extent of this phenotypic overlap in the anterior heart. Additionally,
embryos in which the Shh-responsiveness of SHF had been disrupted survived until
at least El8.5. If, in the Sox4ENU mutant embryos, the anterior SHF is not able to
function correctly, clearly additional roles for Sox4 exist in this cardiac domain to
result in the E14.5 lethality.
Consequences of disruption to the SHF have also been shown at the venous pole of
the heart, in developmental models altering the function of Isll-expressing SHF
cells. Migration of Isll expressing cells was disrupted by conditional expression of a
dominant-negative effector of RhoA signalling (Hildreth et. al. 2009). In this model,
defects were observed at the venous pole at E10.5 and E14.5. Atrial septation was
impaired as a proportion of embryos did not develop the vestibular spine (also, dorsal
mesenchymal projection (DMP)) and thus the primary septum did not fuse with the
atrioventricular cushion. Additionally, some mutant hearts demonstrated a common
atrioventricular junction; ventricular septal defects; and exhibited abnormal OFT
septation (Hildreth et. al. 2009). While the anterior defects of mutant hearts were not
detailed in the above paper, a degree of overlap in the phenotype of hearts in which
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SHF cell migration is impaired, and the phenotype described in this chapter for the
Sox4EEU allele is still evident. However, hearts in which Isll-expressing cell
migration was impaired further demonstrated a defect in the development of the
venous valves - a phenotype not observed with the mutant Sox4 allele. Thus it is
possible that aspects of the Sox4ENU phenotype are a consequence of disruption to
SHF function.
This ENU-induced mutation in Sox4 could not completely ablate the ability of SHF
to contribute to cardiogenesis, since the defects are not as severe as loss of function
of Isll (Cai et.al. 2003). Nor does the Sox4ENb mutant share enough phenotypic
overlap with other homozygous mutants characterised with disruption to SHF genes
where the predominant phenotype includes severe right ventricle and outflow tract
abnormalities. Such mutants have predominantly been reported to be embryonic
lethal about E10 including Mef2c (Lin et. al. 1997), a potential target gene of Isll
(Dodou et. al. 2004); Hand2 (Srivastava et. al. 1997) a marker of the SHF
downstream of Mef2c (Lin, Q et. al. 1997); Foxhl (von Both et. al. 2004); or lethal
about El 1, such as Tbx20 (Cai et. al. 2005; Singh et. al. 2005; Stennard et. al. 2005;
Takeuchi et. al. 2005). An understanding of the expression pattern of Sox4 is further
required to investigate the possible connection between the SHF and Sox4 function.
Clearly the phenotype of the Sox4ENU allele requires considerable further analysis in
order to determine which cell lineages in the heart are influenced by mutation of
Sox4.
Distinguishing between a disruption to NCC and a disruption to the SHF.
In the initial studies of the Sox4 null allele, the contribution of mesenchyme derived
from NCC in Sox4 null hearts was examined by the staining of sections for a-smooth
muscle actin (a-SMA; also now known as Acta2), also a marker of vascular smooth
muscle. a-SMA had been shown to differentiate between NCC-derived and
endocardial-derived mesenchyme (Beall et. al. 1990; Ya et. al. 1997). Using this
marker, Ya et.al. claimed that in Sox4 null embryos, there was a variable ability of
NCC to invade the outflow tract and contribute to arterial septation. Given this
finding, it was suggested that the migration of NCC into the OFT is poorly guided in
more severely affected Sox4 null embryos (Ya et. al. 1998b). However, despite
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being a marker of NCC-derived mesenchyme a-SMA is not specific for cells of
NCC origin, since it marks cardiac smooth muscle cell differentiation and cells of the
OFT myocardium. At E13.5, the Cx43-lacZ transgene, which marks NCC, is found
in cells expressing a-SMA, while a-SMA is also expressed by cells of the OFT
myocardium, not marked by the Cx43-lacZ reporter (Epstein et. al. 2000). In chick it
has also been shown that a-SMA is expressed by a specific regional domain of cells
of SHF origin as they commence differentiation into smooth muscle cells and then
contribute to the vascular myocardium at the level of the semi-lunar valves (Waldo
et. al. 2005a). OFT myocardium contributes to the process of myocardialisation of
the OFT septum initially formed by NCC (van den Hoff et. al. 1999). Although
myocardialisation has been best characterised in chick, the equivalent stage in mouse
at which this process starts is El3.5, a stage examined in Sox4 null embryos (Ya et.
al. 1998b). Thus, a reduction in the cell population expressing a-SMA may reflect
any of these possibilities, depending on the precise timing of expression and specific
location within the arterial pole of the heart: reduced SHF-derived contribution to the
OFT; reduced SHF-derived vascular myocardialisation; and the original possibility
of an abnormality in the guidance of NCC into the endocardial tissue of the OFT.
This, combined with the possibility that, like the Sox4ENU embryos shown in this
study, there is a developmental delay, suggests that their work does not conclusively
show that the defect lies in NCC (Schilham et. al. 1996; Ya et. al. 1998b).
Uncovering the molecular basis for the integration of NCC into the anterior heart,
and the requirement of NCC by the SHF is still a complex challenge. Analysis of
phenotypic mutants can contribute to this understanding. In order to investigate this
issue - whether or not the defect resides with the NCC; the endocardial-derived cell
interaction with NCC or SHF cells; or with the SHF cell infiltration into the heart -
and thus explore the possibilities arising in this chapter (and those of Ya et.al.),
specific markers need to be examined. Wntl-LacZ labelled cells would reveal the
extent of NCC infiltration and positioning in Sox4EhiU embryos (as previously
described), while the SHF derived cells could be examined by monitoring Is11
expressing cells (using an antibody to Isll or by use of Is/1 reporter alleles (Pan et.
al. 2008)) or by use of the Mef2c-LacZ allele (Dodou et. al. 2004), both of which
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would reveal SHF-derived cells when combined with the Sox4EhiU allele. Initial
examination of the contribution of Isll labelled cells, in sections through the relevant
regions of E8.5-E10.5 embryos, could reveal a possible deficiency in SHF cells prior
to and during the appearance of the phenotype in Sox4 mutant hearts. Analysis of the
contribution of SHF to cardiac development in Sox4ENU/ENU embryos would assist in
establishing a possible SHF deficiency and thereby an SHF phenotype.
Thus it is possible to examine the separate contribution of NCC and SHF cells to the
Sox4 mutant heart. Whilst a number of crosses would need to be conducted in order
to obtain sufficient embryos for this to be analysed in detail, such analysis would
contribute to deciphering the involvement of these two cell populations in the Sox4
mutant phenotype, as well as uncovering aspects of the role of Sox4 in cardiogenesis.
There is phenotypic overlap between the Sox4 mutant and the Nfatc mutant
in which aspects ofendocardial EMT are disrupted.
The phenotype observed is not restricted to the possibilities of a defect in neural crest
or SHF infiltration to the heart, since other processes are integral to its development
at this time. The process of EMT is essential for endocardial cushion and ridge
formation. Thus it is possible that a defect in the development of the mesenchyme,
and subsequent derived structures, is a consequence of abnormalities in the process
of EMT within the heart.
Nfatc signalling is required for EMT within the developing heart (section 1.3.3).
Aspects of the Sox4 cardiac phenotype described here at E12.5 and E13.5, and
elsewhere at E14.5 (Bogani et. al. 2004) overlap with Nfatc mutant embryos, to the
point that, in both the study of the Nfatc null allele (de la Pompa et. al. 1998) and the
second study of the Sox4 null allele (Ya et. al. 1998b), each group examined the
expression of the other gene within the heart. Whilst neither group observed
abnormal expression by in situ hybridisation, it was speculated that the pathways in
which they act may converge on the same aspect of cardiac development. In the
Nfatc null, although septation of the OFT is complete, the formation of the
endocardial cushions into semi-lunar valves and the development of the mitral and
tricuspid valves resembled that of earlier embryonic stages. Incomplete
interventricular septation was also observed. Lethality at El4.5 in the case of Nfatc
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mutant embryos was, like that of the Sox4 null, attributed to valvular malfunction
and thus severe defects in forward blood flow - which may also account for the
peripheral oedema and haemorrhaging.
Thus, it is possible that aspects of the cardiac defects observed as part of the E12.5-
E14.5 Sox4enu phenotype, such as defects to the atrioventricular region, are a
consequence of inappropriate or inadequate mesenchyme production or patterning
from earlier stages. The section data presented in this chapter alone is not sufficient
evidence to confirm an EMT defect. In the Nfatc mutant, regions of the heart which
are dependent upon EMT still develop to an extent, as is observed in the Sox4
mutant. The process of EMT is integral to the formation of the endocardial cushions
and in order to uncover a defect in EMT, it is necessary to examine embryos at
earlier stages. This will be discussed in the following section of this chapter.
Does a cardiac defect fully explain the embryonic lethality?
It has been discussed that the Sox4 phenotype overlaps with the phenotype for
mutants in which there is defective or inappropriately patterned NCC, SHF cells or
endocardial EMT. While the overlap with the Nfatc mutant is intriguing and one of
the more similar cardiac mutant phenotypes, the Sox4 phenotype does not overlap
with only one of these, nor can the phenotypes of the examples given completely
explain the Sox4 phenotype. This is particularly evident with respect to the
embryonic lethality. It is possible that the cardiac defects alone are not sufficient to
result in the lethal phenotype. However it is convincing that the valvular deficiency
observed in the Nfatc mutant also results in lethality about El4.5, while mutants in
which OFT and ventricular septation is incomplete, may survive until later stages of
gestation. Although the valvular deficiency has already been proposed by others
(Schilham et. al. 1996; Ya et. al. 1998b), another developmental factor should be
examined in the Sox4 mutant embryos. Data in this chapter has revealed placental
abnormalities (section 3.2.6). While this may be a consequence of the cardiac defect,
it may also be possible that Sox4 plays a role in extra-embryonic development. To
determine this further would require further histology and subsequent analysis of
molecular markers within the placenta, in the first instance, to examine whether the
cell types of each of the layers are correctly patterned in the Sox4 mutant.
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Summary
There are similarities between the later Sox4ENU phenotype described in this chapter
and phenotypes in which NCC function is perturbed. It is likely that a role of Sox4 is
within the field of NCC function, yet significant experiments need to be conducted to
determine the precise nature of this possible role. As an alternative, some mouse
models which have not been shown to have a defect within NCC have been
discussed since there is overlap in aspects of their phenotype with that presented by
the Sox4enu allele. In particular, a degree of overlap exists with mouse mutants in
which the SHF contribution is diminished. Still, results in this chapter imply that the
cardiac requirement for Sox4 begins at least as early as E9.5, and these earlier
phenotypes remain a possible basis for the phenotype observed at the later stages.
Given this, the possible dysregulation of NCC could not account for the earlier E9.5
phenotype. Our findings do not contradict those published, rather they further refine
the regions and the temporal domains in which Sox4 may be required. An
understanding of the expression domains of Sox4 during cardiogenesis will assist in
interpreting this further.
3.3.2 An early onset phenotype at E9.5 may contribute to the late stage heart
defects in Sox4 mutant embryos.
Analysis of the Sox4 mutant allele demonstrates a number of morphological and
histological abnormalities in homozygous class-I and class-II embryos at E9.5,
which, if left to develop, may result in the cardiac defects observed later in gestation.
Aspects ofthe mutant phenotype suggest a possible role for Sox4 in regions
ofEMT during heart development
The process of EMT is essential for cardiac remodelling, ft is not just essential for
formation of the valves and intra-cardiac septation, but mesenchymal cells of the
AVC cushions also give rise to the membranous component of the IVS, during
interventricular septation (section 1.3.3). Coupled with the inadequate looping of the
heart, a delay or a deficiency in mesenchyme production from the AVC could
contribute to the defects observed in Sox4 mutant hearts at E12.5 and E13.5.
At E9.5 Sox4 mutants demonstrate cardiac defects in regions of the heart which
normally involve the process of EMT. The AVC of mutant hearts exhibits variable
148
mesenchymal contribution to the endocardial cushions. It is possible that this is a
consequence of delayed embryonic development as it appears that the AVC is able to
recover to a certain degree, since the atrioventricular septum and primitive valves
appear to develop about E12.5-E13.5. Given these results, it is possible that normal
Sox4 expression is required for appropriate timing of EMT within the developing
heart. In order to discuss this further, the cardiac phenotype of mouse models which
overlap with the phenotype observed here in Sox4ENU/ENU Foxqlsa/sa mutants will be
discussed. This discussion will be followed by mention of key experiments in which
a role for Sox4 in cardiac EMT could be determined, since section data alone, as
presented in this chapter, is uninformative for determining involvement of Sox4 in
this process.
Many signalling pathways have been identified in regulating aspects of EMT in
valve morphogenesis. Characterisation of the phenotype in these mutant embryos
contributes to our understanding of the genetic events that underlie EMT.
Among the mouse models with mutations in Sox genes, the cushion defect most
closely resembles that of mutation in Sox9 (Akiyama et. al. 2004). Sox9 is expressed
within the cells following initial delamination and migration into the ECM/cardiac
jelly, but before definitive mesenchymal transformation. Sox9 resides upstream of
ErbB3, Sox5 and Sox6, whose expression in the cushions is required for EMT.
Given the phenotype of Sox4 mutants, it is plausible that the function of Sox4 resides
alongside that of Sox9. To determine whether this is the case, expression of Sox9
and its target genes would need to be examined in Sox4 mutant heart. Interestingly,
in the field of prostate cancer research, SOX4 has been proposed to function
upstream of SOX9 expression (Liu et.al. 2006). A mechanism for this remains to be
described and, to date, this has not been explored in the heart.
Vegf plays a negative regulatory role in EMT within the heart (Dor, Y et. al. 2001;
Dor, Y et. al. 2003), and its expression must be modulated both to initiate and cease
mesenchyme production during valve formation. In order to initiate heart valve
morphogenesis, Vegf expression in the myocardium must be repressed by
calcineurin/NFATcl signalling from the endocardium (Chang et. al. 2004). The
activity of NFATcl is then limited to the endocardial cells at the site of valve
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formation, while adjacent myocardial cells continue to express Vegf. The levels of
Vegf expression prior to EMT have been shown to be essential for cardiac EMT.
Underdeveloped cushions are one aspect of the phenotype in embryos
haploinsufficient for Vegf (Carmeliet et. al. 1996; Ferrara et. al. 1996). Given the
effect of the ENU mutation on cushion development, it is possible that Vegf levels
have been altered, which would be possible to determine by gene expression and
protein analysis.
The early E9.5 phenotype observed in this study suggests that aspects of the OFT
and AVC defects in Sox4 mutants arise independently of neural crest infiltration.
Whilst this does not eliminate the possibility that neural crest function in the heart is
disrupted, it may be that these phenotypes arise secondary or parallel to a defect in
either the endocardium or myocardium of the E9.5 heart, as a result of Sox4
mutation. To investigate this issue, in vitro analysis of cell migration could be
performed. Each of the OFT and AVC cushions could be microdissected from E9.5
class-I mutant and control heart tubes and grown in culture as explants. A protocol
has been described that utilises collagen gels to examine the ability of cardiac cells to
undergo EMT in vitro (Runyan et. al. 1983). Whole explants would enable
distinction between a defect in the initial delamination of endocardial cells to
migratory cells by the loss of cell-cell contacts, or an inability of endocardial cells to
undergo the transformation from delaminated cells to mesenchyme. In both
circumstances, comparative analysis may be achieved by counting cells which have
moved into the matrix. By supplementing cultures with media conditioned with
specific morphogens (such as BMP2, known to induce expression of the
mesenchyme marker periostin (Inai et. al. 2008)), it would be possible to examine
whether there is a recovery in the ability of mutant endocardial explants to generate
mesenchyme. Further to this, analysis of the endocardial expression of VE-cadherin,
and immunostaining to view localisation, would assist in concluding whether Sox4
mutants retain inappropriate cell contacts, or whether the endocardium is unable to
respond to inductive signals.
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Sox4 mutant embryos demonstrate a swollen heart at E9.5 which may
impair cardiac looping.
At E9.5, the most striking defect in wholemount Sox4 homozygous mutant embryos
is swelling of the heart at E9.5 (Figure 3.8), in 90% of homozygote embryos
examined (n=50) (Table 3.2). It is possible that inappropriate placement of the
primitive cardiac chambers, and of the regions that undergo septation, may account
for aspects of the lethal E13.5 phenotype. In class-I mutant embryos, the heart tube
had undergone looping; however the atria, ventricles and OFT appear distended
relative to wild type. Some class-I I mutants demonstrated more severe swelling such
that boundaries of the primitive chambers were not identifiable. Consequently, in
both classes of mutants, the atrioventricular groove and inner curvature are
inadequately positioned. The E9.5 heart is enlarged in a way that may be
disproportionate to cell proliferation and differentiation, which may exert
consequences on cell-cell and cell-matrix interactions, and this may in turn affect cell
fate. By El2.5 and El3.5, the cardiac structures which have formed appear smaller
than the wild type control hearts. Whether Sox4 is involved in the processes of
proliferation or differentiation in the formation of the heart remains to be examined.
The most well described consequence of inadequate looping is DORV, one of the
common malformations in human syndromes with congenital heart defects. At mid-
gestation, the aorta and pulmonary trunk of the OFT undergo rotation such that they
are appropriately positioned above the ventricles (Dor, X et. al. 1985; Lomonico et.
al. 1986) (Section 1.3.3). Failure of this conotruncal rotation underlies aspects of
congenital heart defects (Bajolle et. al. 2006; Bostrom et. al. 1988; Lomonico et. al.
1988). Thus inadequate spatial organisation at this stage in Sox4 mutant embryos
may contribute to the PTA and DORV septal defects observed.
Mutant Sox4 E12.5 hearts demonstrated displaced ventricles within the cardiac
cavity: the base of the muscular interventricular septum was angled to the left such
that the right ventricle was in a more midline position, while the left ventricle
occupied a more dorsal region of the cavity when compared with control embryos
(Figures 3.4 and 3.5). The inadequate looping of the heart may also contribute to the
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delay in ventricular septation and the VSD at El3.5. The muscular ventricular
septum elongates anteriorly to fuse with the mesenchyme from the atrioventricular
cushions and endocardial ridges. Fusion of the muscular portion to the mesenchyme
creates the membranous septum continuous with the cushions of the OFT (section
1.3.3). These regions are displaced in Sox4 mutant embryos. Although the muscular
portion of the ventricular septum forms, it fails to make the appropriate connections.
This is distinctly different from laterality defects in which rightward looping of the
heart is reversed. Sox4 mutant hearts did not demonstrate such directional looping
defects.
In all embryos examined at dissection, the heart had looped in the normal direction.
Furthermore, examination of serial sections through El2.5 and El3.5 hearts did not
uncover evidence for laterality defects such as isomerism. In particular the atria
appeared to have developed their appropriate left/right features, such as the systemic
venous sinus connecting between the right atrium and the right superior caval vein.
The primary atrial septum is a derivative of the left-programmed atrial myocardium.
Although Sox4 mutant mice do demonstrate an atrial septal defect, the defect appears
to lie with either the development of this structure, possibly as a consequence of
defective mesenchyme, and/or with the developmental delay. This is dissimilar to
the severe ASD observed in mutants which exhibit right atrial isomerism such as
Pitx2 (Gage et. al. 1999; Kitamura et. al. 1999; Lin, C R et. al. 1999) and Cited2
(Bamforth et. al. 2004; MacDonald et. al. 2008; Weninger et. al. 2005). In these
mutants, the primary septum is either absent or does not develop correctly, with
El5.5 embryos demonstrating a large primary atrial septal defect. Other aspects of
correct patterning of the heart would be more prominent at later stages of heart
development, for example, the right atrium develops significantly more pectinate
muscle than the left atrium. Furthermore, extracardiac isomerism often occurs in
parallel with cardiac isomerism since the entire embryo may be affected by bilateral
right or left sidedness. Sidedness is reflected by the spleen, pancreas, stomach and
other regions of the gut. Right atrial isomerism is usually accompanied by a loss of
splenic tissue (asplenia); while embryos with left atrial isomerism also demonstrate
polysplenia (additional splenic tissue). Pulmonary isomerism has been found to
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accompany cardiac isomerism such that in cases of right isomerism, the lungs
develop symmetrically, rather than four lobes on the right and one on the left. Thus,
in addition to the heart, left-right positional information is reflected by other visceral
organs. Although this was not examined in Sox4 mutant embryos in this study,
further examination of the data obtained by MRI of E14.5 embryos (obtained by
Bogani et.al.) may assist in determining whether the Sox4ENU allele alters the
positional information of other organs.
Mutations to the Scrib gene in the Circletail (Crc) mouse mutant , and the Vangl2
gene in the loop-tail (Lp) mutant (Kibar et. al. 2001; Murdoch et. al. 2001) exert
their biological effect by disruption to planar cell polarity (PCP) signalling. In
control embryos, Scrib and Vangl2 both function at the cell membrane and are
involved in cell-cell adhesion. At the cellular level mutation in Scrib relocates N-
cadherin from the cell surface of cardiomyocytes to the cytoplasm, thereby
disrupting cellular polarity and cell-cell adhesion (Phillips et. al. 2007). One aspect
of the Crc/Crc and Lp/Lp mutant phenotypes is inadequate cardiac looping
(Henderson et. al. 2001; Phillips et. al. 2007). While the initial rightward looping of
the heart tube occurs, looping does not progress adequately beyond this
conformation. Interestingly, mutation of Scrib does not inhibit regional specification
of cardiomyocytes within the heart, since the expression of cardiac markers is
normal. Yet by E13.5, some Crc/Crc hearts demonstrate a thin ventricular wall and
minimal myocardial compaction compared with control embryos. DORV and OFT
septation defects are also observed. Therefore, altering cell polarity and cell-cell
contacts of cardiomyocytes can alter looping and result in defects that are similar to
those found in Sox4 mutants. Thus a disruption to looping may explain the Sox4
mutant phenotype, although the specific cellular requirement for Sox4 is unclear.
Early trabeculation is abnormal in Sox4 mutant hearts.
Histological analysis of Sox4 mutant hearts reveals that cardiac development in
homozygotes is variable between embryos. As a component of this, a ventricular
phenotype is evident in sections at E9.5 (Figure 3.9). At E9.5 myocardium at the
outer curvature of the heart wall is programmed to develop into ventricular
myocardium, which then diverges into two cell fates - compact or trabecular
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myocardium. This process is highly dependent upon signalling, and establishing
contact points with the endocardial cells lining the lumen of the heart (Icardo et. al.
1987). Even the least severe Sox4 mutant E9.5 ventricles demonstrate a defect in the
formation of trabeculae. In the least severe mutants, trabecular myocardium is
constructed, but trabeculae appear to lack a cellular base where they join to the
compact myocardium (Figure 3.9). In the more severe mutants the transformation of
myocardium to trabeculae does not appear to take place, despite the endocardium
having established contact points with the myocardium. This suggests that the defect
resides in either: (1) the response of the myocardium to endocardial signals; or (2)
the response of the endocardium to myocardial signals; or (3) proliferation of the
cells that give rise to the trabeculae. Given the differing degree of developmental
delay in mutant embryos, it is possible that the necessary signalling pathways for this
early stage of ventricular development are not appropriately activated.
Several signalling pathways are known to be required for trabecular formation in
ventricular maturation (section 1.3.2 and references therein). Neuregulin-1 (NRG1)
signalling, through the ErbB2 and B4 receptors is critical for trabeculation of
ventricles. NRG1 is expressed in the endocardium while components of its receptor
are expressed on myocardial cells. Signalling through this pathway promotes
proliferation of myocardial cells and their differentiation into trabecular
myocardium. Abolishing NRG1, ErbB2 or ErbB4 ablates this process. Other
signalling molecules are known to be involved in trabecular formation, including
BmplO (Chen, H et. al. 2004) and Notch 1/Delta 1/Delta4 (Grego-Bessa et. al. 2007),
and mutations in these pathways results in specific ventricular dysmorphology. To
examine these processes in Sox4 mutant embryos, analysis could be conducted by
immunohistochemistry or by quantitative PCR to examine levels and distribution of
these regulatory factors. These factors are expressed, as might be expected, in
ventricular endocardium and myocardium, and therefore exert their function locally
on cardiomyocyte proliferation or differentiation. Since some Sox4 mutant embryos
(from class-I) are able to form trabeculae at this stage, it may be that Sox4 is
important for creating a balance between the proliferation and differentiation of the
myocardium in this process.
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Interestingly, myocardial inactivation of Handl, combined with and without
heterozygous inactivation of Hand2, results in a phenotype at E9 whereby looping
morphogenesis is abnormal and trabecular myocardium is poorly formed (McFadden
et. al. 2005). This is similar to the delayed E9.5 phenotype observed in Sox4ENU/ENU
Foxqlsa/sa mutants (Figure 3.8 and 3.9). While Handl is also a marker of the first
heart field (FHF), it has been associated with proliferation of myocardium in the
developing heart. The role of Handl in cell cycle progression has been described
showing it to be a key regulator of the balance between proliferation and
differentiation of cardiomyocytes (Martindill et. al. 2007; Risebro et. al. 2006). This
role in the developing heart is cell-autonomous since overexpression of Handl in
Handl-expressing cells results in enhanced proliferation both in vivo and in vitro
(Risebro et. al. 2006). The phenotype of complete embryonic ablation of either
Handl (Riley et. al. 1998) or Hand2 (Srivastava et. al. 1997) results in far more
severe abnormalities and early embryonic lethality. Thus the overlap in phenotype
of conditional removal of Handl and haploinsufficient Hand2 does not suggest that
Sox4 function resides in the general regulation of either factor, rather it may be
possible that the function of Sox4 in the heart acts in pathways that contribute to the
regulation of proliferation in the early heart. However, the absence of Sox4
expression in the ventricular chambers (ahead, in section 4.2.2) suggests that if it acts
on proliferation, it acts indirectly. The precise mechanism by which this occurs
would require knowledge of the localisation of the Sox4 protein, as well as its ability
to interact with other proteins and downstream target genes.
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Is THIS PHENOTYPE EVIDENCE FOR A GENETIC INTERACTION
BETWEEN THE SOX4 ALLELE AND FOXQ11
Aside from the cardiac phenotype, results presented in this chapter reveal an
interesting possibility - that there is a genetic interaction between Sox4 and Foxql.
The satin homozygous phenotype has been well studied, and anterior
dysmorphologies have not been reported, nor were any deviations from the expected
Mendelian ratio stated for heterozygous crosses of the satin allele (Hong et. al.
2001). Likewise, the study of the Sox4 null, did not detail a craniofacial phenotype
(Schilham et. al. 1996; Ya et. al. 1998b), although it was implied to be present, yet
mild, in a later study of the role of Sox4 in development of the CNS (Cheung et. al.
2000). In contrast, more recently, the phenotype of a Foxql" targeted null mutation
has been reported (Goering et. al. 2008). Embryonic lethality was reported to be
present only on a C57BL/6J x 129/Sv hybrid background. Lethality was not fully
penetrant in heterozygous crosses, with 15% (rather than the expected 25%) of
homozygotes present at birth, exhibiting the Satin phenotype upon hair shaft
differentiation. Homozygous Foxql" intercrosses to determine the timing of
embryonic lethality revealed that only 44% of the expected number of embryos
remained at E15.5. The loss of homozygotes was greatest between E10.5 and E12.5
(from 85% to 69%). At E10.5, a proportion of homozygotes were observed to have
abnormal forebrain development. The research did not reveal the cause of lethality
in these embryos (since forebrain deformities may still be observed in embryos that
complete gestation). Importantly, the heart was morphologically normal and
therefore cannot explain this lethality.
Further evidence for a genetic interaction between satin and another loci within the
Del(13)Svea36H deleted region was obtained by Dr. Catherine Willoughby
(Willoughby 2006), PhD thesis. It was found that some embryos (12/46) in a cross
of satin homozygotes to mice heterozygous for the Del(l3)Svea36H chromosome
demonstrated a mild forebrain phenotype. Embryos were thus hemizygous for the
satin allele and the region surrounding on chromosome 13, including the Sox4 locus.
These embyos are null for one Foxql allele, while the second allele carries the satin
mutation. Crossing to the deletion also causes haploinsufficiency of Sox4, although
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the remaining allele is wild type. This experiment indicates that neighbouring loci
(that is, those included in the Del(l3)Svea36H deletion) may modify the Foxql
phenotype. Both the hemizygous satin phenotype and homozygous Foxql null
overlaps with the non-cardiac E9.5-E10.5 forebrain phenotype observed with the
Sox4enu/enu Foxqlsa/sa mutant presented in this chapter, from the class-I and class-II
phenotypes (Figure 3.8).
Since homozygous loss of function of Foxql is common between the Sox4ENU/ENU
Foxqlsa/sa and satin/ Del(13)Svea36F4 hemizygous mutants, it could be considered
that Sox4 is a candidate modifier of the Foxql locus. The alternative explanation,
that there exists an additional unidentified ENU-induced mutation, closely linked to
both Sox4enu and satin, has been ruled out, as discussed in chapter 1 (section 1.4.3).
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3.4 Summary: Phenotype of Sox4enu/enu Foxq1sa/sa
embryos.
Examination of the phenotype of Sox4ENU/ENU Foxqlsa/sa embryos has enabled
identification and characterisation of the early cardiac phenotype which gives rise to
the ultimate lethal phenotype. By studying E9.5 embryos to determine the basis of
the cardiac phenotype, we have also uncovered that the Sox4 defect is variable and
can be grouped into three classes visible in wholemount. By conducting this analysis
we have provided a possibility for the deficit in the Mendelian ratio observed in both
the study of the null allele and this work at E11.5-E13.5. By analysis of the
phenotype, we have provided new possibilities for the function of Sox4 although the
precise nature of this remains to be elucidated by considerable further
experimentation. This analysis of the phenotype enables us to determine at which
stages of development Sox4 is required, and now provides a basis to explore the
molecular mechanisms by which a Sox4 deficiency leads to cardiac malformations.
Since it is apparent that there is a genetic interaction between Sox4 and Foxql,
segregation of the two alleles will enable a study of the Sox4 allele in isolation from
satin.
158
Chapter 4: Expression of and
FoxqI during mouse embryogenesis
4.1 Introduction
Little is known about the expression of Sox4 and Foxql during development.
Determining the spatio-temporal expression pattern of Sox4 and Foxql is necessary
for an understanding of the phenotype documented in Chapter 3. Limited
documentation is available on the expression of Sox4 during cardiogenesis. In chick,
Sox4 positive cells were found in the endocardial cushions of the atrioventricular
canal and endocardial ridges of the outflow tract, at Hamburger and Hamilton (HH)
stages 20-27 (approximately equivalent to E11.5-E13.5 in mouse) (Maschhoff et. al.
2003). In mouse, the El4.5 lethality observed in the Sox4 null is attributed to a lack
of Sox4 expression at El3.5 in the endocardial ridges of the outflow tract and
endocardial cushions of the atrioventricular septum (Schilham et. al. 1996). Since
the process of valve formation begins several days prior to El3.5, and cellular
patterning precedes the formation, it is difficult to reconcile the published phenotype
with such a late underlying developmental cause; that is, a lack of Sox4 expression at
E13.5. In order to establish how disruption to Sox4 causes the published phenotype
(Schilham et. al. 1996) and the Sox4ENU/ENU Foxqlsa/sa phenotype (chapter 3), it is
necessary to describe Sox4 expression from a much earlier point in time, and in
greater detail at the stages in which a phenotype develops.
Embryonic expression of Foxql in Xenopus has been described (Choi et. al. 2006).
During development, expression domains in Xenopus embryos include the
pharyngeal pouches, gastrointestinal tract and tongue. Examination of adult human
tissue revealed FOXQI expression in the stomach, trachea, bladder and salivary
gland, and cell line carcinomas of the colon and lung (Bieller et. al. 2001).
Additionally, low expression of FOXQI was detected in the adult lung and in both
adult and embryonic kidney (Bieller et. al. 2001). Limited adult mouse expression
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analysis has shown Foxql to be expressed in the liver, kidney, lung, brain, testis,
stomach and hair follicle (Frank et. al. 1998; Hong et. al. 2001). Foxql transcripts
were detected in whole embryo extracts from El0.5 to birth, yet the precise
wholemount spatio-temporal domains have not been described for Foxql in mouse
embryogenesis.
The lack of detail of the published expression domains of Sox4 and Foxql, and the
necessity for knowledge of the expression domains to describe the phenotype
presented in this thesis thus forms the basis of this chapter, with the aim: To
characterise the expression of Sox4 and Foxql daring mouse embryogenesis by in
situ hybridisation.
This chapter focuses primarily on documenting sites of Sox4 expression from pre-
gastrulation (E6.0) to El2.5. Sox4 expression was examined by wholemount in situ
hybridisation to embryos, followed by cryosection to examine expression domains in
greater detail. To examine the expression in the developing heart from E10.5, where
probe penetration was considered to be a problem, analysis was conducted by section
in situ hybridisation. Knowledge of this expression will help to resolve how
mutation in Sox4 (and thus disruption to expression) could cause and perpetuate a
visible phenotype from E9.5. It is pertinent to know where Foxql is expressed, since
the satin allele appears to influence aspects of the Sox4ENU/ENU Foxqlsa/sa phenotype.




4.2.1 Embryonic Sox4 expression during early mouse development
Prior to gastrulation, expression of Sox4 is observed throughout the epiblast (Figure
4.1a). Examination of the level of expression in an early-streak stage embryo
revealed that the Sox4 transcript is not uniform across the epiblast. Rather, embryos
demonstrate a mosaic pattern of expression, which appears to be stronger in the
ectoderm adjacent to the streak (Figure 4.1b). As gastrulation proceeds, the epiblast
retains expression of Sox4 and the definitive endoderm becomes a second embryonic
expression domain (Figure 4.1c and d).
In headfold to early somitogenesis stage embryos, Sox4 is detected in derivatives of
all three germ layers. Expression is most striking in the involuting foregut endoderm
(Figure 4.2 a, c and section b). This endoderm is adjacent to the cardiogenic
mesoderm of the cardiac crescent, and the lateral mesoderm of the SHF. Sagittal
sections demonstrate robust Sox4 expression in the endoderm, predominantly at the
foregut (Figure 4.2 b), but also posterior to the node in the prospective hindgut (data
not shown, evident in wholemount Figure 4.2a). During early somitogenesis, Sox4
expression continues in the epiblast adjacent to the primitive streak (Figure 4.2d).
Anterior neural ectoderm and head mesenchyme also demonstrates low expression at
this stage (Figure 4.2 b).
At E8.5 (approximately 10-somite stage) embryos reveal an increase in Sox4 gene
expression within neural ectoderm (Figure 4.3a and sections e to i). In a dorsal view
of the whole embryo, particularly strong expression is observed in the hindbrain
region (Figure 4.3a and b). This dorsal view also shows equally strong expression in
posterior neural ectoderm adjacent to the primitive streak (Figure 4.3b and i).
Sections through the neural folds of the anterior neural ectoderm reveal that Sox4
expression appears mosaic in both the ectoderm and head mesenchyme, (Figure 4.3e,
f, g and h). Expression is also apparent in cells immediately beneath the surface
ectoderm, possibly corresponding to neural crest (Figure 4.3 e and f). Intense
staining of a 6-somite stage embryo reveals that Sox4 expression is undetectable by
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these methods in the heart tube (Figure 4.3j) but present in the somitic mesoderm
(Figure 4.3k).
To summarise, during development Sox4 demonstrates a complex expression pattern
from the earliest stages. Expression is evident in derivatives of all three germ layers
although it is elevated in the endoderm, with notable expression also in the ectoderm
of the neural plate. Sox4 may also function in the patterning of somites where it is
expressed highly. Although it is expressed in endoderm adjacent to the heart, Sox4
expression was not observed in the heart itself at these stages.
4.2.2 Sox4 expression is highly restricted adjacent to and in cardiac tissues
during development
The first observation of Sox4 expression in mesoderm adjacent to cardiomyogenic
tissue is during early somitogenesis (embryo shown has about 4 somites) (Figure
4.2d sections in e and f). In transverse sections through an embryo at this stage, Sox4
transcripts appear in the mesoderm posterior to the cardiac crescent. This expression
is at the junction where mesoderm divides into either splanchnic (ventral) or somatic
(dorsal) mesoderm. The Sox4 expression domain extends towards splanchnic
mesoderm (Figure 4.2e and f). This region of cardiogenic mesoderm is adjacent to
the region which contributes to the SHF - in contrast to anterior regions of the
cardiac crescent, which contribute predominantly to the primary heart field (Chapter
1; section 1.3.1).
The mesodermal domain of expression is also present in an embryo with 10 somites.
Sox4 is expressed in mesoderm immediately posterior to the heart tube (Figure 4.3d,
g and h). This expression appears to be continuous with the ventral pericardial
mesenchyme, which is an additional site of Sox4 expression at this stage (Figure
4.3f). Expression is not observed by in situ hybridisation in the heart tube at this
stage, even when embryos are stained for long periods of time (Figure 4.3j).
By E9.5 cardiac expression appears in the endocardium of the outflow tract and
atrioventricular canal, with expression apparent in embryos hybridised both in
wholemount (Figure 4.4c and d) and in section (Figure 4.5a and d), to eliminate
trapping as a possible source of false positive results and inadequate probe
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penetration as a source of false negative results. Neither the control embryo for
wholemount analysis, nor control slide for section analysis demonstrated sense probe
binding (Figure 4.4a and Figure 4.5b). It appears that Sox4 expression is certainly
excluded from the myocardium and endocardium of the ventricles and atria. Clear
expression of a marker of left ventricular myocardium, eHand, is detectable in an
adjacent section (Figure 4.5c).
Expression domains in the AVC and OFT continue into the El0.5 stage (Figure
4.4e). Section in situ analysis from early El0.5 stage embryos reveals specific
expression in the endocardium and nascent mesenchyme of the AVC (Figure 4.5e).
These expression domains are continuous in sections from more developed El0.5, in
which the inferior and superior atrioventricular cushions are more densely populated,
than the earlier stage, with mesenchyme that expresses Sox4 (Figure 4.5f and g). At
the level of the OFT, expression is observed with the endocardium (Figue 4.5h and
i). This localisation was confirmed by marker analysis of Nfatcl in an adjacent
section (Figure 4.5i compared with Nfatcl in j). At this stage there is limited Sox4-
expressing mesenchyme evident in these regions of the OFT and it is not possible
here to distinguish between NCC-derived and endocardial-derived mesenchyme,
without double in situ hybridisation analysis with Sox4 and a marker for either NCC
or endocardial-derived mesenchyme. At the level of the aortic sac, strong expression
of Sox4 is observed in the pharyngeal mesenchyme, foregut and endocardium, as
well as the dorsal wall of the aortic sac (Figure 4.5k). Three-dimensional
examination of the expression of Sox4, by optical projection tomography (OPT) of
El0.5 embryos, further supported these results: That the only cardiac expression
domains of Sox4 are within the AVC and OFT endocardium and mesenchyme (data
not shown). Expression is remains absent from the myocardium and endocardium of
both atria and ventricles, as well as the non-chamber myocardium of the AVC and
OFT.
At El 1.5, expression of Sox4 is retained in the endocardium and mesenchyme of the
atrioventricular cushion, which is continuous via the vestibular spine with the
expression in the mesenchymal cap on the developing atrial septum (Figure 4.6a and
b). Sox4 expression did not extend into the adjacent myocardium of the AVC, which
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is marked by expression of Bmp2 (Figure 4.6c). Expression of Sox4 was further not
detected in the atria or ventricles, including the ventricular trabeculae. At the level
of the OFT, strong expression was evident in the endocardium and weak expression
in the mesenchyme, yet no expression was observed in the adjacent myocardium
(Figure 4.6d).
By El2.5, expression in the atrioventricular cushion mesenchyme is less prominent
than in the outer regions from which the tricuspid and mitral valve leaflets develop
(Figure 4.6e). The outer myocardial side of the primitive valve also showed
expression (Figure 4.6f). Expression is absent from myocardial structures including
the ventricles and trabeculae, as well as the atria and atrial septum. At the level of
the OFT, strong expression is observed in the mesenchyme of the atrioventricular
cushion at the anterior region of the ventricular septum (Figure 4.6g). Expression is
further observed in both pulmonary and aortic endocardial ridges at El2.5 by section
in situ analysis (Figure 4.6g and h for pulmonary endocardial ridges and data not
shown for aortic endocardial ridges).
In summary, Sox4 is initially expressed transiently in mesoderm adjacent to the
splanchnic mesoderm of the SHF between the stages of cardiac crescent and linear
heart-tube. In later stages of heart development expression is observed in the
endocardium and endocardial-derived mesenchyme of the AVC and OFT from E9.5
to El 1.5. By El 1.5, this mesenchymal expression also includes the mesenchymal
cap of the atrial septum. In the El2.5 heart, Sox4 expression appears stronger in the
presumptive leaflets of the developing mitral and tricuspid valves than in the
atrioventricular cushion itself. In the OFT, expression is observed in the
endocardium and mesenchyme of the endocardial ridges of both the pulmonary trunk
and the aorta. Thus Sox4 demonstrates an expression pattern which demonstrates
continuity between developmental stages of the heart, implicating possible roles for
the Sox4 protein in early cardiogenesis, and later in valve development and septation.
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Figure 4.1: Sox4 expression is observed in early embryonic development
from E6.5 to E7.5. Lateral view of Sox4 expression in embryos during early
gastrulation stages. (A) Sox4 is expressed throughout the epiblast at the pre-
streak (E6.0) stage; (B) By early-streak (E6.5) stages Sox4 is expression is
revealed as mosaic across the epiblast, with stronger expression at the
primitive streak (arrow); (C) By the late-bud stage, expression of Sox4 is
retained through the epiblast but stronger expression appears at the anterior
primitive-streak (arrow); (D) Sagittal section through a late-bud stage embryo
demonstrates expression of Sox4 in the epiblast with stronger expression in the
emerging definitive endoderm (arrow). At this stage of E7.5, clusters of cells in
the ectoplacental cone demonstrate Sox4 expression (arrowhead, C and D).
Brackets indicate the embryonic region distal to extraembryonic lineages.
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Figure 4.2: Sox4 is expressed during the late headfold stage and early
somitogenesis. (A) Lateral view of an embryo with 2-3 somites. Robust
expression is viewed in the endoderm of the foregut (arrow) and endoderm
adjacent to the streak. Bracket indicates region of section enlarged in (B). (B)
Sagittal section through the embryo in (A) revealing strong expression in the
foregut endoderm and weak expression in the head mesenchyme and adjacent
neurectoderm. (C) Frontal view of a late headfold stage embryo expressing
Sox4 in the definitive endoderm and foregut (arrows). (D) An embryo with 4-5
somites reveals striking expression in both the foregut (arrow) and in posterior
ectoderm adjacent to the streak (arrowhead). (E and F) Transverse section
through the embryo shown in (D) as indicated, viewed by light microscopy with
(E) and without (F) a white background to the section. Expression is revealed
in the endoderm, with a low level of expression in the neurectoderm and head
mesenchyme. Expression is also revealed, in this plane, in lateral mesoderm




Figure 4.3: Sox4 expression during early somitogenesis E8-8.5. An embryo
with 10 somites demonstrates robust Sox4 expression in numerous domains
(A-l). (A) Right lateral and (B) dorsal view reveals Sox4 expression in neural
ectoderm (arrowhead). Expression in alternate rhombomeres of the hindbrain
is marked with a bracket. Particularly strong expression is observed in the
anterior neural folds. (C) Frontal view reveals expression in the anterior
intestinal portal and a domain of mesoderm posterior to the heart. The heart
does not demonstrate Sox4 expression at this stage. The region enlarged in
(D) demonstrates these domains more clearly (endoderm, black arrowheads;
mesoderm, white arrowhead). Additionally expression is revealed in nascent
somties (black arrow). Sox4 expression is emphasised in cryo-sections of the
same embryo (E-l) as indicated in (C). Expression is present in the
neurectoderm (E-l) ventral foregut (E-G), anterior intestinal portal (black arrows,
H) and below the surface ectoderm in some regions (black arrow E).
Expression is not detected at any level in the dorsal mesocardium, or
endocardium and myocardium of the developing heart at this stage.
Mesodermal expression is shown at the base of the heart (white arrowhead H
and G) and this appears to be continuous with the pericardial mesenchyme (F)
but only at posterior regions (absent in E, white arrowhead). (J) An overstained
embryo with 8 somites demonstrates strong expression of Sox4 in the
neurectoderm and foregut. Expression appears absent from the heart tube
(arrowhead) although expression is detected in the region of the septum
transversum mesenchyme (black arrow). Expression in somites is emphasised
in (K). Abbreviations: anf, anterior neural folds; hb, hindbrain; dm, dorsal




Figure 4.4: Expression domains of Sox4 in whole embryos staged E9.5 to E10.5.
Sox4 transcripts are detected at multiple sites at E9.5 (B-D, sections J, K) and E10.5
(E-l, L-N), while no signal is detected with the sense probe for Sox4 (A). (B) Left lateral
view of an E9.5 embryo reveals strong expression in the neural tube, particularly in the
forebrain and midbrain. Expression is detected in the region of the olfactory placode
(white bracket). Less expression is detected in the hindbrain (black arrow marks
midbrain-hindbrain boundary). Expression appears intersomitic between the more
rostral somites, while caudal somites appear to express Sox4 (black arrows). Within
the E9.5 heart, Sox4 is detected in the atrioventricular canal (AVC, in C) and outflow
tract (OFT, in D). (E) In the E10.5 heart Sox4 is expressed in the AVC and OFT, with
strong expression also detected in the first and second pharyngeal arches (labelled I
and II, in E, F, G, H). (F-G) Left lateral view of E10.5 embryos demonstrating
expression of Sox4 in the neural tube, with strong expression detected in the forebrain
telencephalon (Tel) and midbrain (MB); Expression is detected in the olfactory placode
(marked with bracket in F) and the cleft between the mandibular and maxillary regions
of the first pharyngeal arch of the craniofacial region (OF); The foregut endoderm (E) is
another site of Sox4 expression; Sox4 is also expressed in the posterior region of the
forelimb bud (arrow in F and G) and in the hindlimb bud. (H) Closer examination of the
embryo in (G) reveals the extent of the wholemount craniofacial expression domains.
(I) Along the axis, expression is observed in the dorsal- and ventral-most (dS and vS)
regions of the interlimb somites, and also in the dorsal root ganglia (DRG). (J) Section
through the neural tube of the embryo in (B) reveals expression in the dermomyotome.
(K) Section through the neural tube at the level of the hindbrain reveals expression of
Sox4 in cells of the dorsal neural tube and in cells beneath the surface ectoderm. (L)
Dorsal view of an E10.5 embryo reveals expression along the length of the neural tube
(arrow). (L)-(M) Sox4 is differentially expressed within recently formed somites (M) and
between trunk somites (N), although expression is not detected in the tail bud (M).
Abbreviations: I, first pharyngeal arch; II, second pharyngeal arch; avc, atrioventricular
canal; CF, craniofacial region; DRG, dorsal root ganglia; E, endoderm; fg, foregut; Iv,
left ventricle; MB, midbrain; nt, neural tube; oft, outflow tract; som, somite; dS, dorsal
somite; vS, ventral somite; Tel, telencephalon.
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Figure 4.5: Expression domains of Sox4 in the heart and adjacent regions,
in sections of embryos staged E9.5 - E10.5. (A) At E9.5, section in situ
hybridisation to Sox4 reveals that cardiac expression is observed in the
endocardium of the atrioventricular canal (AVC); adjacent to the heart, the
foregut endoderm (fg) is a site of strong Sox4 expression, and also the
pharyngeal mesenchyme (arrows); at this level, expression is further detected
in the neural tube (nt). (B) Transcript binding is not detected with the Sox4
sense probe by section in situ hybridisation. (C) In a section adjacent to that
shown in (A), expression of a control transcript, eHand, is expressed in the
outer curvature myocardium of the future left ventricle. (D) cryosection through
the heart of an embryo stained for Sox4 expression in wholemount reveals
expression in the endocardium of both the AVC and the outflow tract (OFT);
expression is also shown in the endoderm of the foregut, pharyngeal
mesenchyme beneath the surface ectoderm (arrows, in D); trunk somites (som)
and the neural tube (nt) further demonstrate low detection of gene expression.
(E) Early E10.5 stage embryos demonstrate cardiac expression of Sox4 in the
endocardium and nascent mesenchyme of the atrioventricular canal (AVC, in E)
but not in the adjacent non-chamber myocardium or in the cardiac chambers;
expression continues from earlier stages in the foregut endoderm (fg),
pharyngeal mesenchyme (arrows) and the neural tube (nt). (F-G) Expression of
Sox4 in the E10.5 heart is detected in the endocardium and mesenchyme of the
AVC but not elsewhere in the heart at this level of section. Adjacent to the
heart, expression is detected in the foregut (fg, in F) and surrounding
mesenchyme. (H-K) Gene expression at the level of the OFT shows Sox4
transcript present in the endocardium, but not adjacent myocardium (m, in H, I
and K); this expression is consistent with expression of the endocardial marker
Nfatcl (shown in frame J); through the level of the aortic sac (AS), expression is
strongly detected in the pharyngeal mesenchyme (arrows) and the foregut
endoderm (fg), as well as the endocardium (labelled) but not myocardium (m) of
the OFT. Abbreviations: as for previous figures, but also, a, atrium; as, aortic
































































Figure 4.6: Expression domains of Sox4 in sections through the heart of
embryos staged E11.5-12.5. Transverse sections through an E11.5 embryo
(A-D) stained to detect expression of Sox4 (A, B and D) and Bmp2 (C). (A, B)
Expression of Sox4 is revealed in the mesenchyme of the atrioventricular
cushion (AVC) and developing atrial septum (arrowhead). In an adjacent
section, expression of Bmp2 was used to reveal the limits of the atrioventricular
canal, since it labels non-chamber myocardium (arrowheads, C). (D) In the
OFT of the E11.5 heart, expression is detected in the endocardium and
mesenchyme of the developing OFT cushions, but not the adjacent
myocardium: expression in the trachea (T) and esophagus (E) is also shown in
this frame. (E-H) Frontal sections through an E12.5 heart shows low
expression of Sox4 in the AVC, but strong expression in the regions of the
developing tricuspid and mitral valves (TV and MV respectively, in F) between
the atria and ventricles; at the level of the OFT, striking expression is revealed
in the mesenchyme which contributes to both septation of the ventricles and the
proximal OFT (arrowhead); expression is also detected in the endocardial
ridges of the pulmonary trunk (ER in G, and H); outwith the heart, expression is
detected in the trachea (T, in E and G). Abbreviations: as for previous figures,
except for, A, aorta (in G); AS, atrial septum; AVC, atrioventricular cushion; E,
esophagus; ER, endocardial ridges; MV, mitral valves; PT, pulmonary trunk; T,
trachea; TV, tricuspid valves.
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4.2.3 There is widespread expression of Sox4 in non-cardiac sites from mid
gestation to late gestation
Sox4 expression is detected in many non-cardiac embryonic tissues from E9.5 to
El2.5, although transcript levels vary.
From E9.5 to El2.5, Sox4 is strongly expressed in the neural tube (E9.5, Figure 4.4b;
E10.5, Figure 4.4f, g andj; El 1.5, Figure 4.7a and d; E12.5, Figure 4.7e). In neural
tissue, anterior regions of the forebrain and midbrain reveal elevated expression
compared with more posterior neural tube. At E9.5, the transition from high to low
expression at the midbrain-hindbrain junction is striking (Figure 4.4 b) while sections
through the hindbrain reveal a domain of expression below the surface ectoderm at
this level (Figure 4.4k). Strong expression continues in the forebrain and midbrain at
E10.5 (Figure 4.4f and g), El 1.5 (Figure 4.7a and d) and E12.5 (Figure 4.7e).
Expression in the dorsal root ganglia (DRG) adjacent to the somites, is also evident
from E10.5 (E10.5, Figure 4.4i; El 1.5, Figure 4.7b; E12.5, Figure 4.7e). Closer
examination of the dorsal neural tube reveals that Sox4 is expressed in what may be
delaminating neural crest (Figure 4.4k and m).
Expression of Sox4 appears to be upregulated in more recently formed somites (E9.5,
Figure 4.4b; E10.5, Figure 4.41), where it may play a role in early somite patterning.
Although elsewhere along the axis expression appears intersomitic (E9.5, Figure 4.4
b; El0.5, Figure 4.4m). Sox4 expression is not observed in the tail bud (Figure 4.41).
At the level of the atrioventricular canal of the heart (Figure 4.5 d), expression of
Sox4 is apparent in the trunk somites with higher expression in lateral regions
adjacent to the surface ectoderm. Sections through the thoracic region reveal
expression just below the surface ectoderm, appearing to mark the dermomyotome
(Figure 4.4j). Expression in the ventral-most and dorsal-most regions of trunk
somites is evident between the fore- and hind- limb buds from E10.5 to El 1.5
(E10.5, Figure 4.4i; El 1.5 Figure 4.7 b and d).
Another site of Sox4 expression is the foregut endoderm. In wholemount in situ
hybridisation, expression is observed at E9.5 and El0.5, particularly in the ventral
foregut adjacent to the developing heart (figure 4.4b, f and g). In sections,
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expression is observed at E9.5 (Figure 4.5a and d) and El0.5 (Figure 4.5e, f and k).
At El 1.5, in situ to sections through whole embryos reveals strong expression of
Sox4 in the trachea, and also the esophagus, as well as the surrounding mesenchyme
(Figure 4.6d). Expression in the trachea is also evident at E12.5 (Figure 4.6e and g).
Given the craniofacial phenotype of Sox4ENU/ENU Foxqlsa/sa embryos from E9.5 to
El3.5, it is not surprising that Sox4 is expressed in the developing craniofacial
regions. At E9.5, transcript expression is observed in the olfactory placode and the
branchial arches (Figure 4.4b). This is furthermore shown by section in situ
hybridisation of regions adjacent to the heart where strong mesenchymal expression
is detected (E9.5, Figure 4.5a; E10.5, Figure 4.5e and k). By E10.5, expression is
still detected in the olfactory placode (Figure 4.41). Strong expression is observed in
the maxillary and mandibular regions of the first branchial arch (Figure 4.4f and h),
while expression in the second arch is still evident (Figure 4.4e, f, g and h).
Expression in the developing face is present at El 1.5 (Figure 4.7a, c and d) and
E12.5 (Figure 4.7e and f). Also from E12.5, expression is seen in or around the
developing vibrissae follicles (Figure 4.7e and f) and the mammary glands (Figure
4.7e).
Expression of Sox4 is detected in the developing limbs. At E9.5 expression is
observed in the emerging forelimb bud (Figure 4.4b). E10.5 stage embryos
demonstrate limb bud expression, with elevated expression in the superficial
posterior region, possibly surface ectoderm (Figure 4.4 f and g). By El 1.5
expression appears to be concentrated in the condensing mesenchyme of both limbs,
as well as in a proximal domain in the region of the wrist (Figure 4.7a and d). The
El2.5 limbs demonstrate strong expression of Sox4 in the developing digits (Figure
4.7e).
To summarise, Sox4 is expressed in numerous extra-cardiac sites during
development. This includes sites which are known to regulate cardiac development.
The hindbrain neural crest is a site from which cardiac neural crest originates.
Additionally, it is known that the ventral foregut, a site of strong Sox4 expression,
provides inductive signals for heart development. However, not only is the foregut a
source of signals for the heart, it also plays a key role in patterning other organs. A
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number of sites which express Sox4, but are unlikely to impact on cardiogenesis
include the craniofacial regions, somites, trunk neural crest and limb buds. These
expression domains are novel findings and suggest novel roles of Sox4 in other
organ systems.
4.2.4 Sox4 demonstrates a novel expression pattern in the extraembryonic
ectoderm that may correlate to trophoblast giant cells, not apoptotic
cells.
Embryos staged E7-8.5 were dissected from the deciduas and examined for Sox4
expression with extraembryonic membranes attached. Sox4 is expressed in clusters
of cells in the ectoplacental cone (Figure 4.1c and d; Figure 4.8a and b). This
expression pattern resembles that of placental-lactogen II (PL-II), a marker of
secondary trophoblast giant cells (TGC) (El-Hashash et. al. 2005).
Given the distinctive expression pattern of the Sox4 transcript in what may be
trophoblast-derived giant cells of the extraembryonic ectoderm, and the in vitro
evidence that Sox4 attenuates the cytochrome c-dependent apoptotic pathway (Kim
et. al. 2004), the question arose whether it is possible that Sox4 marks distinct
populations undergoing apoptosis. This was addressed using a wholemount protocol
that reveals apoptotic cells. In E7-8.5 embryos cells of Reichert's membrane were
marked - both trophoblast-derived giant cells and cells of the parietal yolk sac
(Figure 4.9 a, b and c). Staining, representing apoptosis, was observed in individual
cells in the extraembryonic ectoderm rather than as clusters of cells as Sox4
expression demonstrates (Figure 4.8). This indicates that Sox4 expression does not
mark apoptotic cells in this tissue.
4.2.5 Attempted correlation with Sox4 protein localisation.
Three commercial antibodies (Sigma, Invitrogen and Santa Cruz) have been
described as reacting to mouse Sox4. Immunohistochemistry of each of these was
attempted on either wax sections with a chemical detection protocol or in toto using a
fluorescent secondary antibody. Additionally, each was attempted on a western blot
using a human colon cancer cell line (SW480) known to express high levels of Sox4.
In all cases, a control antibody, oc-tubulin, showed specific staining. Flowever none
of the commercial Sox4 antibodies yielded results (data not shown). Published
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findings reporting successful immunohistochemistry of Sox4 utilise non-commercial
antibodies (Liu et. al. 2006).
4.2.6 Foxql demonstrates a widespread expression pattern in multiple lineages
during mouse embryogenesis
During the early stages of mouse embryogenesis, Foxql is expressed in cells of both
embryonic and extraembryonic lineages. In a late-streak stage E7.5 embryo, Foxql
is observed strongly in the extraembryonic mesoderm proximal to the exocoelomic
cavity (Figure 4.10a). Weak expression of Foxql is observed at the distal tip in the
anterior definitive endoderm (Figure 4.10a and b). In a 3-somite stage embryo
Foxql is highly expressed in the anterior neural ectoderm and adjacent head
mesenchyme (Figure 4.10c, d and e). Lower expression is detected in the neural
plate along the axis (Figure 4.10c and d). Ectoderm expression is weak along the
primitive streak (Figure 4.10c and d). Low levels of expression are observed
additionally in the allantois. Striking expression is identified in the amnion adjacent
to the most anterior neurectoderm (Figure 4.10c and e).
By E8.5, the Foxql transcript is evident in embryonic endodermal tissue of both the
involuting fore- and hind-gut, although expression is highest in cells at the entrance
to the foregut (Figure 4.11). Expression is weak in the forebrain, somites and
postcranial neural ectoderm (Figure 4.1 la and b).
In situ hybridisation analysis of embryonic tissue at E9.5-E12.5 reveals expression of
Foxql in a number of specific domains including neural tissue, endoderm,
craniofacial domains and the developing limbs (Figure 4.12). The control (sense)
probe does not demonstrate binding to endogenous transcripts (Figure 4.12c).
At E9.5, Foxql is expressed in the anterior neural tissue and cranial-most extreme of
the foregut, while expression is weak in the branchial arches and adjacent endoderm
(Figure 4.12a). Expression late E9.5-E10 is evident in the forebrain, as well as the
first branchial arch, while expression in the second branchial arch is considerably
weaker (Figure 4.12b). Additionally weak expression is observed in the emerging
limb (Figure 4.12b). By El 1.5, expression is evident in the neural tissue of the
forebrain, as well as the neural tube and dorsal root ganglia. In a more posterior
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region of the axis, expression is evident in the somites (Figure 4.12d). Closer
examination of the developing face reveals strong staining of Foxql (Figure 4.12e).
By El2.5, expression continues in the neural tissue, although successful section in
situ analysis would he necessary to determine the precise tissue domains of Foxql
expression. Expression is still evident in the neural tube and in the posterior somites
(Figure 4.12f). Craniofacial expression is retained (data not shown), and expression
is now evident in the region of the developing ear (Figure 4.12g). Within the limb,
expression is observed at the outermost anterior and posterior tissue (Figure 4.12f),
as well as in the interdigital mesenchyme (Figure 4.12g). Further domains of
expression of Foxql at El2.5 include the tissue of or immediately surrounding the
developing vibrissae and mammary glands (Figure 4.12g).
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Figure 4.8: Expression of Sox4 is detected in extraembryonic membranes
at E7.5-E8.5. Embryos were dissected from deciduas and examined for
expression of Sox4 in the extraembryonic tissue. (A) Lateral view of two E7.5
embryos demonstrating extraembryonic expression of Sox4 in Reichert's
membrane. Arrowheads indicate the level of the embryonic/extraembryonic
junction. (B) Proximal view of the extraembryonic tissue of an E8.5 embryo




Figure 4.9: Apoptosis in the extraembryonic membranes during early
development. Apoptosis was detected in extraembryonic membranes by in situ
to TdT in (A) E7; (B) E7.5; and (C) E8.5 staged embryos. Brackets indicate the
extraembryonic portion proximal to the embryo. In (C) Arrowhead indicates
apoptosis in Reichert's membrane and the arrow, yolk sac. Scale bar: A and
B, 140pm, C, 460 pm.
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Figure 4.10: Foxql expression during early stages of development. (A)
Lateral view (anterior to the left) of a late streak stage (E7.5) embryo, showing
strongest Foxql expression in the extra-embryonic ectoderm of the proamniotic
canal (black arrow), proximal to the exocoelomic cavity. Weak expression is
seen at the distal tip in the emerging definitive endoderm (black arrowhead A,
B). Bracket indicates the region of the embryo enlarged in (B). (B) Distal region
of the embryo shown in (A) revealing expression in the definitive endoderm
(black arrowhead). Early somite-stage embryos demonstrate expression
throughout the anterior neural ectoderm (black arrowhead (C-E)). (C) Ventral
view of a flat-mounted presomitic embryo (head fold stage) with neural
ectoderm expression (black arrowhead) running adjacent to the midline. Weak
expression is also observed in the allantois (white arrowhead). Strong amnion
expression is observed adjacent to the head-folds (black arrow). Black lines
indicate planes of sectioning for (D) - (E). (D) Sagittal section through the
embryo in (C) shows the expression of Foxql in the head-fold neurectoderm,
and weaker expression in the head-fold mesenchyme (black arrowhead). (E)




Figure 4.11: Foxql expression at E8.5. (A) Ventral view of a flatmounted 6-
somite embryo, with strong expression in the anterior neural folds and
endoderm. Expression is demonstrated in somitic mesoderm with expression
higher in more recently formed somites towards the posterior (black
arrowhead). Brackets indicate the regions of the embryo enlarged in (C and D).
(B) Lateral view of the embryo in (A) showing Foxql transcripts are expressed
prominently in the endoderm of the foregut (white arrow) and hindgut. (C)
Enlarged frontal view of the embryo in (A and B), revealing expression in the
involuting foregut (black arrow). (D) Frontal view of the involuting hindgut of the




Figure 4.12: Foxql expression in embryos staged between E9-5-E12.5. (A)
Right lateral view of an E9.5 embryo shows expression of Foxql prominently in
the neural tissue of the head, from the caudal-most forebrain (FB) to the otic
vesicle (OV). Expression is also detected in the branchial arches (white
arrowhead), with weak expression in the gut endoderm (FG). (B) Left lateral
view of an E10 stage embryo shows expression of Foxql in the pharyngeal
arches (white arrowhead) and emerging limb buds (black arrow), while at the
same developmental stage in (C), an embryo hybridised with the sense probe
for Foxql does not demonstrate any transcript binding. At later developmental
stages, embryos staged E11.5 (D, magnified in E) and E12.5 (F, magnified in
G) continue to demonstrate weak expression throughout the neural tube (NT),
while the expression is now also detected in the dorsal root ganglia (DRG) and
the somites (S) at both stages. Furthermore, expression is detected in the
limbs at E11.5 (arrow D) and E12.5 (F) by which stage expression appears at
the wrist (arrows, F) and interdigital mesenchyme (arrows, G). (E) At E11.5
expression is detected in the craniofacial region (CF). Expression is also
detected at E12.5 in the vibrissae follicles or adjacent tissue (Vib, in F),
mammary glands (arrowheads, in G), and the tissue adjacent to the developing





To be able to understand the Sox4ENU/ENU Foxqlsa/sa phenotype, it is necessary to
know where the genes are expressed during embryonic development, preceding the
onset of the mutant phenotype (Chapter 3; (Bogani et. al. 2004; Schilham et. al.
1996)). Expression studies in this chapter focussed on comprehensively
documenting Sox4 expression in embryonic tissues from early to midgestation,
suggesting a role in several developmental processes including, but not limited to,
cardiogenesis.
Sox4 demonstrates dynamic expression patterns in many tissues, and does not seem
limited to any one lineage. Expression of Foxql overlaps with multiple embryonic
Sox4 expression domains at early stages. Consistent with a possible genetic
interaction, both transcripts are expressed in the anterior neural ectoderm and first
pharyngeal arch. These tissues give rise to the craniofacial structures with abnormal
morphology in the Sox4ENU/ENU Foxqlsa/sa mutants presented in the previous chapter
(Chapter 3).
Continuing with the primary focus of this thesis - to contribute to understanding the
basis of the cardiac Sox4 mutant phenotype - this section will focus on discussion of
embryonic expression domains which might give insight into the embryonic
requirement of Sox4 in cardiogenesis. For this, expression of Sox4 can be divided
into two categories: 1) Expression domains in cardiogenic cells directly forming the
heart; and 2) extra-cardiac embryonic expression domains which influence cardiac
development.
In the first category, expression domains include the endocardium and mesenchyme
from E9.5 in regions of the presumptive valves and septa, including regions of SHF
and NCC infiltration (Figure 4.4 c, d and e; Figure 4.5a, d, e, f, g, h, i and k; Figure
4.6a, b, d, e, f, g and h).
In the second category, expression domains include the foregut endoderm, where
expression was detected at the early headfold stage through to E9.5 (Figure 4.2,
Figure 4.3 d, e to h and j, Figure 4.5a and d) and E10.5 (Figure 4.5e, f and k).
Additionally, expression is observed in mesoderm adjacent to the posterior heart at
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the 4-somite (Figure 4.2d) and 10-somite stage (Figure 4.3d, g, h and k), possibly
continuous with posterior regions of pericardial mesenchyme (Figure 4.3f). Sox4 is
also expressed in the dorsal neural tube (Figure 4.4 k, 1 and n)
This suggests a role for Sox4 at multiple stages of cardiogenesis through its
embryonic expression within and outside the heart.
4.3.1 Possible roles of Sox4 based on expression domains in the heart
Sox4 is expressed in regions known to be infdtrated by NCC, supporting a
possible requirementfor Sox4 in NCCfunction.
Phenotypic analysis of E12.5- E13.5 Sox4ENU/ENU Foxqlsa/sa hearts revealed
abnormalities in septation of the OFT. Defects including PTA, DORV and abnormal
formation of the endocardial ridges, and their progression into semi-lunar valves,
have been described in this and other Sox4 mutants at E12.5-E 13.5 (chapter 3). To a
point, the Sox4ENU allele is consistent with the published null allele (Penzo-Mendez
et. al. 2007; Ya et. al. 1998b). Analysis of the developmental progression of Sox4
expression, in this chapter, has revealed that in the region of the OFT, Sox4 is
expressed in the endocardium at E9.5 to El 1.5, with additional expression in OFT
mesenchyme from El0.5 to E12.5. At E12.5, confirming previous expression data in
the mouse heart at this stage (Hoser et. al. 2008), the OFT expression was restricted
to the endocardial ridges of the pulmonary trunk and aorta, as well as the
atrioventricular cushion mesenchyme which contributes to the proximal septation of
the OFT and ventricles, positioning the exiting arterial vessels. This expression
further supports the possibility that a requirement for Sox4 may reside in NCC or in
cells which interact with the infiltrating NCC at the level of the OFT.
The mesenchymal population expressing Sox4 may be NCC or endocardial-derived
mesenchyme. To distinguish these cell types, it would be necessary to examine
expression of Sox4 and a marker for NCC in parallel sections or, ideally by co-
immunohistochemistry with antibodies to both Sox4 and, for example, Pax3 as a
marker of NCC in the anterior heart. NCC LacZ reporter lines could, alternatively, be
used, by examining Sox4 mRNA expression by in situ hybridisation or protein by
immunohistochemistry, in X-gal stained embryonic tissue (further to the genetic
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crosses described in chapter 3, section 3.3.1). If it were found that Sox4 were
expressed in the NCC, then further genetic crosses involving the Wntl-cre line (Jiang
et. al. 2000) and the Sox4fox/flox line (Penzo-Mendez et. al. 2007) could be conducted
to uncover this requirement, and thus a potential basis for aspects of the phenotype
observed. If the NCC and Sox4 expressing mesenchyme demonstrated adjacent,
non-overlapping domains of expression, this would also help to clarify the potential
function of Sox4, since the requirement would be in endocardial-derived
mesenchyme, and could be verified by co-expression with Tie2-cre/ R26R lines
(Kisanuki et. al. 2001; Soriano 1999). Further experiments have been detailed with
respect to determining the potential dysregulation of endocardial function in the
phenotype, presented in chapter 3 (section 3.3.1).
In addition to the intra-cardiac expression of Sox4, results in this chapter show strong
expression of Sox4 in the dorsal neural tube, from which neural crest delaminates, as
well as expression below the surface ectoderm, which may pattern transitory cardiac
neural crest (Figure 4.3a, b, e, f and h, Figure 4.4k). Furthermore, Sox4 demonstrates
strong expression in the pharyngeal mesenchyme adjacent to the developing heart,
through which NCC migrate, leaving open the possibility that Sox4 may be required
for appropriate patterning of NCC en route to the heart.
Sox4 demonstrates limited overlap with specific domains ofIsll expression
and thus may be required by the SHF.
Expression of Sox4 within the OFT may also be required in cells of the SHF. While
Sox4 is not expressed in the SHF-derived myocardium, the expression domain of
Sox4 does encompass the pharyngeal mesenchyme at the level of the aortic sac and
the dorsal wall of the aortic sac, between the arch arteries, which are fated to fuse
with the distal OFT cushions. These domains are populated by cells of the SHF and
cells which regulate SHF development, as shown by the markers Isll (Cai et. al.
2003; Yuan et. al. 2000) Mef2c (Dodou et. al. 2004) and Tbxl (Xu et. al. 2004). As
outlined in chapter 3, SHF markers applied to Sox4 mutant hearts would clarify
whether there is a requirement for Sox4 function in these cells. Co-expression of
SHF markers and Sox4 would further provide the indication that such a requirement
is cell-autonomous. Now knowing that Sox4 expression overlaps with this SHF
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domain, there is a basis to examine inactivation of Sox4 in the SHF. This would
address the question: Does Sox4 function in cells of the SHF? To achieve this,
ablation of Sox4 through Mef2c-AHF-cre (Dodou et. al. 2004; Verzi et. al. 2008)
would remove expression of Sox4 specifically in the SHF. By analysis of the hearts
of mutants derived from these crosses, with an antibody to Isl 1, it would be possible
to examine whether the population of the SHF in the heart is affected, thus
determining whether the Sox4 defect resides in cells of the SHF. Nevertheless, it is
not only the distal OFT of the aortic sac which demonstrates overlapping expression
with the published SHF gene expression. At El 1.5, expression of Sox4 was
identified in the mesenchymal cap of the atrial septum. This domain of mesenchyme
is continuous with the mesenchyme of the AVC and the DMP. The DMP is of SHF
origin and is initially identified about El0.5 by expression of SHF markers such as
Isl 1 and Mef2c, and additionally Ptch, since this structure is known to be responsive
to Shh signalling from the pharyngeal endoderm. This expression domain of Sox4
provides a possible origin for the defects or delay in development of the atrial septum
which may originate from a requirement by specific SHF domains for Sox4
expression. Marker analysis with the DMP markers, or further by crossing the
Sox4enu allele to a Ptch-LacZ background to examine whether Shh patterning is
abnormal in mutant embryos, may further elucidate a requirement for Sox4 in this
mesenchymal domain.
Sox4 is expressed in cardiac regions of the heart where the process ofEMT
occurs
In this analysis of the expression of Sox4, it has been shown that at E9.5 the non-
chamber endocardium of the AVC and OFT express Sox4. The emerging
mesenchyme in the cushions also clearly expresses Sox4. A possible disruption to
cushion development in E9.5 mutant embryos has been described (section 3.2.4).
Sox4enu/enu Foxqlsa/sa E9.5 mutants demonstrate either a delay or abnormalities in
the production of mesenchyme and its population of the cushions. This implies a
possible role for Sox4 in cushion morphogenesis. Cushion morphogenesis is
initiated about E9.5 (Dor, Y et. al. 2003) (discussed in section 1.3.3). Cells in the
endocardium respond to signals from the myocardium, both to commence and
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terminate EMT. Cells of the endocardium delaminate from this epithelium,
becoming mesenchyme within the extracellular matrix (ECM) separating the
endocardium and myocardium in these non-chamber regions (presumptive valves).
Correct formation of the cushions in these regions is necessary for later
developmental processes of septation and valve formation (reviewed in (Armstrong
et. al. 2004)).
Consistent with a possible requirement for Sox4 by the non-chamber endocardium
and mesenchyme, the mid-gestation cardiac phenotype of Sox4ENU/ENUFoxqlsa/sa, and
of the Sox4 null, includes septation defects (Chapter 3; (Bogani et. al. 2005)
(Schilham et. al. 1996; Ya et. al. 1998b)). This may be a consequence of a
requirement for Sox4 by the endocardium and mesenchyme from as early as E9.5.
The expression in the cushion endocardium and mesenchyme continues at El0.5 and
El 1.5 in both the AVC and OFT. By E12.5, expression of Sox4 is still restricted to
these cardiac domains, although the structures have developed further. The AVC
mesenchyme still retains low expression of Sox4 with higher expression in the region
of the developing valves - a domain of endothelial cell origin as shown by analysis
of the Tie2-cre/R26R line (de Lange et. al. 2004).
In the OFT at E12.5, expression is observed in the endocardial ridges - consistent
with the limited data published for expression of Sox4 at this stage in mouse
development (Hoser et. al. 2008). Proximal to the pulmonary trunk ridges, but in a
continuous domain, strong expression is observed in the mesenchyme-derived tissue
of the developing ventricular septum. These two domains have been discussed in the
context of a possible role in NCC infiltration and function within the anterior heart.
Further to this possibility, Sox4 expression may be required solely by the
mesenchyme in the OFT endocardial cushions to facilitate cushion maturation. The
cardiac phenotype observed in mutant embryos may be a consequence of inadequate
molecular programming for correct morphogenesis. Methods to examine the
production of mesenchyme in these domains has been described (section 3.3.2), yet it
remains possible that Sox4 function extends beyond the production of mesenchyme.
To determine whether the function of Sox4 resides within the maintenance of
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cushion mesenchyme, a starting point would be to examine the levels of proliferation
and apoptosis in mutant embryos compared with control stage matched controls.
Whilst it is evident that Sox4 is expressed in mesenchyme throughout the body
cavity, it has not yet been examined whether this expression is also evident at other
sites of EMT. There are several means by which Sox4 may regulate appropriate
EMT. Specifically, there are several processes in which Sox4 could act, from its
expression in the endocardium and then mesenchyme from E9.5 in the heart:
- by the secretion of factors into the ECM to promote EMT;
- in the endocardial cells as they receive signals to prime endocardia to commence
delamination into mesenchyme;
- in the endocardium as it proceeds with delamination, by a rearrangement of
cellular proteins, such as surface cadherins;
- in the mesenchyme, to maintain or proliferate.
Certainly given the widespread expression of Sox4 it is possible that it is involved in
one of these cellular process associated with EMT. However the importance needs
to be examined by assays and marker analysis of each of these possibilities
(discussed further in a subsequent chapter, section 5.3.4).
4.3.2 Possible regulation of heart development by Sox4 function outwith the
heart.
Expression ofSox4 in the foregut endoderm may play an indirect role in
cardiogenesis
The foregut endoderm expresses Sox4 from the pre-somitic stage of embryogenesis.
The endoderm plays an important role in heart patterning from the early crescent-
stage of development (section 1.3.4). At this early stage, these results of Sox4
expression appear to overlap with that published for Soxl7 in the prospective foregut
endoderm, although expression of Sox 17 is downregulated in the foregut as
involution occurs, and is no longer expressed in the foregut during early
somitogenesis (Kanai-Azuma et. al. 2002). Soxl7 null embryos demonstrate
apoptosis in the prospective foregut endoderm. The foregut structure forms, but is
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smaller than normal with fewer cells. The consequence of this, in terms of
cardiogenesis, is mild cardiac swelling and aberrant looping from E8.75 (Sakamoto
et. al. 2007). Since Sox4ENb/ u' Foxqlsa/sa embryos demonstrate a similar phenotype,
although evident from E9.5, it is possible that the cardiac swelling is a consequence
of inadequate cardiogenic cell patterning from adjacent endoderm at the headfold
stage.
Gata4 is expressed in both the endoderm and mesoderm during the stage of early
heart-tube formation (Watt et. al. 2007). Ablation of Gata4 expression results in
severe disruption to ventral morphogenesis, including an inability to form the heart
tube (Molkentin et. al. 1997). Endodermal Gata4 expression overlaps with that
observed here for Sox4. It has been shown by studies of chimseric embryos
(introducing Gata4 null ES cells into wild type morulas) that embryonic endodermal
expression of Gata4 is essential for cardiogenesis, while expression from the
embryonic mesoderm is not (Narita et. al. 1997). High contribution Gata4 null
chimseric embryos, with wild type cells only contributing to endoderm derivatives,
were predominantly indistinguishable from wild type.
Although not as severe as either of the Gata4 or Sox17 null mutants, it is possible
that components of the Sox4ENU/ENU Foxqlsa/sa cardiac phenotype may be a
consequence of a requirement for endodermal expression of Sox4. This is especially
the case since this Sox4 expression domain precedes the onset of the visible cardiac
phenotype. This suggests that Sox4 may be involved in early cardiac patterning
from the endoderm.
The phenotype of the Sox4ENU/ENU Foxqlsa/sa embryos from E9.5 also supports a role
for endodermal Sox4 in cardiac structural morphogenesis. The pharyngeal endoderm
is known to be an important source of signalling morphogens for both the SHF and
NCC, as revealed by complex analysis of genetic crosses with conditional alleles. In
an analysis of conditional mutants for Fg/8 expression, Park et.al. identified that
expression of Fg/8 from the pharyngeal endoderm was necessary for OFT septation,
with PTA only being evident in mutants in which Fg/8 expression was also lacking
from the endoderm compared with other genetic crosses examined in their study
(Park, E J et. al. 2006). Furthermore, Shh responsiveness is crucial for both SHF and
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NCC function in the development of the OFT (discussed in chapter 1; section 1.3.4).
Specifically, it has been shown that Shh signalling is required for OFT septation
(Goddeeris et. al. 2007). Embryos in which Shh-responsiveness was ablated in
either lineage were capable of developing OFT cushions, but not undergo septation.
Thus a lack of Sox4 expression in the endoderm may disrupt signalling that
contributes to septation. However since the development of the OFT cushions is
additionally delayed or disrupted in Sox4 mutants, other expression domains of Sox4
clearly are required independently of the endodermal expression.
Of relevance to atrial septation, the DMP is of SHF origin, with its presence in the
developing heart dependent upon expression of Shh from the endoderm, and the
responsiveness of the SHF at this pole of the heart (Goddeeris et. al. 2008). While it
has been shown that at El 1.5, Sox4 is expressed in the mesenchyme continuous with
the DMP, it is possible that Sox4 expression from the endoderm is also required for
the appropriate molecular programming of this dynamic migratory structure.
Although the expression domain overlap of Sox4 with Shh and FgfS does not indicate
functional overlap, it is possible that the role of Sox4 as a transcription factor may be
to maintain appropriate levels of the expression of either of these factors. Whilst
examining the regulatory regions of these genes for conserved Sox4 binding sites
may suggest a mechanism, conclusive proof of an effect on downstream signalling
by marker analysis or receptor activation would be required.
To conclude, the findings in this chapter, presenting the expression of Sox4 in the
pharyngeal endoderm at the stages examined, permit the proposal that this domain of
expression is required for appropriate cardiogenesis. This is further supported by the
overlap in aspects of the Sox4ENU/ENU Foxqlsa/sa cardiac phenotype with those
described for mutants in which endodermal expression or target cell responsiveness
to endodermally derived signalling factors is disrupted. Abolishing Sox4 expression
using Shh-cre (Harfe et. al. 2004) would allow a distinction to be made between the
requirement for endodermal expression of Sox4 and the cardiac expression within the
endoderm and mesenchyme.
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Does Sox4 mark the septum transversum mesenchyme?
Sox4 is expressed in the lateral mesoderm immediately caudal to the heart tube from
the 4-somite stage. It is not clear from sections whether this domain is continuous
with the base of the heart tube. At the 8-somite stage (Figure 4.3j) expression of
Sox4 appears to overlap with published domains of Cited2 (Dunwoodie et. al. 1998).
In an embryo with 10 somites, this Sox4 domain appears to be continuous with
pericardial mesenchyme of the posterior heart as shown by section analysis (Figure
4.3d and f). The fate of this group of Sbx4-expressing cells is not clear, but given the
timing and location of expression, they could be cells of the septum transversum
mesenchyme (STM) which contributes to the early stages of pro-epicardial (PEO)
development (section 1.3.5). Citec/2 and Gata4 mark this mesodermal structure prior
to formation of the PEO (Dunwoodie et. al. 1998; Watt et. al. 2007). Additionally,
this domain of expression closely resembles that of TbxlS, a marker of the STM and
PEO. In mouse, TbxlS expression in the lateral mesoderm appears bilateral (Kraus
et. al. 2001a), however in chick, STM expression of both TbxlS and Bmp4 are
clearly unilateral and on the right side (Schlueter et. al. 2006). In chick, it has been
shown that generation of the PEO is subject to left-right patterning, while in mouse
this is yet to be reported. Expression of Sox4 may correlate to a TbxlS or Bmp4
right-sided expression domains in the mouse heart. However if this is so, then Sox4
expression is downregulated prior to epicardial attachment to the heart - as the
epicardium does not demonstrate Sox4 expression.
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4.4 Summary
Identifying the expression pattern of Sox4 was an essential first step to identifying
which tissues require Sox4. Sox4 is expressed across early developmental stages in
most tissue, although some express Sox4 more highly than others. The expression
domains of Sox4 which are most likely to be relevant for cardiogenesis are: (1)
regions of the heart itself, including non-chamber endocardium and mesenchyme;
and (2) domains of extra-cardiac origin, namely the foregut endoderm and possibly
the STM. Expression of Sox4 in regions unrelated to heart development includes the
dermomyotome of the somites, limbs, trunk neural crest and anterior neural and
craniofacial tissue. Some of these findings are novel and add to the existing
knowledge of localisation of Sox4. The expression reported for Foxql at this stage is
also novel. Expression in the somitic mesoderm, limbs, neural tube, foregut and
hindgut suggests potentially novel roles for Foxql as a factor in the development of
these structures. The broad expression domains of Sox4 and Foxql suggest that
these genes play more diverse roles than currently reported in the literature.
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Chapter 5: Examining Aspects of
the Molecular Consequence of the
Sox4ENl Foxq1sa Mutation.
5.1 Introduction
The phenotype observed for Sox4ENU/ENU Foxqlsasa (also, termed compound mutant)
embryos is complex. By examining compound mutant embryos staged E7.5 to E13.5
we have determined that a cardiac abnormality is visible from E9.5. Among the
embryos where a morphologically distinct heart had developed, a grading of
deformity is evident with class-II embryos exhibiting a more severe phenotype than
that of class-1. At E9.5, mutant hearts are distended to varying degrees. This impairs
the ability of the heart tube to undergo adequate looping, although handedness
appears normal. In order for a phenotype to present at E9.5, the first molecular
requirement for Sox4 function must be prior to this stage. Given the expression
domains of Sox4 documented in the previous chapter, it is reasonable to suggest that
Sox4 expression in the endoderm is required for the patterning of adjacent
cardiomyocytes in the SHF and/or NCC (section 4.3.2). Additionally expression of
Sox4 within the endocardium of the OFT may influence NCC infiltration and
function in the OFT (Section 4.3.1). The E12.5 and E13.5 defects of proximal OFT
septation and abnormalities in ventricular and atrial septation may be a consequence
of inadequate Sox4 expression from earlier developmental stages (section 3.3.2).
Furthermore, cardiac expression of Sox4 is observed from E9.5 in the endocardium
and mesenchyme of the presumptive valve regions (Chapter 4; Figure 4.4 and 4.5),
together with a consistent abnormal phenotype in the AVC at E9.5, this enables us to
consider that Sox4 may be involved in endocardial cushion development, by way of
the production and pattering or maintenance of the mesenchyme and thereby
subsequent valve development in the AVC and proximal OFT.
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Given these many potential functions of Sox4, it is of interest to examine markers at
the earlier developmental stages - to uncover molecular dysregulation as it arises.
Thus, the aim of this chapter is: To examine aspects of the molecular consequence of
the Sox4enu Foxqlsa compound mutation.
This study is the first in which the early Sox4 cardiac phenotype is examined at the
level of gene expression. Given the heterogeneity of the Sox4 phenotype and the
overlap of the resulting defects with those arising from other cardiac gene mutations,
a selection of molecular markers were examined. Later in this chapter, a discussion
of results from these markers will be further complemented by a discussion of more
useful markers for the affected cardiac structures. An added complexity, in deciding
which markers to use, comes from knowledge that, although there are a number of
cardiac phenotypes that have been described which overlap with the Sox4ENUENU
FoxqT" sa E9.5 phenotype, many of the genes dysregulated in these mutants do not
overlap in their expression with domains of Sox4. This is particularly relevant for
the cardiac phenotype which arises in the chambers of the heart - the looping defect
in wholemount, cardiac swelling and abnormal trabeculation. Sox4 is expression is
not detected by in situ hybridisation in the myocardium of the heart. Indeed the only
cardiac expression of Sox4 is from E9.5 within cells of the endocardium and
mesenchyme of non-chamber regions. If abnormal Sox4 exerts an effect on the SHF
(as has been proposed in chapter 3) or if it is involved in regulation of proliferation
or differentiation (also proposed in chapter 3, in the context of early defective
trabeculation), then the role of Sox4 must be upstream of SHF colonisation of the
heart, or Sox4 must act indirectly via signalling from the non-chamber expression
domains or pharyngeal endoderm.
The cardiac defect appears to be largely restricted to derivatives of the secondary
heart field. The proximity of the endodermal expression of Sox4 to cells of the
secondary heart field suggests an indirect patterning role. Hand2 is a marker of the
SHF, labelling the right ventricle and OFT within the anterior heart. Because of this
Hand2 was examined as a secondary heart field marker for the myocardium of the
right ventricle and outflow tract. Given the degree to which Sox4 mutant hearts are
capable of developing (depending on the severity, Sox4 mutants are capable of
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forming the four-chambered heart), it is unlikely that the Sox4 mutation alters
expression of Nkx2.5 or Isll, since both of these genes are required at crucial early
stages of cardiac patterning. Severe cardiac defects arise in the absence of either
gene (Cai et. al. 2003; Lyons et. al. 1995). Thus expression of these genes was not
examined in Sox4ENU/ENUFoxqlsa/sa mutant hearts. In hindsight, examination of Isll
would have proved useful for determining the degree of SHF population in mutant
hearts, as has been described (section 3.3.1 and 4.3.1).
The abnormal cardiac morphology of the Sox4ENU/ENU FoxqF"/sa mutant at E9.5
resembles the phenotype of that described at E9 in the cardiac knockout of Handl,
both with and without heterozygous inactivation of Hand2 (McFadden et. al. 2005)
(Section 3.3.2). It is possible that this overlap in phenotype may be a consequence of
Sox4 and Handl regulatory pathways converging at some level. To explore this
further, expression domains of Handl were examined. Handl is expressed in the
OFT and outer curvature of the left ventricular myocardium (Cserjesi et. al. 1995).
Handl has been associated with proliferation in the developing heart, and therefore
may give some indication whether proliferation is affected in Sox4ENU/ENU Foxqlsasa
compound mutants (Risebro et. al. 2006). In addition to being a marker of the SHF,
Hand2 is, in part, also responsible for stimulating the early proliferation and growth
of regions of the heart tube, as indicated by the severely hypolastic right ventricular
phenotype of Hand2 null embryos (Yamagishi et. al. 2000). The Hand2 transcript is
controlled from E9.5 by the expression of the miRNA, miR-1. Transcription of miR-
7 is a target of cardiac muscle differentiation factors, including SRF, MyoD and
Mef2. As the heart tube loops, expression of inhibitory micro RNA blocks Hand2
translation and thus decreases the production of Hand2 protein and drives
differentiation (Zhao et. al. 2005). Thus expression of Hand2 was examined in
mutant embryos, to label SHF cells and also to examine whether there is a disruption
to proliferation and differentiation levels within the heart, although it is not a direct
marker of either process.
To explore whether myocardial differentiation was affected as a consequence of the
Sox4ENU/ENU Foxqlsa/sa phenotype, despite some mutant embryos appearing
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developmentally delayed, Nppa expression was examined as a marker for chamber
myocardium specification and differentiation.
Given the expression of Sox4 (Chapter 4) and the phenotype described (Chapter 3) it
has been proposed in previous chapters that a function of Sox4 may reside in the
production of cushion mesenchyme in the AVC and OFT. In this chapter, gene
expression was examined in the developing E9.5 OFT, since a dysregulation of gene
expression would be detectable at this stage, resulting in the E9.5 phenotype, which
further in development could lead to the septal defects observed from El2.5. Wntl1
is expressed by the myocardium and endocardium of the OFT (Christiansen et. al.
1995). Fibroblasts expressing Wntl 1 have been shown to transform epithelial cells
to mesenchyme in co-culture experiments (Christiansen et. al. 1996). Embryos null
for Wntll demonstrate OFT defects similar to those observed with Sox4 mutant
homozygotes (Zhou, W et. al. 2007). To date, a direct role of Wntl 1 in the EMT of
the OFT endocardium has not been described. It has been shown that Wntl 1 induces
expression of 7g/)S2 in the myocardium of the OFT (Zhou, W et. al. 2007).
Downregulation of Tgff52 expression in Wntll null mutant hearts results in double
outlet right ventricle (DORV) and ventricular septal defects (Zhou, W et. al. 2007) as
a consequence of inadequate OFT development. In mouse, Tgt]32 has been shown to
be required for EMT in cardiogenesis. Blocking the function of Tgf|32 prevents the
initial transformation of epithelial cell into mesenchyme during EMT of the AVC in
explant cultures (Camenisch et. al. 2002). Little is known about the downstream
targets of Sox4 (section 1.1.3). If Sox4 plays a role in development of the OFT, then
it may be involved in Wntll signalling. To explore this, Wntll, its receptor Fzcl7,
and the Wntl 1 target Tgfj32 mRNA levels were examined in micro-dissected outflow
tracts, comparing a mutant OFT with pooled control outflow tracts.
The appearance of three classes of phenotype, and at least two periods of embryonic
lethality, highlights that Sox4 and Foxql proteins have roles at multiple stages
during development. In addition to the cardiac defects, which are attributed solely to
the Sox4 mutation, some class-I and all class-II mutants examined demonstrate
variable anterior defects (Figure 3.8). This implies that either, or both, Sox4 and
Foxql are involved in forebrain patterning.
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The development of the forebrain requires signalling from two domains: (1) the
anterior-most region of neurectoderm (anterior neural ridge, ANR); and (2) the
prechordal plate, which is the anterior-most axial mesoderm continuous with the
notochord. (Figure 5.1). Expression of Fg/8 from the ANR and of Shh from the
prechordal plate is essential for regionalisation of the forebrain at E9.5 ((Shimamura
et. al. 1997); reviewed in (Rubenstein et. al. 1998)). Since Sox4ENU/ENU Foxqlsa/sa
embryos demonstrate variable forebrain abnormalities, it is possible that signalling
through these two domains, the ANR and prechordal plate, is disturbed. Furthermore
both Sox4 and Foxql are expressed in the anterior neural folds (Chapter 4). It has
been shown that, at E8.5, prior to a morphological defect arising, expression of Sox4
and Foxql is detected in the neurectoderm of the prospective forebrain. This
expression further supports a genetic interaction in anterior development at this
embryonic stage, namely in patterning the presumptive telencephalon. Co-
expression of Sox4 and Foxql at E9.5 in the forebrain and first pharyngeal arch
suggests that both proteins are required for aspects of craniofacial morphology, since
facial development, including formation of the nasal structures and jaw, also appears
impaired in compound mutants at E12.5 (Section 3.2.5; Figure 3.17). An
examination of the molecular changes accompanying this phenotype may provide
information useful to understand the basis of the interaction. In addition to the
primary investigation into the cardiac abnormalities, this chapter shows an in situ
analysis of some forebrain markers in Sox4ENU/ENU Foxqlsa/sa embryos.
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Figure 5.1: Schematic diagram showing the locations of the signalling
centres of the developing forebrain at E9.5.
Within the developing forebrain, the anterior neural ectoderm is the anterior-
most region of the developing telencephalon. A second signalling centre is
the prechordal plate, which is continuous with the notochord, adjacent to the
hypothalamus (hypo). The zona limitans intrathalamica (zli) marks the
boundary between the forebrain and midbrain. Abbreviations: hypo,
hypothalamus, tel, telencephalic vesicles; p, prosomere; me,
mesencephalon; is, isthmus; r, rhombomere; zli, zona limitans intrathalamica.
Adapted from: Rubenstein and Beachy, 1998.
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5.2 Results
5.2.1 Homozygosity of Sox4E!Kl causes an alteration to the expression of Hand2
and Handl and an increase in the expression of Nppa at E9.5-E10.
To explore the molecular basis of the Sox4 mutant cardiac phenotype, we examined
the expression of genes whose products are associated with myocardial cell
proliferation in the heart (Hand2 and Handl) or myocardial cell differentiation
{Nppa) within the heart. Given that Sox4 mutant embryos demonstrate a
predominantly right-sided, and possibly a secondary heart field defect, it was also
predicted that changes in gene expression would be observed in SHF-derived cardiac
regions.
At E9.5 Hand2 expression is observed in the OFT extending into the adjacent region
of the RV (Figure 5.2a and c, (Srivastava et. a/. 1997)). At this stage, weak
expression is also observed through the posterior heart. Adjacent to the heart,
expression of Hand2 is detected in the dorsal mesocardium and the pharyngeal
arches. In Sox4 mutant hearts (n=2), the Hand2 expression is not lost but rather
appears reduced, with weak staining throughout the expression domains observed in
the control (Figure 5.2b and d). The control embryo shown (Figure 5.2a and c) was a
littermate to the mutant embryos. All embryos were subjected to the same in situ
hybridisation conditions, including the in situ development time. It is possible that
the developmental delay in the mutants has contributed to the different level of
expression in mutant hearts. However the extent of this delay, combined with the
cardiac defect, renders the results from this probe inconclusive, since the mutant
embryos could neither be compared with the control littermates nor subsequently
with younger E9 developmental controls, since the normal cardiac development of
earlier stages did not resemble the phenotype of the mutant embryos in which Hand2
was examined. In order to concluded from analysis of the expression of Hand2, or
any other SHF marker, it is necessary to examine mutant embryos at earlier stages,
before the phenotype progresses, or examine embryos at this stage with a less severe
phenotype, such that control embryos are developmentally matched to the mutant
embryos.
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Late-stage E9.5 control hearts demonstrate Handl expression in the OFT and outer
curvature of the left ventricle (Figure 5.3a, (Cserjesi et. at. 1995)). In stage matched
littermate embryos subjected to the same in situ hybridisation conditions,
Sox4ENU/ENU Foxqlsa/sa mutants exhibit reduced cardiac Handl expression (n=2/2).
In the less severe class-I mutant there is a decrease in the Handl transcript in both
cardiac domains of expression (Figure 5.3b). Handl expression is barely detectable
in the more severe class-I mutant, where the heart is more swollen and has failed to
undergo adequate looping (Figure 5.3c). The in situ detection was deliberately
understained to observe this difference between control and mutant embryos. In
contrast, extraembryonic expression of Handl appeared to develop to the same
intensity in all three embryos examined. Despite the looping defects, and although
Handl expression in the OFT is diminished, the length of the OFT does not appear to
have been reduced - although this was not subjected to quantitative measurement.
OFT length should be examined given the possible involvement of SHF and/or NCC
in the Sox4 phenotype (as discussed in chapter 3). Extraembryonic expression of
Handl in the yolk-sac membranes appears unaffected by the Sox4ENU/ENU Foxqlsa/sa
mutation (data not shown).
Nppa expression marks the differentiation of embryonic myocardium into chamber
myocardium of the atria and ventricles ((Zeller et. al. 1987); reviewed in (Houweling
et. al. 2005)). To examine whether the cardiac phenotype of Sox4 mutant embryos
was accompanied by increased differentiation, in situ to Nppa transcripts was
conducted on a control and homozygous mutant heart (n=l at E9.5). At this stage, as
shown by the control littermate, normal expression of Nppa is strong in both atria
and in the left ventricle (Figure 5.4a and b, (Zeller et. al. 1987)). The right ventricle
reveals a gradient of Nppa transcript - extending from the weakest point of
expression at the outer curvature of the myocardium which is continuous with the
OFT, to stronger expression adjoining the left ventricle. The Sox4ENU/ENU Foxqlsa/sa
heart did not demonstrate this gradient. The right ventricle of the mutant heart
demonstrated uniform elevated expression (Figure 5.4c, d), suggestive of either
abnormal right ventricular patterning or increased differentiation. Nevertheless, at
E9.5, expression is distinctly absent from the AVC in both control and mutant, and
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expression levels in the adjacent atrium and left ventricle appear unaffected at this
stage, suggesting that the Sox4 mutation does not alter the patterning and regulation
of Nppa expression in the AVC or to the left side of the heart. Interestingly, the
elevated ventricular expression of Nppa is reminiscent of that in later stage (Ell)
embryos which contain just the Sox4 mutation (chapter 6). However whether it is
reproducible at E9.5 in compound mutants remains to be determined. This in situ is
not quantitative and to determine levels of Nppa it would be necessary to examine a
greater number of hearts both by quantitative-PCR of specific cardiac regions and
also in situ of additional mutant embryos with alternative markers of myocardial
differentiation.
5.2.2 Micro-dissection of E9.5 cardiac regions enabled examination of gene
expression in the OFT.
Often in the literature, comparative results of quantitative cardiac gene expression
are presented from procedures carried out on total heart extracts. To determine more
precisely the genetic alterations within discrete cardiac regions, E9.5 control (Figure
5.5a) and class-I mutant (Figure 5.5b) hearts were micro-dissected into OFT, RV,
LV, AVC and IFT, using glass needles (Figure 5.5c, d and e). Only the mild class-1
mutant embryos could be micro-dissected in this procedure as severe swelling of the
heart tube did not permit visual distinction of the regions in class-11 mutants. Given
that even within the class-I mutants the phenotype may be varied, for the purpose of
examining an alteration to gene expression it was decided that samples from mutant
embryos be kept separate for expression analysis. Using this technique, gene
expression in the OFT was assessed for the expression of genes with a known
association to EMT either in the heart (Tgf/32) or elsewhere in the embryo {Wntl 1).
The levels of Wntl 1, its receptor Fzd7 and the Wntl 1 transcriptional target Tgf/52
were compared between pooled control OFT and a class-I mutant OFT (Figure 5.51).
The one class-I mutant OFT examined demonstrated elevated levels of all three
transcripts.
212
Figure 5.2: Difference in the expression domain of Hand2 in Sox4ENU/ENU
Foxq1sa/sa E9.5 embryos. (A) Wild type and (B) mutant expression of Hand2
is detected throughout the looping heart tube, with higher expression in the
outflow tract (red arrowhead) and right ventricle. Expression is weak in the
left ventricle, atrioventricular canal and inflow tract of the developing atria.
Adjacent to the heart, expression is observed in pharyngeal arches (yellow
arrow). (C) Wild type cardiac expression viewed from a right-lateral
orientation. Strong expression in the outflow tract is indicated (red arrow)
and the domain of right ventricular staining is marked with lines. (D) Mutant
embryos demonstrate lower expression of Hand2 (outflow tract and right
ventricle marked as for wild type). Abbreviations: AVC, atrioventricular canal;
LV, left ventricle; OFT, outflow tract; RV right ventricle. Scale bar: A,B




Figure 5.3: Disruption to expression of Handl in Sox4ENU/ENU Foxq1sa/sa
embryos at 9.5dpc. (A) Expression of Handl is detected in wild type
embryos the outflow tract (arrow) and in the outer curvature of the left
ventricle (arrowhead). Mutant embryos (B,C) demonstrate lower expression
of Handl in these regions. Scale bar: A, B, C, 1mm.
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Figure 5.4: Elevated expression of Nppa in Sox4ENU/ENU Foxq1sa/sa
embryos at E9.5. Wild type (A,B) and mutant (C,D) hearts were examined
for Nppa expression. Hearts are viewed from the posterior side (A,C) and
the left side (B,D). At this stage, expression is strong in the atria and left
ventricle of both wild type and mutant hearts and absent from the
atrioventricular canal (bracket, A, C). A notable difference is observed in the
right ventricle (arrow C compared with A) and outer curvature of the right
ventricle leading into the outflow tract (arrowhead B compared with D).
Abbreviations: LA, left atrium; LV, left ventricle; OFT, outflow tract; RA, right
atrium; RV, right ventricle. Scale bar: A - D 143.5pm
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Figure 5.5: Microdissection of E9.5 hearts for expression analysis of
developmental genes. Analysis of cardiac gene expression by PCR to
microdissected regions of wild type and mutant hearts. Hearts from a wild
type embryos (A) and mutant embryos (B) were microdissected for
quantitative PCR analysis. (C) A whole heart dissected from a wild type
embryo body. A glass needle was used to cut between the left ventricle and
the presumptive right ventricle (bulbus cordis, BC), in the region indicated
(black arrowhead). (D) The outflow tract and bulbus cordis were then
separated as indicated (black arrowhead) as were the (E) left ventricle from
the atrioventricular canal and part of the inflow tract (presumptive atria). (F)
Quantitative expression analysis was performed on cDNA reverse-
transcribed from RNA extracts from the outflow tract, normalised to Tbp as
an internal control. One mutant outflow tract was compared with pooled wild
type samples for gene expression with UPL probes to Wnt11, Fzd7 and
Tgfb2. Error bars represent experimental replicates from the pooled control
RNA and one mutant RNA extracted from a single OFT. Abbreviations: AVC,
atrioventricular canal; BC, bulbus cordis; IFT, inflow tract; LV, left ventricle;
Mu, mutant; Wt, wild type.
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5.2.3 Aspects of the anterior phenotype are revealed by a reduction in Fgf8
expression in class-I and class-II mutant embryos.
To begin to analyse the forebrain defect in Sox4ENU/ENU Foxqlsa/sa embryos, Fg/8
expression was examined. Alteration to Fg/8 expression has demonstrated it to be
essential for anterior patterning and forebrain development (Meyers et. al. 1998). At
E9.5, a lateral view of an Fg/8 stained embryo reveals expression in the first
pharyngeal arch in both mandibular and maxillary regions (Figure 5.6a, (Crossley et.
al. 1995)). Analysis of the staining pattern from the frontal orientation exposes
anterior Fg/8 expression in the telencephalic commissural plate, marking the midline
of the anterior neural endoderm (Figure 5.6c). Adjacent to this domain, expression is
observed in the surface ectoderm of the olfactory placode. These expression
domains are observed in the Sox4ENU/ENU Foxqlsa/s" class-1 embryos (n=2). However,
the regions are diminished, with reduced staining at the midline and weaker staining
in the olfactory placode (Figure 5.6d). It is from this region that the midline
structures of the face are generated and Fg/8 expression in this region is critical for
appropriate patterning of the facial primordium. Additionally, the first pharyngeal
arch is poorly formed such that both the maxillar and mandibular domains are
markedly smaller (Figure 5.6b). Interestingly, class-I mutant embryos revealed a
normal level of Fg/8 expression in the isthmus - a signalling centre responsible for
patterning the adjacent midbrain and anterior hindbrain. This suggests that caudal
brain structures may be unaffected by the compound mutation.
Comparison of wild type expression (Figure 5.6e and f), with that of a class-II
mutant embryo (Figure 5.6g and h), revealed an almost complete absence of Fg/8
expression at the midline, exposing the severity of the forebrain defect in this class of
phenotype. Fgf8 expression is observed in the isthmus. However, this expression
domain is reduced, seemingly proportional to the deformed appearance of the
embryo. The expression domain in pharyngeal arches also appears slightly
diminished in the mutant embryo (Figure 5.6g and h).
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5.2.4 Expression of Shh in a class-II mutant embryo marks the presence of the
forebrain-midbrain boundary, but reveals an absence of regions further
anterior.
Shh is a useful marker at E9.5 for regions of the developing brain, the axis and, of
significance for heart development, foregut and pharyngeal endoderm (Echelard et.
al. 1993). Since class-II mutant embryos demonstrate the most severe forebrain
defect (while still retaining evidence of rostro-caudal neural differentiation), the
expression of Shh was used to detect the presence or absence of specific regions.
Control (Figure 5.7a) and class-II Sox4 mutant (Figure 5.7b) embryos each
demonstrated Shh transcript labelling in the rostral foregut and the zona limitans
intrathalamica (ZLI). The ZLI marks the boundary between the forebrain and
midbrain and signals to pattern the adjacent forebrain and midbrain. Shh expression
is undetected regions anterior to the ZLI in class-II embryos, while expression in the
control is identified in the prechordal plate (Figure 5.7b). It is notable from this
expression analysis that the ventral foregut, and the pharyngeal endoderm of class-II
embryos appear to retain normal expression of Shh (Echelard et. al. 1993),
suggesting that the Sox4 mutation acts either downstream of Shh function, or in a
separate pathway.
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Figure 5.6: Expression of Fgf8 in Sox4ENU/ENUFoxq1sa/sa embryos at E9.5.
Heads of a wild type and class-l mutant were examined for Fgf8 expression
(A-D). In wild type embryos, expression is observed in the mandibular (Md)
and maxillary (Mx) regions of the 1st pharyngeal arch (labelled in A,C). In the
lateral view (A) expression is detected in the isthmus (Isth), while the frontal
view (C) reveals normal expression in the anterior neural ectoderm at the
commissural plate (black arrowhead) and the olfactory placode (black
arrows). Mutant embryos demonstrate expression in the 1st pharyngeal arch,
however this domain is reduced (labelled in B,D). The lateral view (B)
reveals that expression in the isthmus appears similar to wild type. In
contrast the frontal view of a mutant embryo (D) demonstrates a
considerable reduction in the expression of Fgf8 in the commissural plate
(black arrowhead) and olfactory placode (black arrows). Comparison of a
class-ll mutant embryo (G,H) with litter-matched wild type (E,F) reveals
considerable developmental delay, accompanied by diminished expression
of Fgf8 in the mutant forebrain (frontal view, H). In the mutant, expression is
detected in the isthmus (arrowhead) tailbud (arrow) and pharyngeal arches
adjacent to the heart (bracket G compared with E, F). These domains
appear slightly reduced in the class-ll embryo. Abbreviations: Isth., Isthmus;
Md, mandibular first pharyngeal arch; Mx, Maxillary first pharyngeal arch.




Figure 5.7: Expression of Shh in Sox4ENU/ENU Foxq1sa/sa embryos at E9.5.
Wild type (A) and Class II mutant (B) embryos examined together for Shh
expression by in situ hybridisation. Expression is detected in both the mutant
and wild type embryo within the rostral foregut (FG), the zona limitans
intrathalamica (ZLI), ventral foregut (bracket) and forelimb bud (FL), as well
as the notochord and floorplate along the anterior-posterior axis of the
embryo. Expression in the mutant embryo was detected in the same
expression domains as in the wild type. Notably in the mutant embryo
expression of Shh ceased at the ZLI and expression was not observed
adjacent to the telencephalon in the prechordal plate as indicated in the wild
type embryo (A, absent domains in B) Abbreviations: FG, foregut; FL,
forelimb bud; Tele., Telencephalon; ZLI, zona limitans intrathalamica. Scale




Development of the heart relies on strict control over the regional differences of gene
expression. There is a delicate balance between proliferation, growth, expansion of
chambers and differentiation, in addition to appropriate molecular programming.
Alterations to the normal progression of signalling may result in a primary
phenotype. However the reaction of the heart to a primary phenotype may result in
subsequent abnormalities, not directly related to the initial aberration. By examining
dysregulation to gene expression in class-I and class-II embryos at E9.5, we are able
to expand on our understanding of the possible causative embryonic origin of the
cardiac deficiency observed by dysregulation of Sox4. Additionally, these results
enable a degree of dissection of the forebrain abnormalities observed due to a
possible genetic interaction between the mutant allele of Sox4 and satin.
5.3.1 Mutation in Sox4 alters the expression level of Handl.
The dose-sensitivity of the heart to Handl and Hand2 proteins has been well
characterised (McFadden et. al. 2005). It is possible that at least part of the Sox4
phenotype is caused by a mild Handl/Hand2 deficit. Whilst there is evidence of
right ventricle specification in Sox4 mutant hearts, as shown by the presence of
Hand2 expression (Figure 5.2), there is also abnormal looping and poorly
trabeculated myocardium at this stage (Results, Chapter 3). This degree of overlap
with the phenotype resulting from conditional ablation of Handl in myocardium
combined with heterozygosity of Hand2, suggests that Sox4 may be involved in
similar cellular processes as the Hand proteins. It is interesting that expression
domains of Hand2 are not abolished. Although examined in only two embryos at
this stage, the cardiac expression domains appear to correspond with those of the
control littermate embryo (developed under the same conditions), suggesting that
ectopic expression is not observed. Due to the control not being appropriately
staged, it is not possible to draw conclusions about whether Hand2 expression is
reduced. Sox4 mutant embryos demonstrated a reduction in the embryonic
expression domain of Handl. However, expression of Handl was not reduced in all
expression domains, since expression in extraembryonic lineages was still retained at
227
equally strong levels across control and mutant. Whilst it may be the case that the
lineage differences are due to the action of different promoters, the lack of overlap in
expression of Sox4 with Handl (in the left ventricular myocardium) could only be
explained if there was an indirect regulation of the embryonic promoter via
additional intermediate secreted factors. A second explanation is also possible -
mutation in Sox4 has resulted in a reduction of the number of Handl expressing cells
by this stage of development. If aspects of the E9.5 phenotype of Sox4 mutants are a
consequence of reduced Handl, the disruption to Handl and expressing cells may
occur prior to the phenotype arising. To clarify whether a role of Sox4 exists in the
regulation of Handl requires substantial further investigation of their expression
from an earlier stage of cardiogenesis.
5.3.2 Is Sox4 involved in processes leading to cardiac cellular proliferation or
differentiation?
Outwith the heart, studies on Sox4 supports the possibility that Sox4 is involved in
cellular processes leading to proliferation and/ or differentiation during development.
BMP signalling is implicated in hair follicle differentiation from hair follicle stem
cells, which are normally retained as slow-cycling cells in a small niche (termed the
bulge). In this system, the hair germ at the base of the follicle, below the bulge,
normally expresses a low level of Sox4 transcript. Removal of Bmprla leads to
proliferation of cells and ectopic expression of Sox4 within the bulge and elevated
expression in the adjacent hair germ (Kobielak et. al. 2007). In this system it appears
that the hair follicle stem cell population undergoes excessive proliferation.
Furthermore the population affected by the elevated expression of Sox4 is that of the
hair-follicle stem cells, which retain a more undifferentiated state. Further support
for a possible role of Sox4 in the regulation of proliferation has come from analysis
SOX4 in a cancer cell line. Expression of cyclin D1 is regulated by SOX4 in the
human colon cancer cell line, SW480 (Sinner et. al. 2007). It was observed that
knockdown of SOX4 by siRNA resulted in a decrease in proliferation (detected by
phospho-histone H3 staining) and a decrease in cyclin D1 expression. This was
suggested to be due to knockdown of the interaction of SOX4 with (3-catenin, which
is also known to regulate expression of cyclin Dl.
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Results presented in this chapter suggest that expression of a cardiac marker
associated with proliferation is reduced while at the same time, a marker of chamber
myocardial differentiation is enhanced in a Sox4ENU/ENU Foxqlsa/sa E9.5 embryo.
This is a starting point to exploring whether Sox4 plays an indirect role in regulating
proliferation or differentiation of cells which form the heart. There are two ways in
which Sox4 could act in this manner: The first possibility is that wild type Sox4 is
involved in cellular proliferation and thus converges on a function of Handl or
Handl-expressing cells. The second possibility is a role of Sox4 in repressing
differentiation and thus differentiation markers, such as Nppa. Analysis of these
markers alone is insufficient to conclude whether the phenotype in mutant embryos
is a consequence of either a reduction in proliferation or enhanced differentiation,
although their association supports these possibilities. Analysis of the number of
proliferative cells in mutant hearts would be the first step in examining this further.
Detection of phospho-histone H3 levels in sections of mutant hearts prior to and
during development of the abnormal phenotype would be useful to examine this
possibility. Given that Handl expression commences at earlier stages of
development than that shown as results for class-I mutant embryos, this proposed
analysis would be conducted from earlier stages, to examine whether proliferation is
reduced from the heart tube stage prior to and during looping.
5.3.3 What is the cause of increased Nppa expression in the right ventricle in
Sox4enl,/enu Foxqls"/sa mutant hearts?
In a normal E9.5 heart, Nppa transcripts appear lower in the right ventricle,
compared with the left ventricle, during the transition from embryonic myocardium
to functional myocardium. Results in this chapter reveal elevated expression of
Nppa in the right ventricle. Ectopic expression of Nppa may suggest that a lack of
Sox4 results in enhanced differentiation. The only possibility for this change in
expression at the molecular level would be an indirect role of Sox4 from the OFT,
being to direct expression of a signalling factor, which in-turn regulated Nppa
expression in a gradient across the developing RV myocardium. As Sox4 is
expressed in the endocardium of the OFT, adjacent to the SF1F myocardial cells
which contribute to RV development, it may also be possible that expression of Sox4
is required for contribution of progenitor cells to the RV. In the absence of this, the
229
RV may be more populated with normally left ventricular, or FHF, myocardium.
However in situ analysis of Nppa alone is not sufficient to reveal if this is the case.
Rather, it would be necessary to examine mutant embryos for expression of LV or
FHF myocardial markers, such as Tbx5 (Bruneau et. al. 1999).
An alternative possibility, for the increase in expression of Nppa, is that the
expression could be induced as a consequence of the malformed heart attempting to
compensate for the early cardiac defects by enhancing myocardial differentiation and
thus is an indirect consequence of the phenotype. It is known that Nppa expression
is dynamic during the life of the adult heart (reviewed in (Houweling et. al. 2005)).
In cases of heart failure, expression of Nppa is reactivated. During embryogenesis
the heart undergoes a response to cardiac stress if demands on early cardiac function
outweigh the ability of the heart to pump. In the developing mouse heart at El 1.5,
the expression of Nppa has been shown to be associated with populations of more
differentiated cardiomyocytes (Zhang et. al. 2007). However, Nppa expression and
thus differentiation occurs much earlier than this. The cardiac knockout of Handl
demonstrates a substantial increase in the expression of Nppa in the right ventricular
chamber at E9.5 (McFadden et. al. 2005). This is not an expression domain of
Handl and thus expression of Nppa at this stage was attributed to be a secondary
response to cardiac stress. Neither is the RV an expression domain of Sox4.
Furthermore, Sox4 mutants demonstrate inadequate looping and cardiac swelling at
the stage of Nppa upregulation. Thus it is possible that expression of Nppa is an
effect of the phenotype, rather than a contributing cause. Although to verify this
hypothesis, it is necessary to examine cardiomyocyte differentiation by other
markers of differentiation such as by immunohistochemistry on sarcomeric proteins.
There still remains the appearance that the ectopic expression occurs only within the
myocardium of the RV. This may be a consequence of the quality of the Nppa probe
and strong expression already existing within the other three cardiac chambers,
leaving little ability for the in situ hybridisation to be semi-quantitative. To examine
whether the phenotype is RV specific, it would be necessary to examine gene
expression quantitatively in micro-dissected hearts (as detailed in this chapter) to
determine whether the elevation only occurs in the RV.
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5.3.4 Determining whether Sox4 plays a role in the process of EMT in the
developing OFT
To date, the association of Sox4 with the morphological process of an epithelial to
mesenchymal transition comes from examination of cancer cell lines in culture.
Expression of inhibitory micro-RNAs, which block Sox4 translation, is specifically
lost when breast cancer cells develop metastatic potential (Tavazoie et. al. 2008).
Indeed in tumorigenesis, Sox4 expression is predominantly enhanced (section 1.1.3).
It has been proposed, from results in previous chapters, that there is an association of
Sox4 expression with regions in which EMT is required for cardiac development.
The phenotype of the Sox4ENU/ENU mutant may include abnormal production of
mesenchyme. This study has also raised the possibility that the severest class-Ill
embryos are deformed as a consequence of abnormal gastrulation - a process that
also requires EMT. Additionally, it is evident from histology shown in chapter 3 that
a disruption to the body mesenchyme is also a component of the phenotype (chapter
3, not discussed, also evident from sections Figures 3.1, 3.3 and 3.5). Sox4
expression is consistently observed in mesenchyme in all regions examined (chapter
4, not discussed, also evident from section in situ figures 4.5 and 4.6). Thus there
may be a role for Sox4 in the development of mesenchyme. A developmental role
for Sox4 in EMT has not been characterised, nor have other extracardiac domains in
which EMT is required for development, such as the kidney, been examined for a
phenotype in this mutant. The marker analysis conducted by quantitative PCR on
extracts from the OFT was intended to uncover a possible mechanism through which
Sox4 may act.
Embryos null for Wntll demonstrate some overlap in OFT defects with those
observed in Sox4 mutant homozygotes (Zhou, W et. al. 2007). It is for this reason,
and that Wntll was identified as a regulator of Tgf(52, that Wntll expression was
examined. By microdissection and quantitative PCR, one class-I OFT revealed an
increase in the transcript levels of Wntll, its receptor Fzd7 and immediate
downstream target gene Tgff32. Whilst this may seem initially to be a contradiction,
since it is embryos which lack Wntll that resemble the Sox4 mutant OFT phenotype,
it is plausible that Wntll levels are dependent upon expression of Sox4 from the
endocardium or from within the mesenchyme once it is produced. Evidently this
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potential function of Sox4 requires further investigation with increased sample size,
since this analysis was performed on only a single mutant sample compared with
pooled control tissue from multiple hearts. Nevertheless, a few possibilities arise
that require further investigation, with a greater number of mutant embryo OFT
samples:
(1) It may be possible that Tgf|32 acts through Sox4 to regulate an aspect of the
cardiac EMT, and the mutant Sox4 is incapable of transducing the Tgf|32
message.
(2) Given the elevated levels of Wntll, Fzd7 and Tgffil expression, it may be
possible that Sox4 expression from the endocardium and subsequent
myocardium serves to feed back on Wntl 1/Fzd7 expressing cells to regulate
gene transcription both of Wntl 1 and Fzd7 and thereby expression of Tgf '132.
(3) The normal transcriptional level of gene expression may be initially higher
than subsequent developmental stages. Although the mutant embryo was
stage matched to the pooled control embryo tissue, it is possible that not all
were developmentally matched. The elevated gene expression in the mutant
may simply be another consequence of the of a developmental delay.
Whilst these are interesting possibilities, clearly they require further investigation
with an increased number of samples, not only examining expression by quantitative
PCR, but also expression by in situ. Furthermore, although Tgf'132 is known to be
involved in cardiac EMT, and Wntl 1 is known to function upstream of Tgf/52
expression in the heart, Wntl 1 signalling has not yet been shown directly to induce
EMT in the heart, despite evidence from other systems (as outlined in the
introduction to this chapter). Explant cultures (Runyan et. al. 1983), of the OFT
from hearts of Wntll null embryos, would enable determination of whether the
morphogen is essential for normal endocardial EMT. If abnormal migration is
observed in this assay, subsequent addition of Wntl 1 (as conditioned media) and a
recovery of the ability of endocardial cells to undergo EMT would support this
function of Wntll in the heart. Blocking signalling through Fzd7 would further
enable it to be shown conclusively that Wntll signals through this receptor in the
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heart. Additionally, it would be possible to determine whether Sox4 mutant OFT are
able to respond to Wntll signalling by conducting an explant assay. If an EMT
defect was observed in Sox4 mutant tissue, and if this was not recovered by Wntl 1
stimulus, Sox4 would be known to function downstream or independently of Wntl 1.
Whilst the markers examined in this study were initially considered to be most
useful, for the reasons outlined in the introduction to this chapter, in hindsight there
are additional markers which would be useful for uncovering the role of Sox4 in
cardiogenesis. A number of these have been described in detail within earlier
chapters. For the purpose of discerning whether a role for Sox4 exists in cardiac
EMT, an explant assay of mutant cardiac tissue would be informative (as detailed,
chapter 3, section 3.3.2). In the context of marker analysis, E9.5 -E10.5 hearts could
be examined for the localisation of markers, the presence of which is known to be
altered at the cellular level during EMT. Examination of the endocardial cells and
subsequent mesenchyme by immunohistochemistry could show whether the
endocardium inappropriately retains cell-cell contacts and whether the mesenchyme
expresses an appropriate repertoire of markers (for example, Sox9 (Akiyama et. al.
2004), ErbB3 (Lakkis et. al. 1998)). Certainly, examination of these aspects of EMT
biology will contribute substantially to the understanding of the role of Sox4 in
cardiogenesis.
It has been proposed that Sox4 may play a role in the cellular processes regulating
proliferation. Combining this with a possible role for Sox4 in EMT, it may be that
reduced cell number of Sox4 expressing cells may contribute to the phenotype of the
OFT. Whilst the examination of cell number in the developing OFT cushions has
not been quantitative, the El2.5 OFT endocardial cushions demonstrate less
population by cushion mesenchyme (smaller cushions, observed in El2.5 embryos,
Figure 3.2 g, k and h, 1, compared with control c, d). Dysmorphology of the OFT at
E9.5, in addition to the abnormal swelling, may be a consequence of reduced cell
number. It has been shown and discussed in this thesis that the level of Vegf
signalling is critical for EMT and that both elevated levels and haploinsufficiency are
capable of disrupting cardiac EMT (Carmeliet et. al. 1996). A reduced cell number
in the OFT may be causative of a delay or defect in the process of EMT. It has been
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shown that both Sox4 and Nfatc are expressed in the OFT endocardium. Although
the Nfatc expression domain has not been altered in Sox4 null hearts at El2.5 (Ya et.
al. 1998b), expression levels of Nfatc have not been examined at earlier stages in
Sox4E!SlU/ENU mutants at the stage in which Nfatc protein is known to act to induce
cardiac EMT (Chang et. al. 2004). A reduced cell number in the endocardium,
which initially is the only site of Sox4 expression in the heart, may alter Vegf levels.
Thus two markers of the process of endocardial cushion formation, which should
also be examined in Sox4ENU/ENU mutant hearts, are Nfatc and Vegf.
5.3.5 Reduced expression of Fgf8 and Shh in anterior domains exposes the
degree of forebrain abnormality in Class-I and Class-II mutants.
Class-I and class-II mutant embryos were examined to determine the extent of the
forebrain abnormality. FgfS expression marks the anterior-most neurectoderm, the
anterior structures of the commissural plate and olfactory placodes (section 5.1). Shh
marks the prechordal plate and is also useful for analysing the caudal extremity of
the telencephalon, since it marks the ZLI (section 5.1).
It has been shown that even class-II mutants express Shh in the expected pattern at
the telencephalic boundary, whilst development is abnormal anterior to the ZLI. Shh
expression does not appear to be detected in the prechordal plate. Thus, anterior
regions are either incorrectly patterned or are absent. Furthermore, expression of
Fg/8 is barely detectable in the anterior region of class-II embryos, while a reduction
is observed in the anterior expression domains of class-I embryos. Given that
Sox4ENU/ENUFoxqlsa/sa phenotype is observed at E9.5, and that at E8.5 homozygotes
are largely indistinguishable from heterozygotes or control embryos, it is likely that
Sox4 and Foxql are required around E8.5. Since Sox4 and Foxql demonstrate
strong expression in the endoderm from early head-fold stage, it is possible that the
requirement for these genes resides in their endodermal and neurectodermal
expression from the head-fold stages (Chapter 4; figures 4.2 and 4.11).
The anterior phenotype revealed in this study is similar to that reported for other
mutants isolated from the ENU mutagenesis screen, using satin as a selective
recessive marker (Bogani et. al. 2005; Willoughby 2006). Interestingly, Sox4ENU/ENU
Foxqlsa/sa class-I mutants demonstrate a similar reduction or loss of Fg/8 and Shh
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expression as that reported for other isolated ENU mutant lines which do not
demonstrate the cardiac phenotype observed in Sox4 mutant embryos. Other ENU
mutant phenotypes were analysed in hemizygous mutant embryos (crossing to the
Del(13)Svea36H mouse), which lacked one allele of both Sox4 and Foxql, while the
remaining Foxql allele contained the satin deletion. Given this, and the overlap of
phenotype (Chapter 3 discussion, section 3.3 part 2), it is increasingly likely that
Sox4 and Foxql co-function during early anterior patterning, prior to a visible defect
arising at E9.5. Clearly, the requirement for Sox4 and Foxql in anterior structures
requires further investigation.
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5.4 Summary of the identified molecular changes in
Sox4fnlj/enu Foxq1sa/sa embryos, compared with control
embryos
We have been able to study the effect of the dual satin and Sox4 mutations. While
Sox4 null embryos were suggested to have a mild anterior phenotype, the presence of
the satin allele modulates this. This chapter has shown that the development of
anterior structures is severely compromised in a class-II mutant which lacks Shh
expression in anterior domains. Although still defective, class-I mutants demonstrate
some anterior patterning, as indicated by the presence of Fgf8 expression, although
this is reduced relative to wild type.
During cardiogenesis, it appears that homozygosity for the mutant Sox4 allele causes
expression domains Handl to be reduced, but not ablated - perhaps due to an
underlying defect in proliferation, which needs to be examined. An upregulation of
the cardiac marker Nppa in the right ventricle is suggestive of enhanced
differentiation in mutant embryos; although this could be a consequence of cardiac
stress. In order to be conclusive about the embryonic function of Sox4, further
marker analysis is required. In addition it is necessary to explore the phenotype and
molecular consequences of Sox4ENU/ENU with normal expression from the Foxql
allele.
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Chapter 6: Analysis of Sox4enu/env
Embryos, Wild type for FoxqI.
6.1 Introduction
Previous chapters have documented aspects of the embryonic phenotype arising from
the Sox4enu/enu Foxqlsa/sa genotype in compound mutant embryos (chapter 3).
Results indicate that components of this phenotype are a consequence of a genetic
interaction between the Foxqlsa allele and the Sox4IJx' allele, while others are a
consequence of mutation in Sox4 alone. Expression analysis of Sox4 and Foxql
reveals co-expression of these two transcripts in the developing endoderm and
anterior neural ectoderm from the early somitogenesis stage (chapter 4). Together
with evidence of a reduction or absence of anterior structures in some mutant
embryos, as shown by Shh and Fg/8 expression at E9.5 (chapter 5), it is clear that for
normal development, there is a requirement for Sox4 and Foxql in patterning of the
telencephalon and adjacent anterior tissues (eye, olfactory placode, mandibular and
maxillary arches that contribute to the structures of the face) from the early stages of
anterior morphogenesis. Whilst such defects have not been reported for Foxqlsa/sa
embryos (Hong et. al. 2001), anterior defects have been observed in some FoxqF'
embryos (Goering et. al. 2008). It is possible that aspects of this phenotype may still
be observed in some Sox4 single mutant embryos. However, if the phenotype is
exacerbated because of the compound mutation then it would be expected that Sox4
mutants demonstrate a less severe phenotype. Whether there is a direct interaction
between both proteins; whether they act independently on the same signalling
pathway; or whether they exert their function on pathways which simultaneously or
sequentially act in the same tissue, remains unknown. It has been shown that the
phenotype of the compound mutant, Sox4ENU/ENU and Foxqlsa/sa, differs from the
phenotype published for Foxqlsa, FoxqF and Sox4~ alleles. Such an interaction is
237
novel and requires further investigation to determine the embryonic origin of the
defect, and protein analysis to examine functional overlap.
The findings presented in previous chapters have also suggested that mutant Sox4 in
the endoderm from the head-fold stage, combined with expression in OFT and AVC
endocardium and mesenchyme from E9.5, accounts for the cardiac abnormalities
observed in the compound mutant. Although the precise requirement, whether it be
by the NCC, the SHF cells or by endocardium undergoing EMT, remains to be
determined. In order to state conclusively which aspects of the compound mutant
phenotype are attributable to Sox4ENU, this allele needs to be examined in the
genomic context of wild type Foxql. Thus, the aim of this chapter is to: Commence
analysis of the phenotype of Sox4ENU/ENU embryos wild type for Foxql combining
methods ofanalysis used in chapters (3) and (5).
Segregation of the two alleles through breeding was one method through which this
could be accomplished. After six generations of backcrossing from the M91 line
onto C57B1/6J, two mice (from different litters) were observed to have segregated
the mutant alleles and thus harboured only the ENU-induced Sox4 mutation. These
mice were backcrossed to C57B1/6J mice to expand the line and generate sufficient
mice for intercrossing and thus examination of the homozygous phenotype. Marker
analysis in this chapter largely overlaps with that performed on compound mutant
embryos in the previous chapter with the intent to enable comparison of expression.
In addition, given that looping defects appear consistent between the Sox4ENU/ENU
single mutant hearts (results in this chapter) and the Sox4ENU/ENU Foxqlsa/sa
compound mutant hearts (results, chapter 3), the expression of Pitx2 was examined.
Pitx2 marks the inner curvature of the looping heart tube (Campione et. al. 2001). It
was intended to establish whether abnormal looping correlated to perturbed
expression of Pitx2 in this domain in both single and compound mutants. However
time constraints and lack of availability of compound mutants, at the stage at which
Pitx2 was examined in single mutants, prevented this comparison. Continuing with
the analysis of compound mutants in chapter 5, the expression of Fgf8, Handl and
Nppa are examined here with single mutant Sox4ENU/ENU embryos The preliminary
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results in this chapter thus contribute to determining the origin of the cardiac
phenotype induced by mutation in Sox4.
6.2 Results
6.2.1 Phenotypic analysis of homozygosity of the Sox4FNl allele
To determine which regions require Sox4 in development, embryos from
heterozygous intercrosses were examined from E9.5-E13.5. For the analysis of
phenotype, the limited number of embryos examined reflects that this data was
obtained at the end of the breeding programme.
In a manner similar to Sox4~/~ and Sox4ENU/ENU Foxqlsa/sa E12.5-E14.5 embryos, one
E13 Sox4enu homozygote (n=l/l) revealed a visible embryonic phenotype when
compared with a control littermate. Pericardial swelling and severe oedema in the
body cavity was observed, accompanied by trapped blood, both in the heart and body
cavity (Figure 6.1a (control), b and c (frontal and dorsal view of the one mutant El 3
embryo)). Clearly cardiac insufficiency is retained as part of the Sox4ENU/ENU mutant
phenotype. At El3 anterior defects were not observed. Craniofacial development
appears normal, as does eye pigmentation. The difference in eye pigmentation was a
key differential between all observed compound mutants at this stage (Chapter3; n=5
E12.5; n=6 E13.5; Table 3.3) and control embryos (chapter 3; Figure 3.1 and 3.17).
An embryo examined at Ell demonstrated normal anterior development but slight
swelling of the pericardial cavity and, upon dissection, swelling of the heart was
evident (Section 6.2.2 Nppa expression; Figure 6.5). Although neither the El3 nor
Ell embryo demonstrated a craniofacial phenotype, the low number examined in
this study (n=2/2) does not eliminate the possibility that mutation in Sox4 alone is
capable of causing a craniofacial phenotype of variable penetrance and/or
expressivity.
In Sox4 heterozygote crosses, the phenotype was also examined from E9.5-E10.5.
The phenotype of Sox4ENU/ENU embryos is similar to that described for the compound
mutation (Figure 3.8). The phenotype appears to follow a similar pattern of severity
as that of the cardiac aspect of the Sox4ENU/ENU Foxqlsa/sa mutants. In comparison to
control littermates (Figure 6.2a, b), of five homozygotes examined, three class-I
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mutants demonstrated a mild defect in cardiac looping (Figure 6.2c, d), while one
class-II mutant demonstrates a "class-II" swollen heart (as classified in chapter 3) but
only a slightly deficient forebrain (Figure 6.2e). This is in contrast to class-II
compound mutants in which the forebrain defect was significantly more pronounced
(compare figure 6.2 with figure 3.4). Examination of FgfS expression revealed that,
even in the one Sox4ENU/ENU class-II embryo (n=l/l), FgfS domains at the anterior
midline and olfactory placode are present (Figure 6.3). One embryo examined at this
stage could be classified as demonstrating a severe class-II phenotype (Figure 6.21).
This particular embryo lacked appropriate anterior development and demonstrated
exposed cranial neural folds, although neural tube closure has occurred below the
hindbrain. Axis extension had progressed to 30 somites (compared with 35 in a
control littermate) and limb development had commenced. Despite the low number
(n=T/5 of all E9.5-10.5), this suggests that a small proportion of embryos
homozygous for Sox4 still undergo a severe disruption at an early stage of
development, prior to the requirement of Sox4 in formation of the heart. This is also
shown by the ratio of genotypes from heterozygous crosses. (Table 6.1). As the
numbers of embryos was small, it is not possible to state whether there is a
statistically significant change to the expected Mendelian ratio. However, the
presence of one reabsorption site at El 1.5-13.5 suggests that embryonic death before
this stage occurs in Sox4ENU/ENU mutants.
From these results it seems that the craniofacial phenotype observed in the
Sox4enu/enu Foxqlsa/s" compound mutant is possibly derived from a genetic
interaction between these two factors. Additionally, these preliminary results further
suggest the requirement of Sox4 at early stages of development, causing embryonic
death prior to that which is a consequence of cardiac insufficiency at E14.5.
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Figure 6.1: One embryo at E13, homozygous for Sox4ENU, shows
pericardial swelling, haemorrhaging and generalised oedema. The
whole-embryo phenotype of Sox4ENU/ENU is pronounced at E13. When
compared with a wild-type littermate (A), the homozygote embryo (B, frontal;
C, dorsal) exhibits trapped blood in the heart (white arrow, B compared with
wild-type A) and haemorrhaging within the body cavity (black arrowhead, C),
as well as oedema, revealed by swelling and folds of skin (white arrowhead,
C). Scale bar: A - C, 361pm
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Figure 6.2: Embryos at E9.5 homozygous for Sox4ENU demonstrate a
complex phenotype. Wild-type embryos (A,B) demonstrate normal cardiac
development . In contrast, mutant embryos (C-F) demonstrate defective
looping. The mild class-l mutant embryos (C,D) demonstrate inadequate
looping. (E) A severe class-l mutant embryo demonstrated significant
cardiac swelling. (F) One severe class-ll mutant embryo was examined at
this stage and demonstrates hypoplasia of the heart tube and inadequate
folding of the neural tube. Mutant embryos (C-D) do not demonstrate a
significant reduction in anterior structures (arrow indicates rostral
telencephalon). Abbreviations: LV, left ventricle; OFT, outflow tract. Scale
bar: A - F, 570pm.
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Figure 6.3: Expression of Fgf8 in Sox4ENU/ENU mutant embryos E9.5. (A)
Wild-type embryos demonstrate normal expression of Fgf8. (B) A class-ll
mutant embryo do not demonstrate a lack of any expression domains
observed in the wild-type (pharyngeal arches indicated by bracket).
However, expression in the pharyngeal arches appeared reduced (white
arrowhead, B compared with A). Fgf8 expression in the anterior
neurectoderm persists in the mutant embryo (olfactory placode, white arrow;
midline, black arrow). Abbreviations: FL, forelimb bud; HL, hindlimb bud;




Table 6.1: Ratio of genotypes in Sox4+/ENU intercrosses at selected
stages during development.
Stage Number Homozygous Heterozygous Wild type
9.5-10.5 19 5 26% 9 47% 5 26%
11.5-13.5 17 3 (1) 18% 10 59% 4 24%
Stage, embryonic stage of development; Number, observed number of embryos
genotyped at the Sox4 locus, subsequently grouped according to genotype. Findings
are depicted as both the number of embryos for each stage and genotype, and the
percentage for each genotype. Value in brackets shows the number of reabsorption
sites for that genotype at that stage. Reabsorption sites were excluded from
calculation of the percentage of genotype.
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6.2.2 Embryos homozygous for Sox4ENL/E!sl demonstrate an alteration to
cardiac gene expression.
To examine whether the alterations to cardiac gene expression observed in the
compound mutant also occur in single mutant embryos with the Sox4 mutation, we
examined Handl and Nppa expression.
Expression of Handl is associated with proliferative cells in the OFT and in the outer
curvature of the left ventricle (as discussed section 3.3.2). Cardiac Handl transcript
is detected in both regions in the E9.5 single mutant and control embryos. Lower
magnification reveals expression to be relatively similar in both the wild type control
(Figure 6.4a) and class-I mutant (Figure 6.4c). Higher magnification of the cardiac
expression reveals the control heart to have undergone correct looping, and normal
Handl expression is reflected as a gradient of staining along the length of the OFT,
with higher intensity at the dorsal aspect (Figure 6.4b). In the Sox4 mutant this
domain of expression appears reduced in length, although the OFT itself does not
appear to have shortened, as examined here (Figure 6.4d). A degree of defective
looping is prominent in this class-I embryo as the heart is not as tightly looped as in
the control, causing the OFT to still extend anteriorly rather than posteriorly towards
the atria. Expression appears unchanged in the left ventricle, although this was not
confirmed by quantitative analysis.
The domains of cardiac expression are consistent between this experiment and the
Handl analysis in chapter 5. It is striking though, that the intensity of staining
differs. This is due to different in situ conditions in the process of staining. The
gradient of reduced Handl expression, shown in chapter 5, was revealed by
understaining the signal (section 5.2.1). In hindsight consistent timing for exposure
would have enabled a better comparison in this study between the two mutant lines.
Longer staining times may reveal the extent of disruption to the Handl expression
domain more fully. Nevertheless, the cardiac expression domains of Handl differ
consistently in expression levels between the mutant embryo and control embryo.
Since the pattern is similar between both mutant Sox4 lines, the possibilities
discussed in Chapter 5, whereby it was suggested that Sox4 function may converge
on that of Handl, and play a role in proliferation, are further supported here. This
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provides a further reason to explore proliferation in the developing heart, and
examine whether this correlates with a developmental point at which a loss of Sox4
may cause the initial step to result in the appearance of a phenotype.
At E9.5, a Sox4ENU/ENU Foxqlsa/sa mutant demonstrated elevated expression of Nppa
in the right ventricle (Chapter 5; figure 5.4). Since the affected domain of Nppa
expression does not express Sox4, it was proposed that this expression can be
attributed to altered maturation and differentiation of the myocardium. With a lack
of any evidence for downstream signalling by Sox4 target genes at this stage, which
could result in dysregulation of Nppa expression, the enhanced differentiation could
equally be attributed to the abnormal cardiac morphology resulting in stresses on the
early cardiac chambers and thus premature differentiation in RV myocardium.
To explore whether this was consistent in Sox4ENU/ENU embryos, and whether the
elevated expression levels persisted in the subsequent days of development, Nppa
expression was characterised in Ell embryos (Figure 6.5a, b). Control hearts
demonstrated strong expression of Nppa in the left ventricular chamber and in both
atria. Expression in the right ventricle is weak and Nppa transcript is not detected in
the AVC or OFT (Figure 6.5c). Aberrant Sox4 function does not appear to alter
expression of Nppa significantly in the left ventricle or left atrium, nor does it induce
Nppa expression within the OFT or AVC. However, consistent with findings for the
younger compound mutant embryo, the single mutant Sox4ENU/ENU embryo
demonstrates striking right ventricular expression (Figure 6.5d). Furthermore, the
single mutant heart demonstrates substantially stronger staining in the right atrium.
The heart appears larger in the mutant embryo at this stage, with the OFT exhibiting
swelling (Figure 6.5d, compared with control c, further emphasised in (d) by the red
line indicating the extension, on the length of the line shown in (c)). It is possible
that the right atrium is also larger, although the postero-dorsal side of these hearts
were not imaged and this can not be said with certainty.
In the normal heart, the stresses caused by peristaltoid contraction along the heart
tube are thought to regulate the initial formation of trabeculae (Thompson et. al.
Chapter in (Clark et. al. 2000)). With looping and the commencement of ventricular
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septation, the pressure on the myocardium becomes uneven across the heart, and
trabeculations in the left ventricle appear thicker than those in the right ((Sedmera et.
al. 1997; 1998; Wenink 1992; Wenink et. al. 1982) and reviewed in (Sedmera et. al.
2000)). The enhanced level of Nppa expression shown here, combined with the
appearance of a swollen heart in the Sox4ENU/ENU mutant embryo, further supports the
possibility that enhanced differentiation is occurring as a consequence of the
abnormal cardiac morphology and thus elevated stress on the cardiac tissue.
Examination of the histology of the cardiac tissue may reveal this further. Abnormal
maturation of right ventricular myocardium may exert an effect on the development
of anterior cardiac structures, including formation of the OFT endocardial cushions if
the myocardium extends into this region. This, in turn, may contribute to the
septation defects, including DORV and PTA below the developing semi-lunar
valves, as observed with mutation to Sox4 described in chapter 3.
In the normal developing heart, the atria also respond to increases in myocardial
stresses by changes the myocardial architechure (Anderson et. al. 1996; Hu et. al.
1995). The right atrium develops significantly more pectinate muscle than the left.
Elevated staining of Nppa expression in the right atrium is suggestive of altered
differentiation within this chamber, which is not an expression domain of Sox4.
Elevated right atrial contractility may contribute to the defects at the venous pole of
the heart. Although the atrial myocardium was not examined in detail for the stages
shown, the delay in formation of the atrial septum and the appearance of a common
atrioventricular valve through some sections of each mutant heart may be a
consequence of an increase in the stresses on right atrial development from this
earlier El 1 stage.
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Figure 6.4: A Sox4ENU/ENU embryo shows abnormal expression of Handl
at E9.5. In both wildtype (A) and mutant (C) Handl is expressed in the
outflow tract (OFT) and adjacent continuous region of the pharyngeal arches
(I and II). Expression is also detected in the outer curvature of the left
ventricle (LV) and the lateral plate mesoderm (LPM). The cardiac region is
enlarged in (B) wild-type and (D) mutant, as indicated by the bracket in (A)
and (C). (D) The mutant embryo demonstrates a reduced expression
domain of Handl in the outflow tract. Additionally cardiac looping is
impaired, compared with wild-type (B). The magnified region does not reveal
alteration to gene expression in the left ventricle of the mutant compared with
wild-type. Abbreviations: I, first pharyngeal arch; II, second pharyngeal arch;
LV, left ventricle; LPM, lateral plate mesoderm; OFT, outflow tract. Scalebar:
A,C 500pm; B,D enlarged from A,C by same magnification.
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Figure 6.5: A Sox4ENU/ENU embryo demonstrates elevated right
ventricular expression of Nppa at E11. Wild-type (A,C) and mutant (B,D)
embryos were examined for expression of Nppa. Expression of Nppa is
observed in the maturing myocardium of all four cardiac chambers - atria
and ventricles. In the wildtype (A,C) expression is reduced in the right
ventricle, at this stage. In contrast, the mutant heart (B,D) demonstrates
elevated level of expression in the right ventricle. Additionally it is evident
that the heart is distended. The outflow tract is swollen in the mutant heart
as indicated (bracket D, with extension in red, compared with bracket C).
Abbreviations: LA, left atrium; LV, left ventricle; RA, right atrium; RV, right





Figure 6.6: A Sox4ENU/ENU embryo exhibits a reduction in the expression
of Pitx2 at E9.5. In both a wild-type embryo (staged 33 somite pairs)
(A,B,C) and mutant embryo (staged 31 somite pairs) (D,E,F), expression of
Pitx2 is revealed in the mandibular (Md) and maxillary (Mx) regions of the
pharyngeal arch (labelled in A,B,D,E) and in the lateral plate mesoderm (left
in B,E). Enlargement of the cardiac region, reveals expression of Pitx2 in the
inner curvature of the atrioventricular canal and atrium is undetectable in the
mutant embryo (arrows F compared with C). Abbreviations: I, first
pharyngeal arch; L-LM, left lateral plate mesoderm; Md, Mandibular region of
the first pharyngeal arch; Mx, Maxillary region of the first pharyngeal arch.
Scale bar: A, B, D, E, 500pm; C, F, 233pm.
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Pitx2 isoforms are largely responsible for patterning left-side identity of the heart and
indeed left patterning of the embryo (Ryan et. al. 1998). Although Sox4 mutant
hearts do not demonstrate an abnormal direction of looping or cardiac isomerism,
they do demonstrate abnormal looping and inadequate positioning of the future
chambers. Expression of Pitx2 marks the inner curvature (Campione et. al. 2001)
and this domain contributes to appropriate cardiac looping. To examine whether
Sox4 mutation alters Pitx2 expression, a class-I mutant was compared with a stage-
matched control embryo (Figure 6.6a to f). These embryos were matched within two
somite pairs (mutant 31 somite pairs; control 33 somite pairs). At E9.5, Sox4 mutant
hearts lack detectable cardiac expression of Pitx2 in the inner curvature of the AVC
and left atrium (Figure 6.6f compared with c). This domain of expression was the
only significant decrease in Pitx2 expression. Other regions of expression displayed
the expected pattern, although expression appeared slightly reduced consistent with
the smaller embryo size.
The expression of Pitx2 has been shown to be strong in the inner curvature of the
AVC and left atrium at El0.0 (Campione et. al. 2001). The embryos examined in
this study are staged late on the 10th day of gestation (E9.5- E10). To examine
whether a developmental delay may contribute to the differences in expression,
embryos with 7-8 fewer somite pairs, earlier 10th day of gestation, were examined for
expression of Pitx2 in this domain. The younger control embryos did not
demonstrate visible expression of Pitx2 in the inner curvature and left atrium (data
not shown). Thus it is possible that the lack of expression in this domain in the
mutant embryo is a consequence of a cardiac developmental delay.
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6.3 Discussion.
This chapter has presented novel findings from studying embryos homozygous for
the ENU-induced mutation in Sox4. Segregation of the satin allele removes the
potential for a genetic interaction to modulate the phenotype, leaving it possible to
uncover a phenotype that is solely the consequence of mutation in Sox4. The results
presented in this chapter have enabled several points suggested in previous chapters
to be analysed further:
(1) In terms of the craniofacial abnormalities observed in the compound
mutant phenotype, results from this chapter suggest that abnormal Sox4 is capable of
causing a mild anterior phenotype. It is possible that this mild anterior abnormality
is an indirect consequence of the developmental delay in mutant embryos of the
genotype examined in this chapter. If this were the case, expanding on the number
of embryos and developmental stages examined to explore specific markers for
anterior patterning will enable further dissection of this role. It is interesting that the
phenotype observed in this limited number embryos was not as severe as that
observed in embryos harbouring the compound mutation (Figure 6.2, compare with
figure 3.8). This suggests that the severe anterior defects observed with the
compound mutation are a consequence of a genetic interaction between Sox4 and
Foxql, although the nature of this is yet to be determined.
(2) The point mutation in Sox4 results in more severe abnormalities than
those described in published work on Sox4 mutations (Penzo-Mendez et. al. 2007;
Schilham et. al. 1996; Ya et. al. 1998b). Still, embryos with a class-Ill phenotype
were not observed in the Sox4ENU ENU study. This is not surprising since class-Ill
comprises 5% of Sox4ENU/ENU Foxqlsa/sa embryos and in this study only five E9.5-
10.5 Sox4enu/enu embryos were examined.
(3) Sox4ENU/ENU mutant embryos demonstrate a reduction to the OFT domain
expression of F/andl at E9.5 and elevated expression in the Nppa right ventricular
domain and also in the right atrium at Ell. In chapter 5, it was shown that in
Sox4ENU/ENU Foxqlsa/sa hearts the level of Handl expression appeared proportional to
the severity of the compound mutant phenotype. The lower the level of Handl
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expression, the more severe the phenotype appeared to be (Chapter 5; figure 5.3).
Additionally, the level of Nppa expression was shown to be elevated in the right
ventricle (Chapter 5; figure 5.4). Whilst the combined results from this and previous
chapters does not pinpoint further the level at which mutation in Sox4 causes an
alteration to gene expression, these results do verify that mutation in Sox4 and the
phenotype that arises is capable of contributing to a reduction in Handl and an
increase in Nppa. Since the Handl expression domain is reduced, there still remains
the possibility that components of the Sox4 phenotype are a consequence of reduced
levels of proliferation and elevated levels of differentiation. As described in chapter
5 (section 5.3.2), markers of proliferation, as well as cardiac differentiation would be
useful to investigate this further.
A reduction in expression ofPitx2 in the inner curvature correlates to the
phenotype of inadequate looping.
The first visible E9.5 cardiac phenotype observed in both Sox4ENU/ENU and
Sox4enu/enu Foxqlsa/sa embryos was that of inadequate looping. Hearts appeared
distended to varying degrees and curvature was abnormal (this chapter, Figure 6.2;
Chapter 3, Figure 3.8). To examine this and whether the inadequate cardiac looping
could be a consequence of mis-expression of genes known to play a role in looping,
the expression of Pitx2 was examined in a class-I Sox4ENU/ENU mutant embryo.
Expression of Pitx2c within the inner curvature of the heart marks a specific domain
important for cardiac remodelling (Kitamura et. al. 1999).
This domain appeared substantially reduced in the Sox4ENU/ENU mutant, relative to
Pitx2 expression in other areas. Whilst it may be a novel aspect of the role of Sox4
in cardiogenesis, analysis of expression by in situ hybridisation is not necessarily
conclusive. To state with certainty that Sox4 mutation reduces Pitx2 expression in
the inner curvature, it would be necessary to examine expression by more
quantitative methods in this tissue from a larger number of embryos across this
developmental stage, as it is possible that the result is a consequence of a
developmental delay.
If the reduction in Pitx2 expression in this domain is not a consequence of a possible
cardiac developmental delay two possibilities remain: The first possibility in
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embryos at this stage, is that Sox4 functions in the endocardium of the AVC, or via
induction of indirect signalling from the ventral foregut, to act on Pitx2 expressing
cells to repress this specific domain of expression. The second possibility is that the
number of Pitx2 expressing cells in the inner curvature is dependent upon Sox4
expression at an earlier stage of development.
The first possibility could be examined by in situ of Pitx2 at E8, when expression in
the heart is first observed (Campione et. al. 2001) until E10.5, beyond the embryonic
stage when Sox4ENU/ENU mutants demonstrate lower expression than control embryos.
The second possibility could be explored by histological analysis of a number of
mutant embryos at this stage and cell counting in this region. This early loss of Pitx2
may contribute to the phenotype observed in Sox4 mutants, since both gain and loss
of Pitx2 is associated with DORV. It is possible that the loss of Pitx2 levels in Sox4
mutant hearts is causative of the inadequate looping and later El2.5 phenotypes (as
observed in sections of Sox4ENU/ENUFoxqlsa/sa embryos - chapter 4).
A further possibility, as an explanation for the loss of Pitx2 expression in the left
atrium is that this embryo demonstrates early evidence for right atrial isomerism
(RAI). Pitx2 expression is restricted to the left atrium as it develops a molecular left-
identity (Campione et. al. 2001; Ryan et. al. 1998). The cardiac phenotype of
Sox4enu/enu Foxqlsa/sa embryos does not appear to include RAI in the hearts
examined (Chapter 3; section 3.3.2). Since the hearts of compound mutant embryos
do not appear to demonstrate RAI, it is unlikely that single mutant embryos would.
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6.4 Summary of the Sox4enu/eiwu phenotype and
resulting molecular aberration.
This final chapter has documented the embryonic phenotype of a point mutation in
Sox4. Interpreting from whole single mutant embryos at E9.5, the cardiac
morphology appears to be consistent with that described for the compound mutant
embryos presented in previous chapters. A reduction in Pitx2 expression for this
stage of development in the inner curvature of the heart may contribute to the
inability of Sox4 mutant hearts to loop adequately. Given the expression domains of
Sox4, and the continuity of results from those shown in chapter 5, it can be proposed
that Sox4 may play a role converging on a pathway which regulate Handl-
expressing cells. The observed increase in Nppa expression, reflecting myocardial
differentiation, is a likely consequence of cardiac stress. This chapter provides the
first molecular analysis of mutation in Sox4 within the heart at these embryonic
stages. This study has enabled determination of the onset of the cardiac phenotype
with this allele and supported the concept that Sox4 acts prior to a visible phenotype
from E9.5. The molecular analysis has allowed the formulation of novel hypotheses
about the action of Sox4 in cardiogenesis. Additionally, since Sox4ENU/ENU embryos
do not yet appear to demonstrate a severe defect in anterior development, we can
conclude that a genetic interaction with Foxql modulated the severity of the anterior
phenotype presented in previous chapters.
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Chapter 7: General Discussion and
Concluding Remarks
The principal objective of my project is to gain novel insights into the embryonic
requirement for Sox4. My reasoning for this is threefold:
1. The Sox4 null phenotype has been reported (Schilham et. al. 1996; Ya et. al.
1998b), but the underlying embryonic defect which caused the cardiac
phenotype has not been examined.
2. A novel Sox4 ENU-induced mutant allele was identified that phenocopies
the Sox4 null (Bogani et. al. 2005). This provided a system in which to
explore the primary embryonic requirement for Sox4.
3. Studies in cancer genetics show that a wide range of tumours result from
aberrant activity of developmental pathways. Thus, characterising the
multiple roles of Sox4 in mouse embryonic development may contribute to
understanding the molecular basis for dysregulation of SOX4 in
tumorigenesis.
This study contributes to this research by adopting three approaches:
I. Evidence has been presented in this thesis to show that a mutation in Sox4
results in a heterogeneous cardiac phenotype from an early developmental
stage. This extends well beyond the published description of the null allele
cardiac deficiency reported in the literature. These results overlap with
published findings, and furthermore expand upon the current understanding of
the role of Sox4 during cardiogenesis. Firstly, mutant embryos demonstrate a
visible cardiac phenotype from E9.5 (Chapters 3 and 6). This phenotype varies
in severity between embryos, resulting in at least two time points of embryonic
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lethality. Many aspects of the E12.5-E14.5 published phenotype could result
from the early dysmorphology (Chapter 3).
IE Secondly, a comprehensive analysis of the expression of Sox4 revealed
previously uncharacterised cardiac and extra-cardiac expression domains
during early embryogenesis (Chapter 4). Mis-expression from some of these
domains may account for the cardiac phenotype observed, since these domains
coincide with regions of cardiac abnormality in mutants. Thus, it is possible
that Sox4 acts in a multifaceted manner, at a number of different sites and
stages to enable appropriate heart development.
III. Finally, molecular analysis of the cardiac phenotype has given insight into the
possible molecular requirement for Sox4 function during heart development
(Chapter 5 and 6).
Determining the origin of the cardiac defect in Sox4 mutant embryos.
The early cardiac phenotype is grouped into two categories: class-I and class-II
(class-Ill mutants do not demonstrate a functional heart, nor survive past El0.5)
(Chapter 3). Both classes demonstrate a degree of distension of the looping heart
tube at about E9.5 and a variable developmental delay. Also at this stage these
results have shown that early ventricular trabeculation and cushion formation are
disrupted.
Since the visible cardiac phenotype arises about E9.5, the earliest requirement for
appropriate expression of Sox4 must be prior to this developmental stage.
Additionally, results show that expression of Sox4 occurs within the foregut
endoderm adjacent to the cardiac crescent (Chapter 4). Given the importance of the
endoderm for cardiac development (section 1.3.4), dysregulated expression in this
domain, at this stage, may be responsible for the onset of the cardiac phenotype.
Sox4 is also expressed in the endocardial cushions from E9.5 (Chapter 4). Whilst it
may be thought to be too late for the onset of a phenotype at E9.5, it is possible that
Sox4 is expressed earlier at low levels beyond the detection by in situ hybridisation.
Without verification by quantitative analysis of expression in specific regions, from
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the crescent stage, it is not possible to say for certain that Sox4 is not expressed in
endocardium prior to E9.5. Hence, dysregulated expression of Sox4 in the
endocardium may in addition be responsible for the onset of the cardiac phenotype.
Thus two possibilities exist: First, that the early defects are a consequence of aberrant
Sox4 expression within endoderm and/or second, that the early defects are a
consequence of aberrant Sox4 expression within mesoderm. This presents a
distinctly different question from that asked in previous discussions, which relates to
later expression of Sox4.
Further investigations on the conditional Sox4 allele (Penzo-Mendez et. al. 2007)
would be useful to examine this quandary. To distinguish between the two lineage
requirements would require conditional deletion of either endodermal or mesodermal
Sox4 expression at the crescent stage. Although Isll expression is not specific to the
endoderm at the crescent and headfold stages of development, its expression in the
definitive endoderm appears to be the only domain of overlap with the Sox4
expression shown in this thesis. Thus, the Isll-cre may be useful for ablation of
Sox4 specifically in the definitive endoderm (Srinivas et. al. 2001). Before
proceeding with genetic crosses, co-localisation of Sox4 with Isll should be
examined to validate the overlapping domains. The cardiac mesoderm cre-
recombinase, Mesp-l-cre, is well characterised (Saga et. al. 1999). By removing
expression of Sox4 in cells derived from Mesp-1 -expressing mesoderm, it would be
possible to examine which components of the phenotype are caused by mis-
expression of Sox4 in mesoderm-derived cells.
As an alternative approach to this method, it has been shown that ES cells can be
derived from Sox4ENU/ENU Foxqlsa/sa embryos (Appendix 1). Thus it is equally
possible for ES cells to be derived from Sox4ENU/ENU embryos. By introducing a
GFP or lacZ expression cassette into these derived cell lines, the potential of the
Sox4 mutant ES cells to contribute to chimaeric embryos could then be examined.
Preferential inclusion of wild type cells in a specific lineage implies that mutant cells
are unable to contribute due to dysfunction. This method was used to demonstrate
the essential requirement for Gata4 expression by the endoderm, but not the
mesoderm during early heart development (Narita et. al. 1997). It would be equally
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effective in determining whether Sox4 expression is required by either or both the
endoderm and mesoderm.
Thus, this thesis shows that Sox4 is expressed in regions highly relevant for
cardiogenesis. Further work to find the precise requirement of Sox4 expression in
these lineages is discussed.
Determining the possible functions of Sox4 in embryogenesis.
These results also progress our understanding of the role of Sox4 outwith heart
development. Findings in this project have exposed a novel early embryonic
phenotype (class-Ill mutants) linked to the Sox4ENU Foxqlsa mutation. It is not clear
yet whether this is entirely a consequence of Sox4ENU/ENU, since the Sox4ENU/ENU
phenotype has not been examined in detail (Chapter 6). However, class-Ill mutant
embryos demonstrate a severe phenotype which may have its origins during
gastrulation. In addition to the usefulness of Sox4hNU/ENU ES cells for observing the
ability of these cells to contribute to cardiac development, such ES cells will also be
useful to examine whether mutant cells are able to gastrulate correctly and whether
they are able to contribute equally to all three germ layers in the early class-Ill
mutants. A major limitation to this is the substantial number of chimseric embryos
which would need to be created and examined considering this phenotype comprises
about 5% of any litter. Nevertheless, such a study would demonstrate the
requirement for normal Sox4 function during early developmental stages.
As this work has successfully characterised the embryonic expression domains of
Sox4, it is relevant now to explore the requirement for Sox4 expression by other
tissue. Examining the action of Sox4 in multiple tissues will help to uncover the
function of Sox4 as a protein, not just in the process of cardiogenesis, but also for
embryonic development.
Functional analysis of the ENU mutation
Work presented in this thesis provides a fundamental basis for use of the Sox4ENU
allele in characterising the embryonic function of Sox4. The phenotype has been
presented and discussed, and molecular aberrations resulting from mutation in Sox4
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have been shown. In addition to this, it is also necessary to determine how Sox4 acts
at the molecular level.
It is not expected that the point mutation would alter the expression of Sox4, unless
expression in a specific domain is autoregulatory. Indeed, it has been shown that
embryonic stem cells derived from Sox4ENU/ENU Foxqlsa/sa embryos, as well as
heterozygous and control embryos express the Sox4 transcript (Appendix 1). In
order to proceed further with use of the Sox4ENU allele, it will be first necessary to
conduct experiments to answer the following questions:
Does translation occur from the mutant Sox4 transcript and is mutant Sox4
protein present in Sox4ENU/ENU embryos?
Does the mutant protein demonstrate differences in activity compared with wild
type Sox4?
Progress into the functional aspects of Sox4 during development has been hampered
by the lack of a reliable Sox4 antibody. Although some publications have reported
protein localisation studies using commercial Sox4 antibodies (Park, Y K et. al.
2005; Sinner et. al. 2007), further information about the localisation of Sox4 appears
to be from use of non-commercial antibodies (Kim et. al. 2004; Liu et. al. 2006).
Immunohistochemistry to mutant embryos in toto or sections of embryonic tissue
will assist in determining whether cells of the Sox4ENU/ENU genotype generate mutant
Sox4 protein. Undoubtedly, this would assist in answering the first question, as to
whether the mutant protein is generated in Sox4ENU/ENU embryos.
Cloning of the Sox4ENU coding sequence into an expression vector would enable a
number of molecular assays to be carried out, with the intention of characterising
how the mutant protein functions differently from normal Sox4. There are two
aspects of the binding potential of Sox4, as a transcription factor, which must be
examined: 1) Does mutant Sox4 still interact with other proteins?; and 2) Does
mutant Sox4 still bind DNA?
1. To examine the first, requires knowledge of Sox4 binding partners which, to
date, is under-examined. SOX4 has been shown, in vitro, to bind (3-catenin
or Tcf4 (both, but not together) (Sinner et. al. 2007). Additionally,
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overexpression of Sox4 in culture enhanced Wnt-reporter gene expression.
Thus, expression of mutant Sox4 in HEK293 cells could be used to examine
protein interactions. Moreover, co-transfection of HEK293 cells with
constructs designed to demonstrate functional levels of canonical Wnt
signalling (Vleminckx et. al. 1999; Zamparini et. al. 2006) could aid in
assaying transcriptional function, thereby determining whether the mutation
in Sox4 alters canonical Wnt signalling.
2. Examination of the DNA-binding potential of the Sox4 HMG box has been
conducted by other research groups (van Beest et. al. 2000; van de Wetering
et. al. 1993; van Houte et. al. 1995). By the proposed cloning and expression
steps, the mutant protein may be created in vitro and extracted for use in a
DNA binding assay. This would enable us to answer the important question
-does mutant Sox4 still bind DNA?
Both of these assays would give clues as to the mechanism by which the ENU
induced mutation results in aberrant function of Sox4, thereby answering the second
question posed - How does the mutant protein function differently from the wild
type?
Could there be a genetic interaction between Sox4ENl and satin?
Throughout this thesis, results have implied a possible genetic interaction between
the two mutant alleles Sox4KNU and satin.
Chapter 3 demonstrated the variability of the wholemount craniofacial
phenotype in embryos staged E9.5 and El2.5. This aspect of the phenotype
was abrogated in E9.5 and El2.5 embryos which harboured only the Sox4ENU
mutation, as shown in Chapter 6.
Results in Chapter 3 reveal an anterior deficiency, consistent in embryos
homozygous for Sox4tElj and satin, after two to five generations of
backcrossing to C57B1/6J mice. This is supported by previous work
(Willoughby 2006) which suggested that a genetic cause of the anterior
phenotype resided on the satin chromosome and this could be observed in
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some embryos where this region was hemizygous, from a cross of the satin
chromosome with an intra-chromosomal deletion {Del(l3)Svea36H) (section
1.4 and 3.3 part 2).
Chapter 4 reported the expression domains of Sox4 and Foxql transcripts and,
although co-expression studies have not been conducted, in situ analysis of
each gene suggests that both are expressed in the developing anterior
neurectoderm during early somitogenesis (E8-8.5). Additionally, both are
expressed at E9.5 in the pharyngeal arches, which later contribute to the
affected craniofacial structures.
A recent paper examining gene expression in hepatocellular carcinoma observed
FOXQ1 expression elevated in cells in which SOX4 was also highly expressed (Liao
et. al. 2008). Expression levels of FOXQ1 could be reduced upon knockdown of
endogenous SOX4 transcript by RNA interference. The authors subsequently
identified that the FOXQ1 promoter could be bound by SOX4 in chromatin
immunoprecipitation experiments. Although this study focussed on cancer cells and
not embryonic development, these findings further support a possible interaction
between the two genes which may also relate to other systems.
During development, further work is needed to determine the underlying cause of the
embryological defect. In the first instance, evidence in support of a functional
interaction could come from co-localisation of Sox4 and Foxql expression domains
within the anterior neurectoderm. Also examination of whether the Sox4 and Foxql
proteins co-localise could assist in examining functional overlap.
Although the phenotype of the Foxql null includes malformation of the forebrain
(Goering et. al. 2008) and Sox4 has been implicated in neural development (Cheung
et. al. 2000), it is possible that the final phenotypic outcome of the Sox4ENU satin
compound mutation is influenced by other segregating loci from the original satin
chromosome. It has been argued that it is unlikely that another ENU mutation
resides in this region and segregates with Sox4ENU and satin alleles (section 1.4.3).
However, this does not exclude the possibility that the genetic construct of this
region contains modifier loci existing prior to mutagenesis by ENU.
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To determine conclusively whether aspects of the compound phenotype are a
consequence of a genetic interaction between Sox4 and Foxql, the phenotype
observed here would need to be recapitulated using Sox4 null and Foxql null alleles.
A detailed breeding programme between mutant Sox4 heterozygotes and mutant
Foxql null mice (as homozygous Foxql null are viable) would need to be conducted
to ensure generation of heterozygotes with both null alleles on the same
chromosome. It is possible that a shorter route towards generating such mutants
would be to us ES cell recombineering to generate targeted mutations in both genes
on the same chromosome. Generation of homozygous Sox4 null: Foxql null
embryos could then be achieved and the phenotype examined for anterior
malformation and aberrant gene expression.
In addition to uncovering a novel possibility - that Sox4 and Foxql interact
genetically - this finding also highlights the importance of considering gene function
in the context of the genetic neighbourhood.
Summary
The search for a clear function of Sox4 remains in its infancy. This study has
contributed to this search in many respects. Mutation in Sox4 results in a lethal
cardiac deformity which has its origins at early stages of heart development. This
phenotype is highly variable. It appears that certain aspects of the phenotype can be
attributed to dysregulation of Sox4 gene expression in specific cardiac and extra-
cardiac domains. The mouse model characterised in this project will prove relevant
for increasing on the current understanding of heart development. Extended
breeding programmes involving other transgenic mouse lines, together with chimaera
analysis from derived ES cells, will enable further dissection of specific requirements
for Sox4 in embryogenesis. Moreover, cloning of the ENU mutant allele will enable
cell culture and protein experiments to determine the functional properties of the
mutant protein. Combining results from proposed analyses with the findings
presented within this thesis will give insight into determining the molecular and
functional action of Sox4.
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APPENDIX 1: Derivation of Sox4ENU/ENU
Foxq1sa/sa ES cells; and the contribution
of ES cells in chimaeric mice
It is well established that chimaeric mice and chimaeric embryos are useful tools to
study the ability of embryonic stem (ES) cells to contribute to the development and
function of a specific tissue. When subjected to morula aggregation with a control
embryo or micro-injected into the ICM of a wild type blastocyst, ES cells are equally
capable of contributing to all embryonic tissue and, in the case of morula
aggregation, extraembryonic derivatives too (Beddington et. al. 1989). If ES cells
are tagged, by expression of lacZ or GFP, then it is possible to examine contribution
of introduced ES cells within the embryo or mouse. Any unequal distribution
between ES cells and cells from the host blastocyst indicates a problem with the
potential of the ES cells. If the ES cells are of a mutant mouse line, analysis of the
chimaeras can assist in describing the requirement of the mutated gene in embryonic
development.
The following two figures and one table show:
1. Sox4enu/enuFoxqlsa/sa ES cells express Sox4 (Figure 1 );
2. ES cells, derived from Sox4ENU/ENU Foxqlsa/sa delayed-implantation
blastocysts can be grown in culture (Figure 2);
3. Sox4enu/enu Foxqlsasa ES cells are able to contribute to chimaeric mice
(Figure 2);
4. Sox4ENU/ENUFoxqlsa/sa ES cells demonstrate variable contribution to organs of
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Appendix Figure 1: Sox4 is expressed in ES cells.
ES cells heterozygous or homozygous for Sox4ENU were derived from
Sox4+/ENU Foxq1+/sa intercross embryos (table, upper). Sox4 transcript
(top row of bands) is expressed in all ES cell lines examined. E14 is a
control wild type ES cell line. Expression of actin control for amplification is
shown. Final lane reveals no amplification from genomic DNA (minus
reverse transcriptase control). Labels correspond to table as shown.
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Appendix Figure 2: Derived ES cells may be grown in culture, and are
able to contribute to chimaeric mice.
Heterozygous (A,B) and homozygous Sox4ENU/ENU Foxq1sa/sa (C) ES
cells grown in culture. Sox4ENU/ENU Foxq1sa/sa ES cells can contribute to
chimaeric mice (D,E,F,G).
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Appendix Table 1: Contribution of ES cells to organs in chimaeric mice.
Tissue Chimaera 1 Chimaera 2 Chimaera 3
gut equal mostly wildtype equal
eye equal wildtype wildtype
tongue mostly wildtype equal
brain mostly wildtype equal mostly wildtype
ovary equal wildtype
anterior brain mostly wildtype equal mostly wildtype
thymus wildtype mostly wildtype
lung wildtype wildtype wildtype
thyroid equal mostly wildtype wildtype
diaphragm mostly wildtype mostly wildtype equal
tail mostly wildtype mostly wildtype mostly wildtype
skin mostly wildtype mostly wildtype
skull equal wildtype mostly wildtype
spleen mostly wildtype wildtype mostly wildtype
pancreas mostly wildtype equal
kidney wildtype mostly wildtype mostly wildtype
liver equal wildtype wildtype
muscle Wildtype equal equal
femur wildtype wildtype mostly wildtype
bone marrow mostly wildtype wildtype wildtype
atria wildtype mostly wildtype equal
IVS mostly wildtype wildtype
ventricle mostly wildtype mostly wildtype mostly wildtype
heart mostly wildtype mostly wildtype
Semi-quantitative analysis of adult mouse tissue for contribution of the satin allele as
a marker of Sox4ENU/ENU Foxqlsa/sa ES cell contribution to adult chimaeric mice.
White space in chimaera 3 indicates that a particular tissue was not examined.
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Summary
Tissue analysis of chimaeric mice revealed highly variable contribution of
homozygous mutant ES cells to the construction of adult organs (Appendix Table 1).
Although some tissues demonstrate predominantly wild type contribution
(particularly lung), these results are inconclusive because of the significant
variability between other samples. Whilst this was conducted as a general
observation of contribution, cells in adult tissue arise from different origins. Since
the Sox4enu/enu Foxqlsa/sa phenotype is considerably variable (Chapter 3) by
labelling ES cells prior to introduction into host blastocysts, these cell lines may
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